Form 10-Q

Large accelerated filer

Accelerated filer

Non-accelerated
filer

Smaller reporting company

Emerging growth company

0001193125-22-147433.txt : 20220511 0001193125-22-147433.hdr.sgml : 20220511 20220511152429 ACCESSION NUMBER: 0001193125-22-147433 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 75 CONFORMED PERIOD OF REPORT: 20220331 FILED AS OF DATE: 20220511 DATE AS OF CHANGE: 20220511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DELCATH SYSTEMS, INC. CENTRAL INDEX KEY: 0000872912 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 061245881 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-16133 FILM NUMBER: 22913375 BUSINESS ADDRESS: STREET 1: 1633 BROADWAY STREET 2: SUITE 22C CITY: NEW YORK STATE: NY ZIP: 10019 BUSINESS PHONE: (212) 489-2100 MAIL ADDRESS: STREET 1: 1633 BROADWAY STREET 2: SUITE 22C CITY: NEW YORK STATE: NY ZIP: 10019 FORMER COMPANY: FORMER CONFORMED NAME: DELCATH SYSTEMS INC DATE OF NAME CHANGE: 19990607 10-Q 1 d290302d10q.htm FORM 10-Q Form 10-Q

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM

10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2022

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ____________

Commission File

Number: 001-16133

DELCATH SYSTEMS, INC.

(Exact name of registrant as specified in its charter)


Delaware		06-1245881
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

1633 Broadway, Suite 22C

New York, NY 10019

(Address of principal executive offices)

(212)

489-2100

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, $0.01 par value per share	DCTH	The NASDAQ Capital Market

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation

S-T

during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a

non-accelerated

filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule

12b-2

of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Securities Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule

12b-2

of the Exchange Act). Yes ☐ No ☒

As of May 11, 2022, 7,906,728 shares of the Company’s common stock, $0.01 par value, were outstanding.

Table of Contents

DELCATH SYSTEMS, INC.

Table of Contents


		Page
PART I—FINANCIAL INFORMATION

Item 1.	Financial Statements
	Unaudited Condensed Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021		3
	Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2022 and 2021		4
	Unaudited Condensed Consolidated Statements of Stockholders’ Equity for the three months ended March 31, 2022 and 2021		5
	Unaudited Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2022 and 2021		6
	Notes to the Condensed Consolidated Financial Statements		7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		18
Item 4.	Controls and Procedures		20

PART II—OTHER INFORMATION

Item 1.	Legal Proceedings		22

Item 6.	Exhibits		23

SIGNATURES			24

Table of Contents

DELCATH SYSTEMS, INC.

Condensed Consolidated Balance Sheets

(Unaudited)

(in thousands, except share and per share data)


	March 31, 2022			December 31, 2021
Assets
Current assets
Cash and cash equivalents	$	16,340		$	22,802
Restricted cash		4,151			4,151
Accounts receivable, net		178			44
Inventories		2,011			1,412
Prepaid expenses and other current assets		2,704			2,743

Total current assets		25,384			31,152
Property, plant and equipment, net		1,406			1,348
Right-of-use assets		527			624

Total assets	$	27,317		$	33,124

Liabilities and Stockholders’ Equity
Current liabilities
Accounts payable	$	1,243		$	638
Accrued expenses		4,495			4,109
Deferred revenue, current		—			170
Lease liabilities, current		404			416
Loan payable, current		2,520			621

Total current liabilities		8,662			5,954
Lease liabilities, non-current		122			207
Loan payable, non-current		8,633			10,372
Convertible notes payable, non-current		4,675			4,639

Total liabilities		22,092			21,172

Commitments and contingencies (Note 13)		—			—
Stockholders’ equity
Preferred stock, $.01 par value; 10,000,000 shares authorized; 11,357 shares issued and outstanding at March 31, 2022 and December 31, 2021		—			—
Common stock, $.01 par value; 40,000,000 shares authorized; 7,906,728 shares issued and outstanding at March 31, 2022 and December 31, 2021		79			79
Additional paid-in capital		434,305			432,831
Accumulated deficit		(429,179	)		(420,976	)
Accumulated other comprehensive income		20			18

Total stockholders’ equity		5,225			11,952

Total liabilities and stockholders’ equity	$	27,317		$	33,124

See accompanying Notes to Condensed Consolidated Financial Statements.

Table of Contents

DELCATH SYSTEMS, INC.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

(in thousands, except share and per share data)


	Three months ended March 31,
	2022			2021
Product revenue	$	207		$	261
Other revenue		171			127
Cost of goods sold		(33	)		(112	)

Gross profit		345			276

Operating expenses:
Research and development expenses		4,240			3,707
Selling, general and administrative expenses		3,648			3,296

Total operating expenses		7,888			7,003

Operating loss		(7,543	)		(6,727	)
Interest expense, net		(645	)		(41	)
Other income (expense), net		(15	)		21

Net loss		(8,203	)		(6,747	)
Other comprehensive income:
Foreign currency translation adjustments		2			94

Total other comprehensive loss	$	(8,201	)	$	(6,653	)

Common share data:
Basic and diluted loss per common share	$	(1.00	)	$	(1.04	)

Weighted average number of basic and diluted shares outstanding		8,190,483			6,496,922

See accompanying Notes to Condensed Consolidated Financial Statements.

Table of Contents

DELCATH SYSTEMS, INC.

Condensed Consolidated Statements of Stockholders’ Equity

(Unaudited)

(in thousands, except share and per share data)


	Preferred Stock $0.01 Par Value				Common Stock $0.01 Par Value
	No. of Shares		Amount		No. of Shares		Amount		Additional Paid in Capital		Accumulated Deficit			Accumulated Other Comprehensive Income		Total
Balance at January 1, 2022		11,357	$	—		7,906,728	$	79	$	432,831	$	(420,976	)	$	18	$	11,952
Compensation expense for issuance of stock options		—		—		—		—		1,474		—			—		1,474
Net loss		—		—		—		—		—		(8,203	)		—		(8,203	)
Total comprehensive income		—		—		—		—		—		—			2		2

Balance at March 31, 2022		11,357	$	—		7,906,728	$	79	$	434,305	$	(429,179	)	$	20	$	5,225


	Preferred Stock $0.01 Par Value					Common Stock Issued $0.01 Par Value
	No. of Shares			Amount		No. of Shares		Amount		Additional Paid in Capital		Accumulated Deficit			Accumulated Other Comprehensive (Loss)			Total
Balance at January 1, 2021		20,631		$	—		5,996,101	$	60	$	417,449	$	(395,327	)	$	(104	)	$	22,078
Compensation expense for issuance of stock options		—			—		—		—		2,148		—			—			2,148
Shares settled for services		—			—		2,636		—		57		—			—			57
Conversion of Preferred stock into common stock		(150	)		—		15,000		—		—		—			—			—
Exercise of warrants into common stock		—			—		237,520		3		2,373		—			—			2,376
Net loss		—			—		—		—		—		(6,747	)		—			(6,747	)
Total comprehensive income		—			—		—		—		—		—			94			94

Balance at March 31, 2021		20,481		$	—		6,251,257	$	63	$	422,027	$	(402,074	)	$	(10	)	$	20,006

See accompanying Notes to Condensed Consolidated Financial Statements.

Table of Contents

DELCATH SYSTEMS, INC.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(in thousands)


	Three months ended March 31,
	2022			2021
Cash flows from operating activities:
Net loss	$	(8,203	)	$	(6,747	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock option compensation expense		1,474			2,148
Depreciation expense		31			39
Non-cash lease expense		97			155
Amortization of debt discount		194			—
Interest expense accrued related to convertible notes		40			39
Changes in assets and liabilities:
Decrease in prepaid expenses and other assets		39			301
Increase in accounts receivable		(134	)		(18	)
Increase in inventories		(599	)		(254	)
Increase in accounts payable and accrued expenses		953			164
Decrease in lease liabilities		(97	)		(155	)
Decrease in deferred revenue		(170	)		(239	)

Net cash used in operating activities		(6,375	)		(4,567	)

Cash flows from investing activities:
Purchase of property, plant and equipment		(89	)		(9	)

Net cash used in investing activities		(89	)		(9	)

Cash flows from financing activities:
Net proceeds from the exercise of warrants		—			2,376

Net cash provided by financing activities		—			2,376

Foreign currency effects on cash		2			94

Net decrease in total cash		(6,462	)		(2,106	)
Total Cash:
Beginning of period		26,953			28,756

End of period	$	20,491		$	26,650

Cash, Cash Equivalents and Restricted Cash consisted of the following:
Cash	$	16,340		$	26,600
Restricted Cash		4,151			50

Total	$	20,491		$	26,650


	Three months ended March 31,
	2022		2021
Supplemental Disclosure of Cash Flow Information:
Cash paid during the periods for:
Interest expense	$	411	$	3

Supplemental Disclosure of Non-Cash Investing and Financing Activities:
Issuance of restricted stock for accrued fees due to a former board member	$	—	$	57

See accompanying Notes to Condensed Consolidated Financial Statements.

Table of Contents

DELCATH SYSTEMS, INC.

Notes to the Condensed Consolidated Financial Statements

(1)

General

The unaudited interim condensed consolidated financial statements of Delcath Systems, Inc. (“Delcath” or the “Company”) as of and for the three months ended March 31, 2022 and 2021 should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form

10-K

for the fiscal year ended December 31, 2021 (the “Annual Report”), which was filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2022 and may also be found on the Company’s website (www.delcath.com). In these notes to the interim condensed consolidated financial statements the terms “us”, “we” or “our” refer to Delcath and its consolidated subsidiaries.

Description of Business

The Company is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company’s lead product candidate, the HEPZATO

™

KIT (melphalan hydrochloride for injection/hepatic delivery system), or HEPZATO

™

, is a drug/device combination product designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. HEPZATO has not been approved for sale in the United States. In Europe, the hepatic delivery system is a stand-alone medical device having the same device components as HEPZATO, but without the melphalan hydrochloride, and is approved for sale under the trade name CHEMOSAT

Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used at major medical centers to treat a wide range of cancers of the liver.

The Company’s clinical development program for HEPZATO is comprised of the FOCUS Clinical Trial for Patients with Hepatic Dominant Ocular Melanoma (the “FOCUS Trial”), a global registration clinical trial that is investigating objective response rate in metastatic ocular melanoma, or mOM. The Company is currently reviewing the incidence, unmet need, available efficacy data and development requirements for a broad set of liver cancers in order to select a portfolio of

follow-on

indications which will maximize the value of the HEPZATO platform.

In the United States, HEPZATO is considered a combination drug and device product regulated by the Food and Drug Administration (“FDA”). Primary jurisdiction for regulation of HEPZATO has been assigned to the FDA’s Center for Drug Evaluation and Research. The FDA has granted the Company six orphan drug designations (five for melphalan in ocular melanoma, cutaneous melanoma, cholangiocarcinoma, hepatocellular carcinoma, and neuroendocrine tumor indications and one for doxorubicin in the hepatocellular carcinoma indication).

In December 2021, the Company announced that the FOCUS Trial of HEPZATO met its pre-specific endpoint. Based on the FOCUS Trial results, the Company is preparing to submit a new drug application, or NDA, to the FDA for HEPZATO. The Company held a

pre-NDA

meeting with the FDA in April 2022 and is awaiting the official minutes from the meeting. Based on the feedback from the FDA, the Company does not believe any additional

pre-clinical

or clinical studies are required to

re-file

the NDA. Due to vendor delays in delivering certain reports, the Company plans to submit an NDA to the FDA by the end of the third quarter of 2022.

On February 28, 2022, CHEMOSAT received Medical Device Regulation certification under the European Medical Devices Regulation [2017/745/EU], which may be considered by jurisdictions when evaluating reimbursement. As of March 1, 2022, the Company has assumed direct responsibility for sales, marketing and distribution of CHEMOSAT in Europe.

Risks and Uncertainties

Although the Company is not aware of any direct impacts of the war between the Ukraine and the Russian Federation on its supply chain, the war could adversely impact the Company’s ability to obtain components and/or significantly increase the cost of obtaining such components for the Company’s products from its third-party suppliers in a timely manner or at all. In addition, at this time, the Company is not aware of any direct impacts, the increase in COVID cases and associated restrictions, which could adversely impact the Company’s ability to obtain components and/or significantly increase the cost of obtaining such components for the Company’s products from its third-party suppliers in a timely manner or at all.

Liquidity and Going Concern

The accompanying interim condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred significant losses and has an accumulated deficit of $429.2 million as of March 31, 2022. These losses, among other factors, raise substantial doubt about the Company’s ability to continue as a going concern.

Table of Contents

The Company’s existence is dependent upon management’s ability to obtain additional funding sources or to enter into strategic alliances. Adequate additional financing may not be available to the Company on acceptable terms, or at all. If the Company is unable to raise additional capital and/or enter into strategic alliances when needed or on attractive terms, it would be forced to delay, reduce, or eliminate its research and development programs or any commercialization efforts. There can be no assurance that the Company’s efforts will result in the resolution of the Company’s liquidity needs. If the Company is not able to continue as a going concern, it is likely that holders of its common stock will lose all of their investment. The accompanying interim condensed consolidated financial statements do not include any adjustments that might result should the Company be unable to continue as a going concern.

The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. Additional working capital will be required to continue operations. Operations of the Company are subject to certain risks and uncertainties, including, among others, uncertainty of product development and clinical trial results; uncertainty regarding regulatory approval; technological uncertainty; uncertainty regarding patents and proprietary rights; comprehensive government regulations; limited commercial manufacturing, marketing, or sales experience; and dependence on key personnel.

Basis of Presentation

These interim condensed consolidated financial statements are unaudited and were prepared by the Company in accordance with generally accepted accounting principles in the United States of America (GAAP) and with the SEC’s instructions to Form

10-Q

and Article 10 of Regulation

S-X.

They include the accounts of all wholly owned subsidiaries and all significant inter-company accounts and transactions have been eliminated in consolidation.

The preparation of interim condensed consolidated financial statements requires management to make assumptions and estimates that impact the amounts reported. These interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the Company’s results of operations, financial position and cash flows for the interim periods ended March 31, 2022 and 2021; however, certain information and footnote disclosures normally included in our audited consolidated financial statements included in our Annual Report on Form

10-K

have been condensed or omitted as permitted by GAAP. It is important to note that the Company’s results of operations and cash flows for interim periods are not necessarily indicative of the results of operations and cash flows to be expected for a full fiscal year or any interim period.

Significant Accounting Policies

There have been no material changes to our significant accounting policies as set forth in Note 3 Summary of Significant Accounting Policies to the consolidated financial statements included in the Company’s Annual Report on Form

10-K

for the fiscal year ended December 31, 2021.

Recently Adopted Accounting Pronouncements

In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)

2020-06, “Accounting

for Convertible Instruments and Contracts in an Entity’s Own Equity.” ASU

2020-06

simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. ASU

2020-06

requires entities to provide expanded disclosures about the terms and features of convertible instruments and amends certain guidance in Accounting Standards Codification 260, Earnings per Share, relating to the computation of earnings per share for convertible instruments and contracts in an entity’s own equity. The guidance becomes effective for the Company on January 1, 2024, with early adoption permitted. The Company early adopted ASU

2020-06

on January 1, 2022 and the adoption did not have any immediate effect on the Company’s condensed consolidated financial statements. Going forward, the Company will no longer be required to assess convertible instruments for beneficial conversion features.

In October 2020, the FASB issued ASU

2020-10

“Codification Improvements”, which improves consistency by amending the Codification to include all disclosure guidance in the appropriate disclosure sections and clarifies application of various provisions in the Codification by amending and adding new headings, cross referencing to other guidance, and refining or correcting terminology. The guidance was effective for the Company beginning in the first quarter of fiscal year 2022 with early adoption permitted. The Company adopted this guidance on January 1, 2022 and it did not have a material impact on its condensed consolidated financial statements.

Table of Contents

On May 3, 2021, the FASB issued ASU

2021-04,

“Earnings Per Share” (Topic 260), “Debt—Modifications and Extinguishments” (Subtopic

470-50),

“Compensation—Stock Compensation” (Topic 718), and “Derivatives and Hedging—Contracts in Entity’s Own Equity” (Subtopic

815-40):

“Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options.” This new standard provides clarification and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (such as warrants) that remain equity classified after modification or exchange. This standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Issuers should apply the new standard prospectively to modifications or exchanges occurring after the effective date of the new standard. Early adoption is permitted, including adoption in an interim period. If an issuer elects to early adopt the new standard in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The Company adopted this guidance on January 1, 2022 and it did not have a material impact on its condensed consolidated financial statements.

(2)	Cash, Cash Equivalents and Restricted Cash

Cash and cash equivalents that are restricted as to withdrawal or use under the terms of certain contractual agreements are recorded in

Restricted Cash

on the balance sheets. Restricted cash does not include required minimum balances.

Cash, cash equivalents, and restricted cash balances were as follows (in thousands):


	March 31, 2022		December 31, 2021
Cash and cash equivalents	$	16,340	$	22,802
Restricted balance for loan agreement		4,000	$	4,000
Letters of credit		101		101
Security for credit cards		50		50

Total cash, cash equivalents and restricted cash shown in the statements of cash flows	$	20,491	$	26,953

Under the terms of a

sub-lease

agreement for office space at 1633 Broadway, New York, NY, as of March 31, 2022, the Company is required to maintain a letter of credit which will expire with the sublease in February 2023.

(3)	Inventories

Inventories consist of the following (in thousands):


	March 31, 2022		December 31, 2021
Raw materials	$	841	$	767
Work-in-process		881		645
Finished goods		289		—

Total inventories	$	2,011	$	1,412

(4)	Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following (in thousands):


	March 31, 2022		December 31, 2021
Clinical trial expenses	$	1,630	$	1,630
Insurance premiums		645		890
Other		429		223

Total prepaid expenses and other current assets	$	2,704	$	2,743

Table of Contents

(5)	Property, Plant, and Equipment

Property, plant, and equipment consist of the following (in thousands):


	March 31, 2022			December 31, 2021			Estimated Useful Life
Buildings and land	$	1,222		$	1,222			30 years- Buildings
Enterprise hardware and software		1,858			1,858			3 years
Leaseholds		1,788			1,796			Lesser of lease term or estimated useful life
Equipment		1,184			1,094			7 years
Furniture		202			203			5 years

Property, plant and equipment, gross		6,254			6,173
Accumulated depreciation		(4,848	)		(4,825	)

Property, plant and equipment, net	$	1,406		$	1,348

Depreciation expense for the three months ended March 31, 2022 was approximately $31,000 as compared to approximately $39,000 for the same period in 2021.

(6)	Accrued Expenses

Accrued expenses consist of the following (in thousands):


	March 31, 2022		December 31, 2021
Clinical expenses	$	1,578	$	1,517
Compensation, excluding taxes		796		893
Short term financing		315		551
Professional fees		1,298		603
Interest on convertible note		433		393
Other		75		152

Total accrued expenses	$	4,495	$	4,109

(7)

Leases

The Company recognizes

right-of-use

(“ROU”) assets and lease liabilities when it obtains the right to control an asset under a leasing arrangement with an initial term greater than twelve months. The Company leases its facilities under

non-cancellable

operating and financing leases.

The Company evaluates the nature of each lease at the inception of an arrangement to determine whether it is an operating or financing lease and recognizes the ROU asset and lease liabilities based on the present value of future minimum lease payments over the expected lease term. The Company’s leases do not generally contain an implicit interest rate and therefore the Company uses the incremental borrowing rate it would expect to pay to borrow on a similar collateralized basis over a similar term in order to determine the present value of its lease payments.

Table of Contents

The following table summarizes the Company’s operating leases as of and for the three months ended March 31, 2022 (in thousands):


	U.S.			Ireland			Total
Lease cost:
Operating lease cost	$	101		$	8		$	109

Other information:
Operating cash flows out from operating leases	$	(101	)	$	(8	)	$	(109	)
Weighted average remaining lease term		0.9			4.4
Weighted average discount rate - operating leases		8	%		8	%

Remaining maturities of the Company’s operating leases, excluding short-term leases, are as follows (in thousands):


	U.S.			Ireland			Total
Year ended December 31, 2022	$	304		$	35		$	339
Year ended December 31, 2023		67			46			113
Year ended December 31, 2024		—			46			46
Year ended December 31, 2025		—			46			46
Year ended December 31, 2026		—			26			26

Total		371			199			570
Less present value discount		(14	)		(30	)		(44	)

Operating lease liabilities included in the consolidated balance sheets at March 31, 2022	$	357		$	169		$	526

(8)	Loans and Convertible Notes Payable

(in thousands):

	March 31, 2022									December 31, 2021
	Gross			Discount			Net			Gross			Discount			Net
Loan - Avenue [1]		12,638			(1,485	)		11,153			12,638			(1,645	)		10,993
Loan - Avenue [1] - Less Current Portion		(2,856	)		336			(2,520	)		(714	)		93			(621	)

Total - Loans Payable, Non-Current	$	9,782		$	(1,149	)	$	8,633		$	11,924		$	(1,552	)	$	10,372

Convertible Note Payable - Rosalind		2,000			—			2,000			2,000			—			2,000
Convertible Portion of Loan Payable - Avenue		3,000			(325	)		2,675			3,000			(361	)		2,639

Total - Convertible Notes Payable - Non-Current	$	5,000		$	(325	)	$	4,675		$	5,000		$	(361	)	$	4,639

[1]	The gross amount includes the 4.25% final payment of $638,000.

Remaining maturities of the Company’s loan and convertible note payables are as follows (in thousands):


	Loans		Convertible Notes		Total
Year ended December 31, 2022	$	714	$	—	$	714
Year ended December 31, 2023		8,571		—		8,571
Year ended December 31, 2024		3,353		5,000		8,353

Total	$	12,638	$	5,000	$	17,638

Table of Contents

Term Loan from Avenue Venture Opportunities Fund, L.P.

million

(the “Avenue Loan”). The Avenue Loan bears interest at an annual rate equal to the greater of (a) the sum of 7.70% plus the prime rate as reported in The Wall Street Journal and (b) 10.95%. The interest rate at March 31, 2022 was 10.95%. The Avenue Loan is secured by all of the Company’s assets globally, including intellectual property. The Avenue Loan matures on August 1, 2024.

The initial tranche of the Avenue Loan is $15.0

million,

including $4.0

million

which has been funded into a restricted account and will be released upon achievement of (a)(x) positive FOCUS trial efficacy per the trial’s predefined Statistical Analysis Plan (SAP) (specifically the Overall Response Rate exceeds the

pre-specified

threshold for success defined in the SAP by a statistically significant amount); and (y) based on data contained within the FOCUS trial database and appropriate for use with the U.S. Food and Drug Administration, safety and tolerability among FOCUS trial participants is within the range of currently approved and commonly used cytotoxic chemotherapeutic agents; and (b) raising subsequent net equity proceeds of at least $20

million

. The Company may request an additional $5.0

million

of gross proceeds between October 1, 2022 and December 31, 2022, with funding, subject to the approval of Avenue’s Investment Committee.

Up to $3

million

of the principal amount of the Avenue Loan outstanding may be converted, at the option of Avenue, into shares of the Company’s common stock at a conversion price of $11.98 per share.

In connection with the Avenue Loan, the Company issued to Avenue a warrant (the “Avenue Warrant”) to purchase 127,755 shares of common stock at an exercise price per share equal to $0.01. The Avenue Warrant is exercisable until August 31, 2026.

The Company will make monthly interest-only payments during the first fifteen months of the term of the Avenue Loan, which could be increased to up to twenty-four months upon the achievement of specified performance milestones. Following the interest-only period, the Company will make equal monthly payments of principal plus interest until the maturity date, when all remaining principal outstanding and accrued interest must be paid. If the Company prepays the Avenue Loan, it will be required to pay (a) a prepayment fee of 3% if the Avenue Loan is prepaid during the interest-only period; and (b) a prepayment fee of 1% if the Avenue Loan is prepaid after the interest-only period. The Company must make an incremental final payment equal to 4.25% of the aggregate funding.

The Company paid an aggregate commitment fee of $150,000 at closing. Upon funding a second tranche of the Avenue Loan, the Lender will earn a 1.0% fee on the $5.0 million of incremental committed capital, for a total commitment fee of $0.2 million.

The Avenue Loan Agreement requires the Company to make and maintain representations and warranties and other agreements that are customary in loan agreements of this type. The Avenue Loan Agreement also contains customary events of default, including

non-payment

of principal or interest, violations of covenants, bankruptcy and material judgments.

The Company determined that the embedded conversion option associated with the Avenue Loan was not required to be bifurcated. The Company determined that the Avenue Warrant met the criteria to be equity-classified. The $0.6 million value of the final payment was treated as original issue discount. The $1.2 million relative fair value of the Avenue Warrant was credited to Additional Paid in Capital while it was debited as debt discount. Of the $563,000 of cash issuance costs, $519,000 was allocated to the Avenue Loan and was recorded as debit discount, while $44,000 was allocated to the Avenue Warrant and was debited to Additional Paid in Capital. Of the $2.3 million of aggregate debt discount, $1.9 million was allocated to the

non-convertible

portion of the Avenue Loan, while $418,000 was allocated to the convertible portion of the Avenue Loan. Aggregate debt discount amortization of $0.2 million was recorded during the three months ended March 31, 2022, including $159,000 related to the

non-convertible

portion of the Avenue Loan and $35,000 related to the convertible portion of the Avenue Loan. The Company also determined that the convertible portion of the Avenue Loan did not include a beneficial conversion feature, because the effective conversion price exceeded the commitment date market price of the Company’s common stock. Interest expense incurred was $0.4 million for the three months ended March 31, 2022.

The Avenue Warrant was valued at issuance at $1.3 million using the Black-Scholes option pricing method using the following assumptions:


	August 6, 2021
Contractual term (years)		5.07
Expected volatility		187.0	%
Risk-free interest rate		0.77	%
Expected dividends		0.00	%

Table of Contents

Convertible Notes Payable

The Company has $2.0 million of principal outstanding related to Senior Secured Promissory Notes (the “Rosalind Notes”) which bear interest at 8% per annum. Pursuant to their original terms, the Rosalind Notes were convertible into Series E Preferred Stock at a price of $1,500 per share and were to mature on July 16, 2021

Interest expense was $40 for the three months ended March 31, 2022 and 2021, respectively.

On August 6, 2021, the Company executed an agreement to amend the Rosalind Notes to (a) reduce the conversion price to $1,198 per share of the Company’s Series E Convertible Preferred Stock; and (b) extend the maturity date to October 30, 2024.

In addition, in order to induce Avenue. to provide the Avenue Loan described above, the holders of the Rosalind Notes agreed to subordinate (a) all of the Company’s indebtedness and obligations to the holders; and (b) all of the holders’ security interest, to the Avenue Loan and Avenue’s security interest in the Company’s property.

(9)	Stockholders’ Equity

Authorized Shares

The Company is authorized to issue 40,000,000 shares of common stock, $0.01 par value, and

10,000,000 shares of preferred stock, $0.01 par value. To date, the Company has designated the following preferred stock: Series A (4,200 shares), Series B (2,360 shares), Series C (590 shares), Series D (10,000 shares), Series E (40,000 shares) and Series

E-1

(12,960 shares).

Preferred Stock

As of March 30, 2022, there were an aggregate of 11,707 shares of Series E and Series E-1 Convertible Preferred Stock outstanding.

Omnibus Equity Incentive Plan

On September 30, 2020, the Company’s 2020 Omnibus Equity Incentive Plan (the “2020 Plan”) was adopted by the Company’s Board of Directors. On November 23, 2020, the Company’s stockholders approved the 2020 Plan. The 2020 Plan will continue in effect until the tenth anniversary of the date of its adoption by the Board or until earlier terminated by the Board. The 2020 Plan is administered by the Board of Directors or a committee designated by the Board of Directors. The 2020 Plan provides for the grant of incentive stock options,

non-qualified

stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards, as well as other stock-based awards or cash awards that are deemed to be consistent with the purposes of the plan to Company employees, directors and consultants. As of March 31, 2022, there are 2,475,000 shares of common stock reserved under the 2020 Plan, of which 737,957 remained available to be issued.

Employee Stock Purchase Plan

In August 2021, the Company’s Board of Directors, with shareholder approval in May 2022, adopted the Employee Stock Purchase Plan (ESPP). The Company ESPP’s plan provides for a maximum of 260,295 shares of common stock to

be purchased by

participating employees. Employees who elect to participate in the Company’s ESPP will be able to purchase common stock at the lower of 85% of the fair market value of common stock on the first or last day of the applicable six-month offering period.

Equity Offerings and Placements

At-the-Market

Offering

On August 18, 2020, the Company entered into a sales agreement with Cantor Fitzgerald & Co. (“Cantor Fitzgerald”), pursuant to which the Company may offer and sell, from time to time, through Cantor Fitzgerald, as sales agent or principal, shares of the Company’s common stock, (the “Placement Shares”), having an aggregate offering price of up to $10.0 million (the “ATM Offering”). The Company has no obligation to sell any Placement Shares under the sales agreement. Subject to the terms and conditions of the sales agreement, Cantor Fitzgerald is required to use commercially reasonable efforts, consistent with its normal trading and sales practices, applicable state and federal law, rules and regulations and the rules of the Nasdaq Stock Market, to sell Placement Shares from time to time based upon the Company’s instructions, including any price, time or size limits specified by the Company. The Company will pay Cantor Fitzgerald a commission of 3.0% of the aggregate gross proceeds from each sale of Placement Shares, reimburse Cantor Fitzgerald’s legal fees and disbursements up to $50,000 and provide Cantor Fitzgerald with customary indemnification and contribution rights. The sales agreement may be terminated by Cantor Fitzgerald or the Company upon notice to the other party as provided in the sales agreement, or by Cantor Fitzgerald at any time in certain circumstances, including the occurrence of a material and adverse change in the Company’s business or financial condition that makes it impractical or inadvisable to market the Placement Shares or to enforce contracts for the sale of the Placement Shares.

Table of Contents

In connection with the ATM Offering, in consideration for a fee equal to 1.05% of the gross sales price per share sold in the ATM Offering, ROTH Capital Advisors, LLC (“Roth”) waived, solely with respect to the ATM Offering, (i) Roth’s right, pursuant to certain engagement letters dated August 14, 2019 and January 13, 2020 between Roth and the Company, to act as placement agent or underwriter with respect to offerings of the Company’s securities and to receive a minimum of 35% of the fees paid to the agents or underwriters for such offerings and (ii) the

lock-up

provision included in a certain underwriting agreement dated May 1, 2020 between Roth and the Company requiring the prior written consent of Roth for any offer or sale of the Company’s common stock by the Company during the

90-day

period following the date of such underwriting agreement.

There were no shares sold during the three months ended March 31, 2022.

Stock Options

The Company values stock options using the Black-Scholes option pricing model and used the following assumptions during the reporting periods:


	Three months ended March 31,
	2022			2021
Expected terms (years)		5.46 - 6.46		N/A
Expected volatility		174.81% - 177.09	%	N/A
Risk-free interest rate		1.75% - 1.90	%	N/A
Expected dividends		0.00	%	N/A

The weighted average estimated fair value of the stock options granted during the three months ended March 31, 2022 was approximately $6.86 per share.

Table of Contents

The following is a summary of stock option activity for the three months ended March 31, 2022:


	Number of Option			Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Outstanding at January 1, 2022		1,732,460		$	11.69
Granted		549,333			7.10
Expired		(6,650	)		10.88
Cancelled/Forfeited		(37,040	)		10.42

Outstanding at March 31, 2022		2,238,103		$	10.60		9.2	$	—

Exercisable at March 31, 2022		766,619		$	11.83		8.7	$	—

The following table summarizes information for stock option shares outstanding and exercisable at March 31, 2022:


			Options Exercisable
Range of Exercise Prices	Outstanding Number of Options		Weighted Average Remaining Option Term (in years)		Number of Options
$6.61 - $9.99		825,256		9.2		110,389
$10.00 - $14.99		1,280,348		8.7		592,317
$15.00 - $24.99		132,000		8.5		63,414
$25 +		499		6.8		499

		2,238,103		8.7		766,619

The following is a summary of share-based compensation expense in the statement of operations for the three months ended March 31, 2022 (in thousands):


	Three months ended March 31,
	2022		2021
Selling, general and administrative	$	919	$	1,466
Research and development		503		630
Cost of goods sold		52		52

Total	$	1,474	$	2,148

At March 31, 2022, there was $9.2

million of aggregate unrecognized compensation expense related employee and board stock option grants. The cost is expected to be recognized over a weighted average period of 3 years.

Warrants

The following is a summary of warrant activity for the three months ended March 31, 2022:


	Warrants		Weighted Average Exercise Price		Weighted Average Remaining Life (in years)
Outstanding at January 1, 2022		3,894,498	$	9.27
Warrants issued		—		—
Warrants exercised		—		—
Warrants expired		—		—

Outstanding at March 31, 2022		3,894,498	$	9.27		3.0

Exercisable at March 31, 2022		3,894,498	$	9.27		3.0

Table of Contents

The following table presents information related to stock warrants at March 31, 2022


			Warrants Exercisable
Range of Exercise Prices	Outstanding Number of Warrants		Weighted Average Remaining Warrant Term (in years)		Number of Warrants
$0.01		283,755		3.7		283,755
$10.00		3,610,743		2.9		3,610,743

		3,894,498		3.0		3,894,498

(10)	Net Loss per Common Share

Basic net loss per share is determined by dividing net loss by the weighted average shares of common stock outstanding during the period, without consideration of potentially dilutive securities, except for those shares that are issuable for little or no cash consideration. Diluted net loss per share is determined by dividing net loss by diluted weighted average shares outstanding. Diluted weighted average shares reflects the dilutive effect, if any, of potentially dilutive common shares, such as stock options and warrants calculated using the treasury stock method. In periods with reported net operating losses, all common stock options and warrants are generally deemed anti-dilutive such that basic net loss per share and diluted net loss per share are equal.

The following potentially dilutive securities were excluded from the computation of earnings per share as of March 31, 2022 and 2021 because their effects would be anti-dilutive:


	March 31,
	2022		2021
Stock options		2,238,103		1,078,499
Common stock warrants - equity		3,894,498		3,994,107
Assumed conversion of Series E and Series E-1 Preferred Stock		1,135,721		2,048,101
Assumed conversion of convertible notes		488,031		146,288

Total		7,756,353		7,266,995

At March 31, 2022, the Company had 283,755

pre-funded

warrants outstanding. The following table provides a reconciliation of the weighted average shares outstanding calculation for the three months ended March 31, 2022 and 2021:


	Three months ended March 31,
	2022		2021
Weighted average shares issued		7,906,728		6,125,922
Weighted average pre-funded warrants		283,755		371,000

Weighted average shares outstanding		8,190,483		6,496,922

(11)	Income Taxes

As discussed in Note 14 Income Taxes of the Company’s Annual Report, the Company has a valuation allowance against the full amount of its net deferred tax assets. The Company currently provides a valuation allowance against deferred tax assets when it is more likely than not that some portion or all of its deferred tax assets will not be realized. The Company has not recognized any unrecognized tax benefits in its balance sheet.

The Company is subject to income tax in the U.S., as well as various state and international jurisdictions. The federal and state tax authorities can generally reduce a net operating loss (but not create taxable income) for a period outside the statute of limitations in order to determine the correct amount of net operating loss which may be allowed as a deduction against income for a period within the statute of limitations. Additional information regarding the statutes of limitations can be found in Note 14 Income Taxes of the Company’s Annual Report.

Table of Contents

(

)

Commitments and Contingencies

Litigation, Claims and Assessments

medac Matter

In April 2021, the Company issued an invoice for €1

million

(which currently converts to approximately $1.2

million)

to medac GmbH, a privately held, multi-national pharmaceutical company based in Germany (“medac”), the Company’s EU product distribution partner, for a milestone payment due under the License, Supply and Marketing Agreement (the “License Agreement”) dated December 10, 2018, between the Company and medac. Pursuant to the License Agreement, a milestone is due upon achieving positive efficacy in the FOCUS

rial as defined by the FOCUS

rial

protocol. Per the

rial

protocol and associated Statistical Analysis Plan, positive efficacy is based on whether the Objective Response Rate (ORR) exceeds a pre

specified threshold. A preliminary analysis of the FOCUS

rial data based on 87% of enrolled patients was released on March 31, 2021, and subsequently

presented

at the American Society of Clinical Oncology (ASCO) Annual Meeting held virtually from the 4th through the 8th of June 2021. Per that analysis, the ORR exceeded the pre

specified threshold. While the final ORR is not yet known, given the magnitude by which the ORR exceeded the pre

specified endpoint and the small number of patients yet to be assessed, the final ORR will be greater than the pre

specified endpoint regardless of the responder status of the remaining patients. medac disagrees that the milestone is due and claims that a full clinical study report is required in addition to the existing ORR analysis. medac has not disputed the accuracy of the ORR analysis or underlying data, but simply asserts that a full clinical study report is required prior to payment. While the Company disagrees with this interpretation, since medac has stated

it doe

not intend to pay the invoice at this time, under revenue recognition criteria set out in ASC 606, the Company cannot recognize the revenue.

On October 12, 2021, the Company notified medac in writing that it was terminating the License Agreement due to medac’s nonpayment of the milestone payment due under the License Agreement, with the effective date of termination of the License Agreement being April 12, 2022. medac disputed having an obligation to make a milestone payment under the Agreement and demanded withdrawal of the termination notice. The Company declined to withdraw the termination notice and, on December 16, 2021, the Company initiated an arbitration proceeding pursuant to the dispute resolution provisions of the License Agreement.

On December 30, 2021, the Company received a letter from medac stating that, due to its failure to withdraw the termination notice, medac was terminating the License Agreement with immediate effect. In the letter, medac reserved its rights in full, including a purported claim for damages for wrongful termination. In a separate letter, medac agreed to an orderly transition through February 28, 2022 in order to minimize the impact of any termination on patients and physicians. The Company agreed to purchase inventory held at medac in

March 2022 for approximately

$0.2 million.

The arbitration proceeding is moving forward with the parties agreeing to stay the arbitration for a finite period to pursue settlement

discussions.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of the financial condition and results of operations of Delcath Systems, Inc. (“Delcath” or the “Company”) should be read in conjunction with the unaudited interim condensed consolidated financial statements and notes thereto contained in Item 1 of Part I of this Quarterly Report on Form

10-Q

and the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form

10-K

for the fiscal year ended December 31, 2021 to provide an understanding of its results of operations, financial condition and cash flows.

All references in this Quarterly Report to “we,” “our,” “us” and the “Company” refer to Delcath Systems, Inc., and its subsidiaries unless the context indicates otherwise.

Disclosure Regarding Forward-Looking Statements

This Quarterly Report on Form

10-Q

contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 with respect to our business, financial condition, liquidity, and results of operations. Words such as “anticipates,” “expects,” “intends,” “plans,” “predicts,” “believes,” “seeks,” “estimates,” “could,” “would,” “will,” “may,” “can,” “continue,” “potential,” “should,” and the negative of these terms or other comparable terminology often identify forward-looking statements. Statements in this Quarterly Report on Form

10-Q

that are not historical facts are hereby identified as “forward-looking statements” for the purpose of the safe harbor provided by Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from the results contemplated by the forward-looking statements, including the risks discussed in Item 3 “Quantitative and Qualitative Disclosures About Market Risk,” and the risks discussed in our Annual Report on Form

10-K

for the fiscal year ended December 31, 2021 in Item 1A under “Risk Factors” and the risks detailed from time to time in our future reports filed with the Securities and Exchange Commission (the “SEC”). These forward-looking statements include, but are not limited to, statements about:

•

our estimates regarding sufficiency of our cash resources, anticipated capital requirements and our need for additional financing;

•

the commencement of future clinical trials and the results and timing of those clinical trials;

•

our ability to successfully commercialize CHEMOSAT and HEPZATO, generate revenue and successfully obtain reimbursement for the procedure and system;

•

the progress and results of our research and development programs;

•

submission and timing of applications for regulatory approval and approval thereof;

•

our ability to successfully source certain components of CHEMOSAT and HEPZATO and enter into supplier contracts;

•

our ability to successfully manufacture CHEMOSAT and HEPZATO;

•

our ability to successfully negotiate and enter into agreements with distribution, strategic and corporate partners; and

•

our estimates of potential market opportunities and our ability to successfully realize these opportunities.

Many of the important factors that will determine these results are beyond our ability to control or predict. You are cautioned not to put undue reliance on any forward-looking statements, which speak only as of the date of this Quarterly Report on Form

10-Q.

Except as otherwise required by law, we do not assume any obligation to publicly update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this Quarterly Report on Form

10-Q

or to reflect the occurrence of unanticipated events.

Company Overview

We are an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our lead product candidate, the HEPZATO

™

KIT (melphalan hydrochloride for injection/hepatic delivery system), or HEPZATO

™

, is a drug/device combination product designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. HEPZATO has not been approved for sale in the United States. In Europe, the hepatic delivery system is a stand-alone medical device having the same device components as HEZPATO, but without the melphalan hydrochloride, and is approved for sale under the trade name CHEMOSAT

Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used at major medical centers to treat a wide range of cancers of the liver.

In the United States, HEPZATO is considered a combination drug and device product and is regulated as a drug by the United States Food and Drug Administration, or the FDA. Primary jurisdiction for regulation of HEPZATO has been assigned to the FDA’s Center for Drug Evaluation and Research. The FDA has granted Delcath six orphan drug designations (five for melphalan in the treatment of patients with ocular (uveal) melanoma, cutaneous melanoma, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and neuroendocrine tumors) and one for doxorubicin in the treatment of patients with hepatocellular carcinoma).

Table of Contents

Our most advanced development program is the treatment of ocular melanoma liver metastases, or mOM, a type of primary liver cancer. We are currently reviewing the incidence, unmet need, available efficacy data and development requirements for a broad set of liver cancers in order to select a portfolio of indications which will maximize the value of the HEPZATO platform. We believe that the disease states we are investigating and intend to investigate are unmet medical needs that represent significant market opportunities.

In December 2021, the Company announced that the FOCUS Trial for HEPZATO met its pre-specified endpoint. Based on the FOCUS Trial results, the Company is preparing to submit a new drug application, or NDA, to the FDA for HEPZATO. The Company held a

pre-NDA

meeting with the FDA in April 2022 and is awaiting the official minutes from the meeting. Based on the feedback from FDA, the Company does not believe any additional

pre-clinical

or clinical studies are required to

re-file

the NDA. Due to vendor delays in delivering certain reports, we plan to submit an NDA to the FDA by the end of the third quarter of 2022.

Results of Operations for the three months ended March 31, 2022 (in thousands)

Three months ended March 31, 2022 Compared with Three months ended March 31, 2021

Revenue

We recorded approximately $378,000 in revenue for the three months ended March 31, 2022 compared to $388,000 for the three months ended March 31, 2021. The slight decrease in product revenue was primarily due to the transition to direct sales in Europe beginning in March 2022.

Cost of Goods Sold

For the three months ended March 31, 2022, we recorded cost of goods sold of approximately $33,000 compared to $112,000 for the three months ended March 31, 2021 which decrease was attributable to the transition of direct sales in Europe beginning in March 2022.

Research and Development Expenses

Research and development expenses are incurred for the development of HEPZATO and consist primarily of payroll and payments to contract research and development companies. To date, these costs are related to generating

pre-clinical

data and the cost of manufacturing HEPZATO for clinical trials and conducting clinical trials. For the three months ended March 31, 2022, research and development expenses increased to $4.2 million from $3.7 million in the prior year period. The increase of $0.5 million is primarily due to higher expenses in preparation of the

pre-NDA

meeting in April 2022 and preparation for the NDA submission by the third quarter of 2022.

Selling, General and Administrative Expenses

Selling, general and administrative expenses consist primarily of payroll, rent and professional services such as accounting and legal services. For the three months ended March 31, 2022 and 2021, selling, general and administrative expenses were $3.6 million and $3.3 million, respectively. The increase is primarily higher costs in the preparation for commercialization of HEPZATO in the United States early next year.

Other Income/Expense

Other income (expense) is primarily related to income or expense associated with financial instruments. For the three months ended March 31, 2022 and 2021, other expenses were $0.6 million and $20,000, respectively. The increase in other expenses is primarily due to the interest expense and amortization expense for the original issue discount on the debt financing transaction discussed below between the Company and its lender, Avenue Venture Opportunities Fund, L.P.

Liquidity and Capital Resources

At March 31, 2022, we had cash, cash equivalents and restricted cash totaling $20.5 million, During the three months ended March 31, 2022, the Company used $6.4 million of cash in our operating activities.

Our future results are subject to substantial risks and uncertainties. We have operated at a loss for our entire history and there can be no assurance that we will ever achieve consistent profitability. We have historically funded our operations through a combination of private placements and public offerings of our securities. We will need to raise additional capital under structures available to us, including debt and/or equity offerings.

Table of Contents

These circumstances raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. Our financial statements do not include adjustments to the amounts and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern. Our ability to continue as a going concern depends on our ability to raise additional capital through the sale of equity or debt securities to support our future operations.

Our capital commitments over the next twelve months include $6.1 million to satisfy March 31, 2022 accounts payable, accrued expenses and lease liabilities and $2.9 million of loan principal payments. Our capital commitments past the next twelve months include (a) $0.1 million of lease liabilities; (b) $9.8 million of loan principal payments; and (c) $5.0 million of convertible note principal payments, if the holders do not elect to convert the notes into equity.

We also expect to use cash, cash equivalents and investment proceeds to fund our clinical research and operating activities. Our future liquidity and capital requirements will depend on numerous factors, including the initiation and progress of clinical trials and research and product development programs; obtaining regulatory approvals and complying with applicable laws and regulations; the timing and effectiveness of product commercialization activities, including marketing arrangements; the timing and costs involved in preparing, filing, prosecuting, defending and enforcing intellectual property rights; and the effect of competing technological and market developments.

If we are unable to secure additional capital, we may be required to curtail our research and development initiatives and take additional measures to reduce costs in order to conserve our cash.

On August 6, 2021, the Company entered into a Loan and Security Agreement (the “Avenue Loan Agreement”) with Avenue Venture Opportunities Fund, L.P. (the “Lender,” or “Avenue”) for a term loan in an aggregate principal amount of up to $20.0 million (the “Avenue Loan”). The Avenue Loan bears interest at an annual rate equal to the greater of (a) the sum of 7.70% plus the prime rate as reported in The Wall Street Journal and (b) 10.95%. The interest rate at March 31, 2022 was 10.95%. The Avenue Loan is secured by all of the Company’s assets globally, including intellectual property. The Avenue Loan matures on August 1, 2024. Additional information regarding the Avenue Loan can be found in Note 8 to the Company’s unaudited interim consolidated financial statements contained in this Quarterly Report on Form

10-Q.

Critical Accounting Estimates

During the three months ended March 31, 2022, there were no material changes to critical accounting estimates as reported in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “Annual Report”), which was filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2022 and may also be found on the Company’s website (www.delcath.com).

Application of Critical Accounting Policies

Our financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America. During the three months ended March 31, 2022, there were no material changes to our critical accounting policies as reported in our Annual Report on Form

10-K

for the fiscal year ended December 31, 2021. A description of certain accounting policies that may have a significant impact on amounts reported in the financial statements is disclosed in Note 3 to the Company’s Annual Report for the fiscal year ended

December 31, 2021.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

The Company’s management, with the participation of our principal executive and principal accounting officer, evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Rule

13a-15(e)

and

15d-15(e)

of the Exchange Act). Based on that evaluation, our principal executive and principal accounting officer concluded that our disclosure controls and procedures as of March 31, 2022 (the end of the period covered by this Quarterly Report on Form

10-Q),

have been designed and are functioning effectively to provide reasonable assurance that the information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management, including our principal executive and principal accounting officer, as appropriate to allow timely decisions regarding required disclosure.

Table of Contents

Changes in Internal Controls over Financial Reporting

There was no change in our internal control over financial reporting (as defined in Rules

13a-15(f)

and

15d-15(f)

under the Exchange Act) that occurred during the quarter ended March 31, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II: OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, claims are made against the Company in the ordinary course of business, which could result in litigation. Claims and associated litigation are subject to inherent uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties, or injunctions prohibiting us from selling our products or engaging in other activities.

medac Matter

In April 2021, the Company issued an invoice for €1 million (which currently converts to approximately $1.2 million) to medac GmbH, a privately held, multi-national pharmaceutical company based in Germany (“medac”), the Company’s EU product distribution partner, for a milestone payment due under the License, Supply and Marketing Agreement (the “License Agreement”) dated December 10, 2018, between the Company and medac. Pursuant to the License Agreement, a milestone is due upon achieving positive efficacy in the FOCUS Trial as defined by the FOCUS Trial protocol. Per the trial protocol and associated Statistical Analysis Plan, positive efficacy is based on whether the Objective Response Rate (ORR) exceeds a pre-specified threshold. A preliminary analysis of the FOCUS Trial data based on 87% of enrolled patients was released on March 31, 2021, and subsequently presented at the American Society of Clinical Oncology (ASCO) Annual Meeting held virtually from the 4th through the 8th of June 2021. Per that analysis, the ORR exceeded the pre-specified threshold. While the final ORR is not yet known, given the magnitude by which the ORR exceeded the pre-specified endpoint and the small number of patients yet to be assessed, the final ORR will be greater than the pre-specified endpoint regardless of the responder status of the remaining patients. medac disagrees that the milestone is due and claims that a full clinical study report is required in addition to the existing ORR analysis. medac has not disputed the accuracy of the ORR analysis or underlying data, but simply asserts that a full clinical study report is required prior to payment. While the Company disagrees with this interpretation, since medac has stated they do not intend to pay the invoice at this time, under revenue recognition criteria set out in ASC 606, the Company did not recognize the revenue.

On December 30, 2021, the Company received a letter from medac stating that, due to its failure to withdraw the termination notice, medac was terminating the License Agreement with immediate effect. In the letter, medac reserved its rights in full, including a purported claim for damages for wrongful termination. In a separate letter, medac agreed to orderly transition through February 28, 2022 in order to minimize the impact of any termination on patients and physicians. The Company agreed to purchase inventory held at medac in March 2022 for approximately $0.2 million. The arbitration proceeding is moving forward with the parties agreeing to stay the arbitration for a finite period to pursue settlement discussions.

Table of Contents

Item 6. Exhibits


Exhibit No.		Description

3.1		Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement on Form S-1/A filed September 25, 2019).

3.2		Amendment to the Amended and Restated Certificate of Incorporation of the Company dated October 17, 2019 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on October 23, 2019).

3.3		Certificate of Correction to Amendment to the Amended and Restated Certificate of Incorporation of the Company dated October 22, 2019 (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed on October 23, 2019).

3.4		Amendment to the Amended and Restated Certificate of Incorporation of the Company, effective December 24, 2019 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on December 30, 2019).

3.5		Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company, dated November 23, 2020 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on November 24, 2020).

3.6		Amended and Restated By-Laws of the Company (incorporated by reference to Exhibit 3.2 to Amendment No. 1 to Company’s Registration Statement on Form SB-2).

31.1		Certification by Chief Executive Officer Pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

31.2		Certification by Principal Accounting Officer Pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

32.1		Certification by Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**

32.2		Certification by Principal Accounting Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**

101.INS		XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

101.SCH		Inline XBRL Taxonomy Extension Schema Document

101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document

104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

*	Filed herewith.

This exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any filing, except to the extent the Company specifically incorporates it by reference.

Table of Contents

DELCATH SYSTEMS, INC.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


						DELCATH SYSTEMS, INC.

May 11, 2022						/s/ Gerard Michel
						Gerard Michel
						Chief Executive Officer (Principal Executive Officer)

May 11, 2022						/s/ Anthony Dias
						Anthony Dias
						Principal Accounting Officer

EX-31.1 2 d290302dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

DELCATH SYSTEMS, INC.

CERTIFICATION

PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF THE SECURITIES

EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

I, Gerard Michel, certify that:

1)	I have reviewed this Quarterly Report on Form 10-Q of Delcath Systems, Inc.;

2)	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3)	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5)	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

EX-31.2 3 d290302dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

DELCATH SYSTEMS, INC.

CERTIFICATION

PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF THE SECURITIES

EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

I, Anthony Dias, certify that:

1)	I have reviewed this Quarterly Report on Form 10-Q of Delcath Systems, Inc.;

2)	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3)	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(a)

(b)

(c)

(d)

5)	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

EX-32.1 4 d290302dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

DELCATH SYSTEMS, INC.

CERTIFICATION

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of DELCATH SYSTEMS, INC. (the “Company”) on Form 10-Q for the period ended March 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Gerard Michel, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

EX-32.2 5 d290302dex322.htm EX-32.2 EX-32.2

Exhibit 32.2

DELCATH SYSTEMS, INC.

CERTIFICATION

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of DELCATH SYSTEMS, INC. (the “Company”) on Form 10-Q for the period ended March 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Anthony Dias, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1) The report fully complies with the requirements of section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the report fairly presents, in all material respects, the financial condition and results of operations of the Company.

EX-101.SCH 6 dcth-20220331.xsd XBRL TAXONOMY EXTENSION SCHEMA 1001 - Document - Cover Page link:presentationLink link:definitionLink link:calculationLink 1002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:definitionLink link:calculationLink 1005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) link:presentationLink link:definitionLink link:calculationLink 1006 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 1007 - Disclosure - General link:presentationLink link:definitionLink link:calculationLink 1008 - Disclosure - Cash, Cash Equivalents and Restricted Cash link:presentationLink link:definitionLink link:calculationLink 1009 - Disclosure - Inventories link:presentationLink link:definitionLink link:calculationLink 1010 - Disclosure - Prepaid Expenses and Other Current Assets link:presentationLink link:definitionLink link:calculationLink 1011 - Disclosure - Property, Plant, and Equipment link:presentationLink link:definitionLink link:calculationLink 1012 - Disclosure - Accrued Expenses link:presentationLink link:definitionLink link:calculationLink 1013 - Disclosure - Leases link:presentationLink link:definitionLink link:calculationLink 1014 - Disclosure - Loans and Convertible Notes Payable link:presentationLink link:definitionLink link:calculationLink 1015 - Disclosure - Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 1016 - Disclosure - Net Loss per Common Share link:presentationLink link:definitionLink link:calculationLink 1017 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 1018 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 1019 - Disclosure - General (Policies) link:presentationLink link:definitionLink link:calculationLink 1020 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Tables) link:presentationLink link:definitionLink link:calculationLink 1021 - Disclosure - Inventories (Tables) link:presentationLink link:definitionLink link:calculationLink 1022 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) link:presentationLink link:definitionLink link:calculationLink 1023 - Disclosure - Property, Plant, and Equipment (Tables) link:presentationLink link:definitionLink link:calculationLink 1024 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:definitionLink link:calculationLink 1025 - Disclosure - Leases (Tables) link:presentationLink link:definitionLink link:calculationLink 1026 - Disclosure - Loans and Convertible Notes Payable (Tables) link:presentationLink link:definitionLink link:calculationLink 1027 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:definitionLink link:calculationLink 1028 - Disclosure - Net Loss per Common Share (Tables) link:presentationLink link:definitionLink link:calculationLink 1029 - Disclosure - General - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink 1030 - Disclosure - Cash, Cash Equivalents and Restricted Cash - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details) link:presentationLink link:definitionLink link:calculationLink 1031 - Disclosure - Inventories - Schedule of Inventories (Details) link:presentationLink link:definitionLink link:calculationLink 1032 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:definitionLink link:calculationLink 1033 - Disclosure - Property, Plant, and Equipment - Components of Property, Plant, and Equipment (Details) link:presentationLink link:definitionLink link:calculationLink 1034 - Disclosure - Property, Plant, and Equipment - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink 1035 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details) link:presentationLink link:definitionLink link:calculationLink 1036 - Disclosure - Leases - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink 1037 - Disclosure - Leases - Summary of Operating and Financing Leases (Details) link:presentationLink link:definitionLink link:calculationLink 1038 - Disclosure - Leases - Schedule of Remaining Maturity of Operating Leases Excluding Short-Term Leases (Details) link:presentationLink link:definitionLink link:calculationLink 1039 - Disclosure - Loans and Convertible Notes Payable - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink 1040 - Disclosure - Loans and Convertible Notes Payable - Summary of Loans and Convertible Notes Payable (Details) link:presentationLink link:definitionLink link:calculationLink 1041 - Disclosure - Loans and Convertible Notes Payable - Summary of Loans and Convertible Notes Payable (Details) (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1042 - Disclosure - Loans and Convertible Notes Payable - Summary of Remaining Maturities of Company's Loan and Convertible Note Payables (Details) link:presentationLink link:definitionLink link:calculationLink 1043 - Disclosure - Loans and Convertible Notes Payable - Summary of Avenue Warrant Valued Using the Black-Scholes Option Pricing Method (Details) link:presentationLink link:definitionLink link:calculationLink 1044 - Disclosure - Stockholders' Equity - Preferred Stock Issuances - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink 1045 - Disclosure - Stockholders' Equity - Equity Incentive Plan - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink 1046 - Disclosure - Stockholders' Equity - Summary of Employee Stock Purchase Plan (Details) link:presentationLink link:definitionLink link:calculationLink 1047 - Disclosure - Stockholders' Equity - At-the-Market Offering - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink 1048 - Disclosure - Stockholders' Equity - Stock Incentive Plans - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink 1049 - Disclosure - Stockholders' Equity - Schedule of Assumptions to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model (Details) link:presentationLink link:definitionLink link:calculationLink 1050 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Details) link:presentationLink link:definitionLink link:calculationLink 1051 - Disclosure - Stockholders' Equity - Summary of Stock Option Shares Outstanding and Exercisable (Details) link:presentationLink link:definitionLink link:calculationLink 1052 - Disclosure - Stockholders' Equity - Summary of Recognized Share-based Compensation Cost (Details) link:presentationLink link:definitionLink link:calculationLink 1053 - Disclosure - Stockholders' Equity - Summary of Warrant Activity (Details) link:presentationLink link:definitionLink link:calculationLink 1054 - Disclosure - Stockholders' Equity - Summary of Warrants Outstanding and Exercisable (Details) link:presentationLink link:definitionLink link:calculationLink 1055 - Disclosure - Net Loss per Common Share - Anti-Dilutive Securities Excluded from Computation of Earnings Per Share (Details) link:presentationLink link:definitionLink link:calculationLink 1056 - Disclosure - Net Loss per Common Share - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink 1057 - Disclosure - Net Loss per Common Share - Summary of Reconciliation of Weighted Average Shares Outstanding Calculation (Details) link:presentationLink link:definitionLink link:calculationLink 1058 - Disclosure - Commitments and contingencies - Additional Information (Details) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 dcth-20220331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 dcth-20220331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 dcth-20220331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Address, Address Line Two Entity Address, Address Line Two Entity Current Reporting Status Entity Current Reporting Status Entity Filer Category Entity Filer Category Entity Interactive Data Current Entity Interactive Data Current Entity Address, Address Line One Entity Address, Address Line One Document Transition Report Document Transition Report Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Entity Shell Company Entity Shell Company Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Document Quarterly Report Statement of Financial Position [Abstract] Assets [Abstract] Assets Assets, Current [Abstract] Current assets Assets, Current Total current assets Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Total prepaid expenses and other current assets Inventory, Net Inventories Total inventories Inventory Accounts Receivable, after Allowance for Credit Loss, Current Accounts receivable, net Restricted Cash and Cash Equivalents, Current Restricted cash Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Assets Total assets Operating Lease, Right-of-Use Asset Right-of-use assets Property, Plant and Equipment, Net Property, plant and equipment, net Property, plant, and equipment, net Liabilities and Equity Total liabilities and stockholders' equity Liabilities, Current [Abstract] Current liabilities Accounts Payable, Current Accounts payable Operating Lease, Liability, Current Lease liabilities, current Deferred Revenue, Current Deferred revenue, current Loans Payable, Noncurrent Loan payable, non-current Total - Loans Payable, Non-Current, Net Accrued Liabilities, Current Accrued expenses Total accrued expenses Liabilities, Current Total current liabilities Operating Lease, Liability, Noncurrent Lease liabilities, non-current Convertible Notes Payable, Noncurrent Convertible notes payable, non-current Loans Payable, Current Loan payable, current Less Current Portion, Net Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity Retained Earnings (Accumulated Deficit) Accumulated deficit Retained Earnings Accumulated Deficit Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income Stockholders' Equity Attributable to Parent Total stockholders' equity Balance Balance Additional Paid in Capital Additional paid-in capital Common Stock, Value, Issued Common stock, $.01 par value; 40,000,000 shares authorized; 7,906,728 shares issued and outstanding at March 31, 2022 and December 31, 2021 Preferred Stock, Value, Issued Preferred stock, $.01 par value; 10,000,000 shares authorized; 11,357 shares issued and outstanding at March 31, 2022 and December 31, 2021 Commitments and Contingencies Commitments and contingencies (Note 13) Liabilities Total liabilities Common Stock, Shares, Issued Common stock, shares issued (in shares) Common Stock, Shares Authorized Common stock, shares authorized (in shares) Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Preferred Stock, Shares Outstanding Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Issued Preferred stock, shares issued (in shares) Preferred Stock, Shares Authorized Preferred stock, shares authorized (in shares) Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Common Stock, Shares, Outstanding Common stock, shares outstanding (in shares) Income Statement [Abstract] Statement [Table] Statement [Table] Statement [Line Items] Statement [Line Items] Interest Income (Expense), Nonoperating, Net Interest expense, net Earnings Per Share, Basic and Diluted [Abstract] Common share data: Earnings Per Share, Basic and Diluted Basic and diluted loss per common share Weighted Average Number of Shares Outstanding, Basic and Diluted Weighted average number of basic and diluted shares outstanding Weighted average shares outstanding Other Comprehensive Income (Loss), Net of Tax [Abstract] Other comprehensive income: Comprehensive Income (Loss), Net of Tax, Attributable to Parent Total other comprehensive loss Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Foreign currency translation adjustments Net Income (Loss) Attributable to Parent Net loss Net loss Other Nonoperating Income (Expense) Other income (expense), net Operating Income (Loss) Operating loss Revenue from Contract with Customer, Excluding Assessed Tax Revenue Operating Expenses [Abstract] Operating expenses: Operating Expenses Total operating expenses Selling, General and Administrative Expense Selling, general and administrative expenses Research and Development Expense Research and development expenses Gross Profit Gross profit Cost of Revenue Cost of goods sold Product and Service [Axis] Product and Service Product and Service [Domain] Product and Service Product [Member] Product Revenue [Member] Product and Service, Other [Member] Other Revenue [Member] Statement of Stockholders' Equity [Abstract] Equity Components [Axis] Equity Components Equity Component [Domain] Equity Component Common Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Additional Paid in Capital [Member] Preferred Stock [Member] Preferred Stock [Member] AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income (Loss) [Member] Retained Earnings [Member] Accumulated Deficit [Member] Class of Warrant or Right [Axis] Class of Warrant or Right Class of Warrant or Right [Domain] Class of Warrant or Right Class of Stock [Axis] Class of Stock Class of Stock [Domain] Class of Stock Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Total comprehensive income Shares, Outstanding Balance (in shares) Balance (in shares) Stock Issued During Period Value Exercise Of Warrants For Common Stock Exercise of warrants into common stock Stock issued during period value exercise of warrants for common stock Stock Issued During Period Value Exercise Of Warrants For Common Stock Shares Exercise of warrants into common stock (in shares) Stock issued during period value exercise of warrants for common stock shares Stock Issued During Period, Shares, Conversion of Convertible Securities Conversion of Preferred stock into common stock (in shares) Stock Issued During Period, Shares, Issued for Services Shares settled for services (in shares) Stock Issued During Period, Value, Issued for Services Shares settled for services APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition Compensation expense for issuance of stock options Statement of Cash Flows [Abstract] Supplemental Cash Flow Information [Abstract] Supplemental Disclosure of Cash Flow Information: Interest Paid, Excluding Capitalized Interest, Operating Activities Interest expense Noncash Investing and Financing Items [Abstract] Supplemental Disclosure of Non-Cash Investing and Financing Activities: Shares settled for services Issuance of restricted stock for accrued fees due to a former board member Shares settled for services. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations [Abstract] Total Cash: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations End of period Beginning of period Total Total cash, cash equivalents and restricted cash shown in the statements of cash flows Cash Cash Restricted Cash Restricted Cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net decrease in total cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Foreign currency effects on cash Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities: Proceeds from Warrant Exercises Net proceeds from the exercise of warrants Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Payments to Acquire Property, Plant, and Equipment Purchase of property, plant and equipment Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Increase (Decrease) in Operating Capital [Abstract] Changes in assets and liabilities: Increase Decrease In Operating Lease Liabilities Decrease in lease liabilities Increase decrease in operating lease liabilities. Increase (Decrease) in Contract with Customer, Liability Decrease in deferred revenue Increase (Decrease) in Accounts Payable and Accrued Liabilities Increase in accounts payable and accrued expenses Increase (Decrease) in Inventories Increase in inventories Increase (Decrease) in Accounts Receivable Increase in accounts receivable Increase (Decrease) in Prepaid Expense and Other Assets Decrease in prepaid expenses and other assets Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Stock Option Compensation Income Expense Stock option compensation expense Stock option compensation (income) expense. Amortization of Debt Issuance Costs and Discounts Amortization of debt discount Amortization Of Right Of Use Assets Non-cash lease expense Amortization of right of use assets. Paid-in-Kind Interest Interest expense accrued related to convertible notes Depreciation Depreciation expense Sale of Stock [Axis] Sale of Stock Sale of Stock [Domain] Sale of Stock Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] General Cash and Cash Equivalents [Abstract] Cash and Cash Equivalents Disclosure [Text Block] Cash, Cash Equivalents and Restricted Cash Inventory Disclosure [Abstract] Inventory Disclosure [Text Block] Inventories Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Prepaid Expenses And Other Current Assets [Text Block] Prepaid Expenses And Other Current Assets Prepaid expenses and other current assets. Property, Plant and Equipment [Abstract] Property, Plant and Equipment Disclosure [Text Block] Property, Plant, and Equipment Payables and Accruals [Abstract] Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Expenses Leases [Abstract] Lessee Operating And Finance Leases [Text Block] Leases Lessee operating and finance leases. Debt Disclosure [Abstract] Debt Disclosure [Text Block] Loans and Convertible Notes Payable Stockholders' Equity Note [Abstract] Stockholders' Equity Note Disclosure [Text Block] Stockholders' Equity Earnings Per Share [Abstract] Earnings Per Share [Text Block] Net Loss per Common Share Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] Income Taxes Commitments and Contingencies Disclosure [Abstract] Commitments Disclosure [Text Block] Commitments and Contingencies Accounting Policies [Abstract] New Accounting Pronouncements, Policy [Policy Text Block] Recently Adopted and Issued Accounting Pronouncements Liquidity And Going Concern Policy [Text Block] Liquidity and Going Concern Liquidity and going concern. Risk And Uncertainties Policy [Text Block] Risk and Uncertainties Risk and uncertainties. Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Restrictions on Cash and Cash Equivalents [Table Text Block] Schedule of Cash, Cash Equivalents, and Restricted Cash Schedule of Inventory, Current [Table Text Block] Schedule of inventories Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Prepaid Expenses and Other Current Assets Property, Plant and Equipment [Table Text Block] Components of property, plant and equipment Schedule of Accrued Liabilities [Table Text Block] Schedule of accrued expenses Lessee, Operating Lease, Liability, Maturity [Table Text Block] Schedule of Remaining Maturity of Operating Leases Excluding Short-Term Leases Schedule Of Operating And Financing Leases Table [Text Block] Summary of Operating and Financing Leases Schedule of operating and financing leases. Long-term Debt [Text Block] Summary of Loans and Convertible Notes Payable Schedule of Maturities of Long-term Debt [Table Text Block] Summary of Remaining Maturities of Company's Loan and Convertible Note Payables Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Summary of Avenue Warrant Valued Using the Black-Scholes Option Pricing Method Schedule Of Information Related To Stock Warrants Outstanding And Exercisable Table [Text Block] Schedule of Information Related to Stock Warrants Outstanding and Exercisable Schedule of Information Related to Stock Warrants Outstanding and Exercisable. Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Summary of Warrant Activity EX-101.PRE 10 dcth-20220331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT

Cover Page - shares	3 Months Ended
Cover Page - shares	Mar. 31, 2022	May 11, 2022
Cover [Abstract]
Entity Registrant Name	DELCATH SYSTEMS, INC.
Entity Central Index Key	0000872912
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Quarterly Report	true
Document Transition Report	false
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Incorporation, State or Country Code	DE
Entity Interactive Data Current	Yes
Entity File Number	001-16133
Entity Tax Identification Number	06-1245881
Entity Address, Address Line One	1633 Broadway
Entity Address, Address Line Two	Suite 22C
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10019
City Area Code	212
Local Phone Number	489-2100
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		7,906,728
Document Period End Date	Mar. 31, 2022
Document Fiscal Year Focus	2022
Trading Symbol	DCTH
Title of 12(b) Security	Common stock, $0.01 par value per share
Document Fiscal Period Focus	Q1
Document Type	10-Q
Amendment Flag	false
Security Exchange Name	NASDAQ

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 16,340	$ 22,802
Restricted cash	4,151	4,151
Accounts receivable, net	178	44
Inventories	2,011	1,412
Prepaid expenses and other current assets	2,704	2,743
Total current assets	25,384	31,152
Property, plant and equipment, net	1,406	1,348
Right-of-use assets	527	624
Total assets	27,317	33,124
Current liabilities
Accounts payable	1,243	638
Accrued expenses	4,495	4,109
Deferred revenue, current	0	170
Lease liabilities, current	404	416
Loan payable, current	2,520	621
Total current liabilities	8,662	5,954
Lease liabilities, non-current	122	207
Loan payable, non-current	8,633	10,372
Convertible notes payable, non-current	4,675	4,639
Total liabilities	22,092	21,172
Commitments and contingencies (Note 13)
Stockholders' equity
Preferred stock, $.01 par value; 10,000,000 shares authorized; 11,357 shares issued and outstanding at March 31, 2022 and December 31, 2021
Common stock, $.01 par value; 40,000,000 shares authorized; 7,906,728 shares issued and outstanding at March 31, 2022 and December 31, 2021	79	79
Additional paid-in capital	434,305	432,831
Accumulated deficit	(429,179)	(420,976)
Accumulated other comprehensive income	20	18
Total stockholders' equity	5,225	11,952
Total liabilities and stockholders' equity	$ 27,317	$ 33,124

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	11,357	11,357
Preferred stock, shares outstanding (in shares)	11,357	11,357
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	40,000,000	40,000,000
Common stock, shares issued (in shares)	7,906,728	7,906,728
Common stock, shares outstanding (in shares)	7,906,728	7,906,728

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cost of goods sold	$ (33)	$ (112)
Gross profit	345	276
Operating expenses:
Research and development expenses	4,240	3,707
Selling, general and administrative expenses	3,648	3,296
Total operating expenses	7,888	7,003
Operating loss	(7,543)	(6,727)
Interest expense, net	(645)	(41)
Other income (expense), net	(15)	21
Net loss	(8,203)	(6,747)
Other comprehensive income:
Foreign currency translation adjustments	2	94
Total other comprehensive loss	$ (8,201)	$ (6,653)
Common share data:
Basic and diluted loss per common share	$ (1.00)	$ (1.04)
Weighted average number of basic and diluted shares outstanding	8,190,483	6,496,922
Product Revenue [Member]
Revenue	$ 207	$ 261
Other Revenue [Member]
Revenue	$ 171	$ 127

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Common Stock [Member]	Preferred Stock [Member]	Additional Paid in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Balance at Dec. 31, 2020	$ 22,078	$ 60		$ 417,449	$ (395,327)	$ (104)
Balance (in shares) at Dec. 31, 2020		5,996,101	20,631
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Compensation expense for issuance of stock options	2,148			2,148
Shares settled for services	57			57
Shares settled for services (in shares)		2,636
Conversion of Preferred stock into common stock (in shares)		15,000	(150)
Exercise of warrants into common stock	2,376	$ 3		2,373
Exercise of warrants into common stock (in shares)		237,520
Net loss	(6,747)				(6,747)
Total comprehensive income	94					94
Balance at Mar. 31, 2021	20,006	$ 63		422,027	(402,074)	(10)
Balance (in shares) at Mar. 31, 2021		6,251,257	20,481
Balance at Dec. 31, 2021	11,952	$ 79		432,831	(420,976)	18
Balance (in shares) at Dec. 31, 2021		7,906,728	11,357
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Compensation expense for issuance of stock options	1,474			1,474
Net loss	(8,203)				(8,203)
Total comprehensive income	2					2
Balance at Mar. 31, 2022	$ 5,225	$ 79		$ 434,305	$ (429,179)	$ 20
Balance (in shares) at Mar. 31, 2022		7,906,728	11,357

XML 16 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net loss	$ (8,203)	$ (6,747)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock option compensation expense	1,474	2,148
Depreciation expense	31	39
Non-cash lease expense	97	155
Amortization of debt discount	194
Interest expense accrued related to convertible notes	40	39
Changes in assets and liabilities:
Decrease in prepaid expenses and other assets	39	301
Increase in accounts receivable	(134)	(18)
Increase in inventories	(599)	(254)
Increase in accounts payable and accrued expenses	953	164
Decrease in lease liabilities	(97)	(155)
Decrease in deferred revenue	(170)	(239)
Net cash used in operating activities	(6,375)	(4,567)
Cash flows from investing activities:
Purchase of property, plant and equipment	(89)	(9)
Net cash used in investing activities	(89)	(9)
Cash flows from financing activities:
Net proceeds from the exercise of warrants		2,376
Net cash provided by financing activities		2,376
Foreign currency effects on cash	2	94
Net decrease in total cash	(6,462)	(2,106)
Total Cash:
Beginning of period	26,953	28,756
End of period	20,491	26,650
Cash	16,340	26,600
Restricted Cash	4,151	50
Total	20,491	26,650
Supplemental Disclosure of Cash Flow Information:
Interest expense	$ 411	3
Supplemental Disclosure of Non-Cash Investing and Financing Activities:
Issuance of restricted stock for accrued fees due to a former board member		$ 57

XML 17 R7.htm IDEA: XBRL DOCUMENT

General

3 Months Ended

Mar. 31, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

General

(1)

General

10-K

Description of Business

The Company is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company’s lead product candidate, the HEPZATO

™

KIT (melphalan hydrochloride for injection/hepatic delivery system), or HEPZATO

™

Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used at major medical centers to treat a wide range of cancers of the liver.

follow-on

indications which will maximize the value of the HEPZATO platform.

pre-NDA

meeting with the FDA in April 2022 and is awaiting the official minutes from the meeting. Based on the feedback from the FDA, the Company does not believe any additional

pre-clinical

or clinical studies are required to

re-file

the NDA. Due to vendor delays in delivering certain reports, the Company plans to submit an NDA to the FDA by the end of the third quarter of 2022.

Risks and Uncertainties

Liquidity and Going Concern

Basis of Presentation

10-Q

and Article 10 of Regulation

S-X.

They include the accounts of all wholly owned subsidiaries and all significant inter-company accounts and transactions have been eliminated in consolidation.

10-K

Significant Accounting Policies

10-K

for the fiscal year ended December 31, 2021.

Recently Adopted Accounting Pronouncements

In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)

2020-06, “Accounting

for Convertible Instruments and Contracts in an Entity’s Own Equity.” ASU

2020-06

simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. ASU

2020-06

In October 2020, the FASB issued ASU

2020-10

On May 3, 2021, the FASB issued ASU

2021-04,

“Earnings Per Share” (Topic 260), “Debt—Modifications and Extinguishments” (Subtopic

470-50),

“Compensation—Stock Compensation” (Topic 718), and “Derivatives and Hedging—Contracts in Entity’s Own Equity” (Subtopic

815-40):

XML 18 R8.htm IDEA: XBRL DOCUMENT

Cash, Cash Equivalents and Restricted Cash

3 Months Ended

Mar. 31, 2022

Cash and Cash Equivalents [Abstract]

Cash, Cash Equivalents and Restricted Cash

(2)	Cash, Cash Equivalents and Restricted Cash

Cash and cash equivalents that are restricted as to withdrawal or use under the terms of certain contractual agreements are recorded in

Restricted Cash

on the balance sheets. Restricted cash does not include required minimum balances.

Cash, cash equivalents, and restricted cash balances were as follows (in thousands):


	March 31, 2022		December 31, 2021
Cash and cash equivalents	$	16,340	$	22,802
Restricted balance for loan agreement		4,000	$	4,000
Letters of credit		101		101
Security for credit cards		50		50

Total cash, cash equivalents and restricted cash shown in the statements of cash flows	$	20,491	$	26,953

Under the terms of a

sub-lease

agreement for office space at 1633 Broadway, New York, NY, as of March 31, 2022, the Company is required to maintain a letter of credit which will expire with the sublease in February 2023.

XML 19 R9.htm IDEA: XBRL DOCUMENT

Inventories

3 Months Ended

Mar. 31, 2022

Inventory Disclosure [Abstract]

Inventories

(3)	Inventories

Inventories consist of the following (in thousands):


	March 31, 2022		December 31, 2021
Raw materials	$	841	$	767
Work-in-process		881		645
Finished goods		289		—

Total inventories	$	2,011	$	1,412

XML 20 R10.htm IDEA: XBRL DOCUMENT

Prepaid Expenses and Other Current Assets

3 Months Ended

Mar. 31, 2022

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Prepaid Expenses And Other Current Assets

(4)	Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following (in thousands):


	March 31, 2022		December 31, 2021
Clinical trial expenses	$	1,630	$	1,630
Insurance premiums		645		890
Other		429		223

Total prepaid expenses and other current assets	$	2,704	$	2,743

XML 21 R11.htm IDEA: XBRL DOCUMENT

Property, Plant, and Equipment

3 Months Ended

Mar. 31, 2022

Property, Plant and Equipment [Abstract]

Property, Plant, and Equipment

(5)	Property, Plant, and Equipment

Property, plant, and equipment consist of the following (in thousands):


	March 31, 2022			December 31, 2021			Estimated Useful Life
Buildings and land	$	1,222		$	1,222			30 years- Buildings
Enterprise hardware and software		1,858			1,858			3 years
Leaseholds		1,788			1,796			Lesser of lease term or estimated useful life
Equipment		1,184			1,094			7 years
Furniture		202			203			5 years

Property, plant and equipment, gross		6,254			6,173
Accumulated depreciation		(4,848	)		(4,825	)

Property, plant and equipment, net	$	1,406		$	1,348

Depreciation expense for the three months ended March 31, 2022 was approximately $31,000 as compared to approximately $39,000 for the same period in 2021.

XML 22 R12.htm IDEA: XBRL DOCUMENT

Accrued Expenses

3 Months Ended

Mar. 31, 2022

Payables and Accruals [Abstract]

Accrued Expenses

(6)	Accrued Expenses

Accrued expenses consist of the following (in thousands):


	March 31, 2022		December 31, 2021
Clinical expenses	$	1,578	$	1,517
Compensation, excluding taxes		796		893
Short term financing		315		551
Professional fees		1,298		603
Interest on convertible note		433		393
Other		75		152

Total accrued expenses	$	4,495	$	4,109

XML 23 R13.htm IDEA: XBRL DOCUMENT

Leases

3 Months Ended

Mar. 31, 2022

Leases [Abstract]

Leases

(7)

Leases

The Company recognizes

right-of-use

non-cancellable

operating and financing leases.

The following table summarizes the Company’s operating leases as of and for the three months ended March 31, 2022 (in thousands):


	U.S.			Ireland			Total
Lease cost:
Operating lease cost	$	101		$	8		$	109

Other information:
Operating cash flows out from operating leases	$	(101	)	$	(8	)	$	(109	)
Weighted average remaining lease term		0.9			4.4
Weighted average discount rate - operating leases		8	%		8	%

Remaining maturities of the Company’s operating leases, excluding short-term leases, are as follows (in thousands):


	U.S.			Ireland			Total
Year ended December 31, 2022	$	304		$	35		$	339
Year ended December 31, 2023		67			46			113
Year ended December 31, 2024		—			46			46
Year ended December 31, 2025		—			46			46
Year ended December 31, 2026		—			26			26

Total		371			199			570
Less present value discount		(14	)		(30	)		(44	)

Operating lease liabilities included in the consolidated balance sheets at March 31, 2022	$	357		$	169		$	526

XML 24 R14.htm IDEA: XBRL DOCUMENT

Loans and Convertible Notes Payable

3 Months Ended

Mar. 31, 2022

Debt Disclosure [Abstract]

Loans and Convertible Notes Payable

(8)	Loans and Convertible Notes Payable

(in thousands):

	March 31, 2022									December 31, 2021
	Gross			Discount			Net			Gross			Discount			Net
Loan - Avenue [1]		12,638			(1,485	)		11,153			12,638			(1,645	)		10,993
Loan - Avenue [1] - Less Current Portion		(2,856	)		336			(2,520	)		(714	)		93			(621	)

Total - Loans Payable, Non-Current	$	9,782		$	(1,149	)	$	8,633		$	11,924		$	(1,552	)	$	10,372

Convertible Note Payable - Rosalind		2,000			—			2,000			2,000			—			2,000
Convertible Portion of Loan Payable - Avenue		3,000			(325	)		2,675			3,000			(361	)		2,639

Total - Convertible Notes Payable - Non-Current	$	5,000		$	(325	)	$	4,675		$	5,000		$	(361	)	$	4,639

[1]	The gross amount includes the 4.25% final payment of $638,000.

Remaining maturities of the Company’s loan and convertible note payables are as follows (in thousands):


	Loans		Convertible Notes		Total
Year ended December 31, 2022	$	714	$	—	$	714
Year ended December 31, 2023		8,571		—		8,571
Year ended December 31, 2024		3,353		5,000		8,353

Total	$	12,638	$	5,000	$	17,638

Term Loan from Avenue Venture Opportunities Fund, L.P.

million

The initial tranche of the Avenue Loan is $15.0

million,

including $4.0

million

pre-specified

million

. The Company may request an additional $5.0

million

of gross proceeds between October 1, 2022 and December 31, 2022, with funding, subject to the approval of Avenue’s Investment Committee.

Up to $3

million

of the principal amount of the Avenue Loan outstanding may be converted, at the option of Avenue, into shares of the Company’s common stock at a conversion price of $11.98 per share.

non-payment

of principal or interest, violations of covenants, bankruptcy and material judgments.

non-convertible

The Avenue Warrant was valued at issuance at $1.3 million using the Black-Scholes option pricing method using the following assumptions:


	August 6, 2021
Contractual term (years)		5.07
Expected volatility		187.0	%
Risk-free interest rate		0.77	%
Expected dividends		0.00	%

Convertible Notes Payable

Interest expense was $40 for the three months ended March 31, 2022 and 2021, respectively.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

XML 25 R15.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

3 Months Ended

Mar. 31, 2022

Stockholders' Equity Note [Abstract]

Stockholders' Equity

(9)	Stockholders’ Equity

Authorized Shares

The Company is authorized to issue 40,000,000 shares of common stock, $0.01 par value, and

E-1

(12,960 shares).

Preferred Stock

As of March 30, 2022, there were an aggregate of 11,707 shares of Series E and Series E-1 Convertible Preferred Stock outstanding.

Omnibus Equity Incentive Plan

non-qualified

Employee Stock Purchase Plan

be purchased by

Equity Offerings and Placements

At-the-Market

Offering

lock-up

90-day

period following the date of such underwriting agreement.

There were no shares sold during the three months ended March 31, 2022.

Stock Options

The Company values stock options using the Black-Scholes option pricing model and used the following assumptions during the reporting periods:


	Three months ended March 31,
	2022			2021
Expected terms (years)		5.46 - 6.46		N/A
Expected volatility		174.81% - 177.09	%	N/A
Risk-free interest rate		1.75% - 1.90	%	N/A
Expected dividends		0.00	%	N/A

The weighted average estimated fair value of the stock options granted during the three months ended March 31, 2022 was approximately $6.86 per share.

The following is a summary of stock option activity for the three months ended March 31, 2022:


	Number of Option			Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Outstanding at January 1, 2022		1,732,460		$	11.69
Granted		549,333			7.10
Expired		(6,650	)		10.88
Cancelled/Forfeited		(37,040	)		10.42

Outstanding at March 31, 2022		2,238,103		$	10.60		9.2	$	—

Exercisable at March 31, 2022		766,619		$	11.83		8.7	$	—

The following table summarizes information for stock option shares outstanding and exercisable at March 31, 2022:


			Options Exercisable
Range of Exercise Prices	Outstanding Number of Options		Weighted Average Remaining Option Term (in years)		Number of Options
$6.61 - $9.99		825,256		9.2		110,389
$10.00 - $14.99		1,280,348		8.7		592,317
$15.00 - $24.99		132,000		8.5		63,414
$25 +		499		6.8		499

		2,238,103		8.7		766,619

The following is a summary of share-based compensation expense in the statement of operations for the three months ended March 31, 2022 (in thousands):


	Three months ended March 31,
	2022		2021
Selling, general and administrative	$	919	$	1,466
Research and development		503		630
Cost of goods sold		52		52

Total	$	1,474	$	2,148

At March 31, 2022, there was $9.2

million of aggregate unrecognized compensation expense related employee and board stock option grants. The cost is expected to be recognized over a weighted average period of 3 years.

Warrants

The following is a summary of warrant activity for the three months ended March 31, 2022:


	Warrants		Weighted Average Exercise Price		Weighted Average Remaining Life (in years)
Outstanding at January 1, 2022		3,894,498	$	9.27
Warrants issued		—		—
Warrants exercised		—		—
Warrants expired		—		—

Outstanding at March 31, 2022		3,894,498	$	9.27		3.0

Exercisable at March 31, 2022		3,894,498	$	9.27		3.0

The following table presents information related to stock warrants at March 31, 2022


			Warrants Exercisable
Range of Exercise Prices	Outstanding Number of Warrants		Weighted Average Remaining Warrant Term (in years)		Number of Warrants
$0.01		283,755		3.7		283,755
$10.00		3,610,743		2.9		3,610,743

		3,894,498		3.0		3,894,498

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

XML 26 R16.htm IDEA: XBRL DOCUMENT

Net Loss per Common Share

3 Months Ended

Mar. 31, 2022

Earnings Per Share [Abstract]

Net Loss per Common Share

(10)	Net Loss per Common Share

The following potentially dilutive securities were excluded from the computation of earnings per share as of March 31, 2022 and 2021 because their effects would be anti-dilutive:


	March 31,
	2022		2021
Stock options		2,238,103		1,078,499
Common stock warrants - equity		3,894,498		3,994,107
Assumed conversion of Series E and Series E-1 Preferred Stock		1,135,721		2,048,101
Assumed conversion of convertible notes		488,031		146,288

Total		7,756,353		7,266,995

At March 31, 2022, the Company had 283,755

pre-funded

warrants outstanding. The following table provides a reconciliation of the weighted average shares outstanding calculation for the three months ended March 31, 2022 and 2021:


	Three months ended March 31,
	2022		2021
Weighted average shares issued		7,906,728		6,125,922
Weighted average pre-funded warrants		283,755		371,000

Weighted average shares outstanding		8,190,483		6,496,922

XML 27 R17.htm IDEA: XBRL DOCUMENT

Income Taxes

3 Months Ended

Mar. 31, 2022

Income Tax Disclosure [Abstract]

Income Taxes

(11)	Income Taxes

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

XML 28 R18.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

3 Months Ended

Mar. 31, 2022

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

(

)

Commitments and Contingencies

Litigation, Claims and Assessments

medac Matter

In April 2021, the Company issued an invoice for €1

million

(which currently converts to approximately $1.2

million)

rial as defined by the FOCUS

rial

protocol. Per the

rial

protocol and associated Statistical Analysis Plan, positive efficacy is based on whether the Objective Response Rate (ORR) exceeds a pre

specified threshold. A preliminary analysis of the FOCUS

rial data based on 87% of enrolled patients was released on March 31, 2021, and subsequently

presented

at the American Society of Clinical Oncology (ASCO) Annual Meeting held virtually from the 4th through the 8th of June 2021. Per that analysis, the ORR exceeded the pre

specified threshold. While the final ORR is not yet known, given the magnitude by which the ORR exceeded the pre

specified endpoint and the small number of patients yet to be assessed, the final ORR will be greater than the pre

it doe

not intend to pay the invoice at this time, under revenue recognition criteria set out in ASC 606, the Company cannot recognize the revenue.

March 2022 for approximately

$0.2 million.

The arbitration proceeding is moving forward with the parties agreeing to stay the arbitration for a finite period to pursue settlement

discussions.

XML 29 R19.htm IDEA: XBRL DOCUMENT

General (Policies)	3 Months Ended
General (Policies)	Mar. 31, 2022
Accounting Policies [Abstract]
Risk and Uncertainties	Risks and Uncertainties Although the Company is not aware of any direct impacts of the war between the Ukraine and the Russian Federation on its supply chain, the war could adversely impact the Company’s ability to obtain components and/or significantly increase the cost of obtaining such components for the Company’s products from its third-party suppliers in a timely manner or at all. In addition, at this time, the Company is not aware of any direct impacts, the increase in COVID cases and associated restrictions, which could adversely impact the Company’s ability to obtain components and/or significantly increase the cost of obtaining such components for the Company’s products from its third-party suppliers in a timely manner or at all.
Liquidity and Going Concern	Liquidity and Going Concern The accompanying interim condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred significant losses and has an accumulated deficit of $429.2 million as of March 31, 2022. These losses, among other factors, raise substantial doubt about the Company’s ability to continue as a going concern. The Company’s existence is dependent upon management’s ability to obtain additional funding sources or to enter into strategic alliances. Adequate additional financing may not be available to the Company on acceptable terms, or at all. If the Company is unable to raise additional capital and/or enter into strategic alliances when needed or on attractive terms, it would be forced to delay, reduce, or eliminate its research and development programs or any commercialization efforts. There can be no assurance that the Company’s efforts will result in the resolution of the Company’s liquidity needs. If the Company is not able to continue as a going concern, it is likely that holders of its common stock will lose all of their investment. The accompanying interim condensed consolidated financial statements do not include any adjustments that might result should the Company be unable to continue as a going concern. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. Additional working capital will be required to continue operations. Operations of the Company are subject to certain risks and uncertainties, including, among others, uncertainty of product development and clinical trial results; uncertainty regarding regulatory approval; technological uncertainty; uncertainty regarding patents and proprietary rights; comprehensive government regulations; limited commercial manufacturing, marketing, or sales experience; and dependence on key personnel.
Basis of Presentation	Basis of Presentation These interim condensed consolidated financial statements are unaudited and were prepared by the Company in accordance with generally accepted accounting principles in the United States of America (GAAP) and with the SEC’s instructions to Form 10-Q and Article 10 of Regulation S-X. They include the accounts of all wholly owned subsidiaries and all significant inter-company accounts and transactions have been eliminated in consolidation. The preparation of interim condensed consolidated financial statements requires management to make assumptions and estimates that impact the amounts reported. These interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the Company’s results of operations, financial position and cash flows for the interim periods ended March 31, 2022 and 2021; however, certain information and footnote disclosures normally included in our audited consolidated financial statements included in our Annual Report on Form 10-K have been condensed or omitted as permitted by GAAP. It is important to note that the Company’s results of operations and cash flows for interim periods are not necessarily indicative of the results of operations and cash flows to be expected for a full fiscal year or any interim period.
Recently Adopted and Issued Accounting Pronouncements	Recently Adopted Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, “Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity.” ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. ASU 2020-06 requires entities to provide expanded disclosures about the terms and features of convertible instruments and amends certain guidance in Accounting Standards Codification 260, Earnings per Share, relating to the computation of earnings per share for convertible instruments and contracts in an entity’s own equity. The guidance becomes effective for the Company on January 1, 2024, with early adoption permitted. The Company early adopted ASU 2020-06 on January 1, 2022 and the adoption did not have any immediate effect on the Company’s condensed consolidated financial statements. Going forward, the Company will no longer be required to assess convertible instruments for beneficial conversion features. In October 2020, the FASB issued ASU 2020-10 “Codification Improvements”, which improves consistency by amending the Codification to include all disclosure guidance in the appropriate disclosure sections and clarifies application of various provisions in the Codification by amending and adding new headings, cross referencing to other guidance, and refining or correcting terminology. The guidance was effective for the Company beginning in the first quarter of fiscal year 2022 with early adoption permitted. The Company adopted this guidance on January 1, 2022 and it did not have a material impact on its condensed consolidated financial statements. On May 3, 2021, the FASB issued ASU 2021-04, “Earnings Per Share” (Topic 260), “Debt—Modifications and Extinguishments” (Subtopic 470-50), “Compensation—Stock Compensation” (Topic 718), and “Derivatives and Hedging—Contracts in Entity’s Own Equity” (Subtopic 815-40): “Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options.” This new standard provides clarification and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (such as warrants) that remain equity classified after modification or exchange. This standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Issuers should apply the new standard prospectively to modifications or exchanges occurring after the effective date of the new standard. Early adoption is permitted, including adoption in an interim period. If an issuer elects to early adopt the new standard in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The Company adopted this guidance on January 1, 2022 and it did not have a material impact on its condensed consolidated financial statements.

XML 30 R20.htm IDEA: XBRL DOCUMENT

Cash, Cash Equivalents and Restricted Cash (Tables)

3 Months Ended

Mar. 31, 2022

Cash and Cash Equivalents [Abstract]

Schedule of Cash, Cash Equivalents, and Restricted Cash

Cash, cash equivalents, and restricted cash balances were as follows (in thousands):


	March 31, 2022		December 31, 2021
Cash and cash equivalents	$	16,340	$	22,802
Restricted balance for loan agreement		4,000	$	4,000
Letters of credit		101		101
Security for credit cards		50		50

Total cash, cash equivalents and restricted cash shown in the statements of cash flows	$	20,491	$	26,953

XML 31 R21.htm IDEA: XBRL DOCUMENT

Inventories (Tables)

3 Months Ended

Mar. 31, 2022

Inventory Disclosure [Abstract]

Schedule of inventories

Inventories consist of the following (in thousands):


	March 31, 2022		December 31, 2021
Raw materials	$	841	$	767
Work-in-process		881		645
Finished goods		289		—

Total inventories	$	2,011	$	1,412

XML 32 R22.htm IDEA: XBRL DOCUMENT

Prepaid Expenses and Other Current Assets (Tables)

3 Months Ended

Mar. 31, 2022

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following (in thousands):


	March 31, 2022		December 31, 2021
Clinical trial expenses	$	1,630	$	1,630
Insurance premiums		645		890
Other		429		223

Total prepaid expenses and other current assets	$	2,704	$	2,743

XML 33 R23.htm IDEA: XBRL DOCUMENT

Property, Plant, and Equipment (Tables)

3 Months Ended

Mar. 31, 2022

Property, Plant and Equipment [Abstract]

Components of property, plant and equipment

(5)	Property, Plant, and Equipment

Property, plant, and equipment consist of the following (in thousands):


	March 31, 2022			December 31, 2021			Estimated Useful Life
Buildings and land	$	1,222		$	1,222			30 years- Buildings
Enterprise hardware and software		1,858			1,858			3 years
Leaseholds		1,788			1,796			Lesser of lease term or estimated useful life
Equipment		1,184			1,094			7 years
Furniture		202			203			5 years

Property, plant and equipment, gross		6,254			6,173
Accumulated depreciation		(4,848	)		(4,825	)

Property, plant and equipment, net	$	1,406		$	1,348

XML 34 R24.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Tables)

3 Months Ended

Mar. 31, 2022

Payables and Accruals [Abstract]

Schedule of accrued expenses

Accrued expenses consist of the following (in thousands):


	March 31, 2022		December 31, 2021
Clinical expenses	$	1,578	$	1,517
Compensation, excluding taxes		796		893
Short term financing		315		551
Professional fees		1,298		603
Interest on convertible note		433		393
Other		75		152

Total accrued expenses	$	4,495	$	4,109

XML 35 R25.htm IDEA: XBRL DOCUMENT

Leases (Tables)

3 Months Ended

Mar. 31, 2022

Leases [Abstract]

Summary of Operating and Financing Leases

The following table summarizes the Company’s operating leases as of and for the three months ended March 31, 2022 (in thousands):


	U.S.			Ireland			Total
Lease cost:
Operating lease cost	$	101		$	8		$	109

Other information:
Operating cash flows out from operating leases	$	(101	)	$	(8	)	$	(109	)
Weighted average remaining lease term		0.9			4.4
Weighted average discount rate - operating leases		8	%		8	%

Schedule of Remaining Maturity of Operating Leases Excluding Short-Term Leases

Remaining maturities of the Company’s operating leases, excluding short-term leases, are as follows (in thousands):


	U.S.			Ireland			Total
Year ended December 31, 2022	$	304		$	35		$	339
Year ended December 31, 2023		67			46			113
Year ended December 31, 2024		—			46			46
Year ended December 31, 2025		—			46			46
Year ended December 31, 2026		—			26			26

Total		371			199			570
Less present value discount		(14	)		(30	)		(44	)

Operating lease liabilities included in the consolidated balance sheets at March 31, 2022	$	357		$	169		$	526

XML 36 R26.htm IDEA: XBRL DOCUMENT

Loans and Convertible Notes Payable (Tables)

3 Months Ended

Aug. 06, 2021

Mar. 31, 2022

Debt Disclosure [Abstract]

Summary of Loans and Convertible Notes Payable

	March 31, 2022									December 31, 2021
	Gross			Discount			Net			Gross			Discount			Net
Loan - Avenue [1]		12,638			(1,485	)		11,153			12,638			(1,645	)		10,993
Loan - Avenue [1] - Less Current Portion		(2,856	)		336			(2,520	)		(714	)		93			(621	)

Total - Loans Payable, Non-Current	$	9,782		$	(1,149	)	$	8,633		$	11,924		$	(1,552	)	$	10,372

Convertible Note Payable - Rosalind		2,000			—			2,000			2,000			—			2,000
Convertible Portion of Loan Payable - Avenue		3,000			(325	)		2,675			3,000			(361	)		2,639

Total - Convertible Notes Payable - Non-Current	$	5,000		$	(325	)	$	4,675		$	5,000		$	(361	)	$	4,639

[1]	The gross amount includes the 4.25% final payment of $638,000.

Summary of Remaining Maturities of Company's Loan and Convertible Note Payables

Remaining maturities of the Company’s loan and convertible note payables are as follows (in thousands):


	Loans		Convertible Notes		Total
Year ended December 31, 2022	$	714	$	—	$	714
Year ended December 31, 2023		8,571		—		8,571
Year ended December 31, 2024		3,353		5,000		8,353

Total	$	12,638	$	5,000	$	17,638

Summary of Avenue Warrant Valued Using the Black-Scholes Option Pricing Method

The Avenue Warrant was valued at issuance at $1.3 million using the Black-Scholes option pricing method using the following assumptions:


	August 6, 2021
Contractual term (years)		5.07
Expected volatility		187.0	%
Risk-free interest rate		0.77	%
Expected dividends		0.00	%

The Company values stock options using the Black-Scholes option pricing model and used the following assumptions during the reporting periods:


	Three months ended March 31,
	2022			2021
Expected terms (years)		5.46 - 6.46		N/A
Expected volatility		174.81% - 177.09	%	N/A
Risk-free interest rate		1.75% - 1.90	%	N/A
Expected dividends		0.00	%	N/A

XML 37 R27.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

3 Months Ended

Aug. 06, 2021

Mar. 31, 2022

Stockholders' Equity Note [Abstract]

Summary of Avenue Warrant Valued Using the Black-Scholes Option Pricing Method

The Avenue Warrant was valued at issuance at $1.3 million using the Black-Scholes option pricing method using the following assumptions:


	August 6, 2021
Contractual term (years)		5.07
Expected volatility		187.0	%
Risk-free interest rate		0.77	%
Expected dividends		0.00	%

The Company values stock options using the Black-Scholes option pricing model and used the following assumptions during the reporting periods:


	Three months ended March 31,
	2022			2021
Expected terms (years)		5.46 - 6.46		N/A
Expected volatility		174.81% - 177.09	%	N/A
Risk-free interest rate		1.75% - 1.90	%	N/A
Expected dividends		0.00	%	N/A

Summary of Stock Option Activity

The following is a summary of stock option activity for the three months ended March 31, 2022:


	Number of Option			Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Outstanding at January 1, 2022		1,732,460		$	11.69
Granted		549,333			7.10
Expired		(6,650	)		10.88
Cancelled/Forfeited		(37,040	)		10.42

Outstanding at March 31, 2022		2,238,103		$	10.60		9.2	$	—

Exercisable at March 31, 2022		766,619		$	11.83		8.7	$	—

Summary of Stock Option Shares Outstanding and Exercisable

The following table summarizes information for stock option shares outstanding and exercisable at March 31, 2022:


			Options Exercisable
Range of Exercise Prices	Outstanding Number of Options		Weighted Average Remaining Option Term (in years)		Number of Options
$6.61 - $9.99		825,256		9.2		110,389
$10.00 - $14.99		1,280,348		8.7		592,317
$15.00 - $24.99		132,000		8.5		63,414
$25 +		499		6.8		499

		2,238,103		8.7		766,619

Summary of Recognized Share-based Compensation Cost

The following is a summary of share-based compensation expense in the statement of operations for the three months ended March 31, 2022 (in thousands):


	Three months ended March 31,
	2022		2021
Selling, general and administrative	$	919	$	1,466
Research and development		503		630
Cost of goods sold		52		52

Total	$	1,474	$	2,148

Summary of Warrant Activity

The following is a summary of warrant activity for the three months ended March 31, 2022:


	Warrants		Weighted Average Exercise Price		Weighted Average Remaining Life (in years)
Outstanding at January 1, 2022		3,894,498	$	9.27
Warrants issued		—		—
Warrants exercised		—		—
Warrants expired		—		—

Outstanding at March 31, 2022		3,894,498	$	9.27		3.0

Exercisable at March 31, 2022		3,894,498	$	9.27		3.0

Schedule of Information Related to Stock Warrants Outstanding and Exercisable

The following table presents information related to stock warrants at March 31, 2022


			Warrants Exercisable
Range of Exercise Prices	Outstanding Number of Warrants		Weighted Average Remaining Warrant Term (in years)		Number of Warrants
$0.01		283,755		3.7		283,755
$10.00		3,610,743		2.9		3,610,743

		3,894,498		3.0		3,894,498

XML 38 R28.htm IDEA: XBRL DOCUMENT

Net Loss per Common Share (Tables)

3 Months Ended

Mar. 31, 2022

Earnings Per Share [Abstract]

Anti-dilutive securities excluded from the computation of earnings per share

The following potentially dilutive securities were excluded from the computation of earnings per share as of March 31, 2022 and 2021 because their effects would be anti-dilutive:


	March 31,
	2022		2021
Stock options		2,238,103		1,078,499
Common stock warrants - equity		3,894,498		3,994,107
Assumed conversion of Series E and Series E-1 Preferred Stock		1,135,721		2,048,101
Assumed conversion of convertible notes		488,031		146,288

Total		7,756,353		7,266,995

Summary of reconciliation of weighted average shares outstanding calculation

The following table provides a reconciliation of the weighted average shares outstanding calculation for the three months ended March 31, 2022 and 2021:


	Three months ended March 31,
	2022		2021
Weighted average shares issued		7,906,728		6,125,922
Weighted average pre-funded warrants		283,755		371,000

Weighted average shares outstanding		8,190,483		6,496,922

XML 39 R29.htm IDEA: XBRL DOCUMENT

General - Additional Information (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Basis Of Condensed Consolidated Financial Statement Presentation [Abstract]
Retained Earnings Accumulated Deficit	$ (429,179)	$ (420,976)

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References + Details

XML 40 R30.htm IDEA: XBRL DOCUMENT

Cash, Cash Equivalents and Restricted Cash - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	$ 16,340	$ 22,802
Restricted balance for loan agreement	4,000	4,000
Letters of credit	101	101
Security for credit cards	50	50
Total cash, cash equivalents and restricted cash shown in the statements of cash flows	$ 20,491	$ 26,953	$ 26,650	$ 28,756

XML 41 R31.htm IDEA: XBRL DOCUMENT

Inventories - Schedule of Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 841	$ 767
Work-in-process	881	645
Finished goods	289	0
Total inventories	$ 2,011	$ 1,412

XML 42 R32.htm IDEA: XBRL DOCUMENT

Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Prepaid Expense and Other Assets, Current [Abstract]
Clinical trial expenses	$ 1,630	$ 1,630
Insurance premiums	645	890
Other	429	223
Total prepaid expenses and other current assets	$ 2,704	$ 2,743

XML 43 R33.htm IDEA: XBRL DOCUMENT

Property, Plant, and Equipment - Components of Property, Plant, and Equipment (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 6,254	$ 6,173
Accumulated depreciation	(4,848)	(4,825)
Property, plant, and equipment, net	1,406	1,348
Buildings and Land [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	1,222	1,222
Enterprise Hardware and Software [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 1,858	1,858
Property, plant and equipment, estimated useful life	3 years
Leaseholds [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 1,788	1,796
Property, plant and equipment, estimated useful life	Lesser ofleaseterm orestimatedusefullife
Equipment [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 1,184	1,094
Property, plant and equipment, estimated useful life	7 years
Furniture [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 202	$ 203
Property, plant and equipment, estimated useful life	5 years
Buildings [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, estimated useful life	30 years

XML 44 R34.htm IDEA: XBRL DOCUMENT

Property, Plant, and Equipment - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 31	$ 39

XML 45 R35.htm IDEA: XBRL DOCUMENT

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Clinical expenses	$ 1,578	$ 1,517
Compensation, excluding taxes	796	893
Short-term financing	315	551
Professional fees	1,298	603
Interest on convertible note	433	393
Other	75	152
Total accrued expenses	$ 4,495	$ 4,109

XML 46 R36.htm IDEA: XBRL DOCUMENT

Leases - Additional Information (Details)	Mar. 31, 2022
Lease term	12 months

XML 47 R37.htm IDEA: XBRL DOCUMENT

Leases - Summary of Operating and Financing Leases (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2022 USD ($)
Lease Cost
Operating lease cost	$ 109
Other information
Operating cash flows out from operating leases	(109)
U.S. [Member]
Lease Cost
Operating lease cost	101
Other information
Operating cash flows out from operating leases	$ (101)
Weighted average remaining lease term	10 months 24 days
Weighted average discount rate - operating leases	8.00%
Ireland [Member]
Lease Cost
Operating lease cost	$ 8
Other information
Operating cash flows out from operating leases	$ (8)
Weighted average remaining lease term	4 years 4 months 24 days
Weighted average discount rate - operating leases	8.00%

XML 48 R38.htm IDEA: XBRL DOCUMENT

Leases - Schedule of Remaining Maturity of Operating Leases Excluding Short-Term Leases (Details) $ in Thousands	Mar. 31, 2022 USD ($)
Lessee Lease Description [Line Items]
Year ended December 31, 2022	$ 339
Year ended December 31, 2023	113
Year ended December 31, 2024	46
Year ended December 31, 2025	46
Year ended December 31, 2026	26
Total	570
Less present value discount	(44)
Operating lease liabilities included in the condensed consolidated balance sheets at March 31, 2022	526
U.S. [Member]
Lessee Lease Description [Line Items]
Year ended December 31, 2022	304
Year ended December 31, 2023	67
Total	371
Less present value discount	(14)
Operating lease liabilities included in the condensed consolidated balance sheets at March 31, 2022	357
Ireland [Member]
Lessee Lease Description [Line Items]
Year ended December 31, 2022	35
Year ended December 31, 2023	46
Year ended December 31, 2024	46
Year ended December 31, 2025	46
Year ended December 31, 2026	26
Total	199
Less present value discount	(30)
Operating lease liabilities included in the condensed consolidated balance sheets at March 31, 2022	$ 169

XML 49 R39.htm IDEA: XBRL DOCUMENT

Loans and Convertible Notes Payable - Additional Information (Details) - USD ($)		3 Months Ended
	Aug. 06, 2021	Mar. 31, 2022	Jun. 30, 2021
Debt Instrument [Line Items]
Avenue warrant value		$ 1,300,000
Debt instrument, commitment fee	$ 150,000
Interest expense incurred		$ 400,000
Secured Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Debt instrument, principal face amount	$ 2,000,000.0
Series E Preferred Stock [Member]
Debt Instrument [Line Items]
Debt instrument, conversion price			$ 1,500
Series E Preferred Stock [Member] \| Secured Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Debt instrument maturity date	Oct. 30, 2024
Debt instrument, conversion price	$ 1,198
Term Loan from Avenue Venture Opportunities Fund L.P [Member]
Debt Instrument [Line Items]
Debt instrument maturity date	Aug. 01, 2024
Debt instrument, interest rate	7.70%
Debt instrument, interest rate	10.95%	10.95%
Debt instrument, interest rate term	The Avenue Loan bears interest at an annual rate equal to the greater of (a) the sum of 7.70% plus the prime rate as reported in The Wall Street Journal and (b) 10.95%. The interest rate at March 31, 2022 was 10.95%. The Avenue Loan is secured by all of the Company’s assets globally, including intellectual property.
Initial tranche of loan	$ 15,000,000.0
Loan amount funded into restricted account	4,000,000.0
Gross proceeds from ATM Offering	20,000,000
Second tranche of loan	$ 5,000,000.0
Frequency of periodic payment	monthly
Periodic interest payments, term	15 months
Debt instrument, incremental final payment	4.25%
Debt instrument, commitment fee, percentage	1.00%
Debt instrument, commitment fee upon funding of second tranche of loan	$ 200,000
Original issue discount	600,000
Cash issuance costs	563,000
Debit discount	519,000
Fair value of warrants reclassified from liability to equity	44,000
Aggregate debt discount	$ 2,300,000
Amortization of debt discount		$ 200,000
Current interest rate	7.70%
Term Loan from Avenue Venture Opportunities Fund L.P [Member] \| Warrant [Member]
Debt Instrument [Line Items]
Warrants issued to purchase of common stock	127,755
Warrant exercise price	$ 0.01
Warrants, maturity date	Aug. 31, 2026
Fair value of the Avenue Warrant	$ 1,200,000
Term Loan from Avenue Venture Opportunities Fund L.P [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Debt instrument, principal face amount	$ 20,000,000
Periodic interest payments, term	24 months
Prepayment fee, percentage	3.00%
Term Loan from Avenue Venture Opportunities Fund L.P [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Prepayment fee, percentage	1.00%
Term Loan from Avenue Venture Opportunities Fund L.P [Member] \| Non Convertible Debt [Member]
Debt Instrument [Line Items]
Aggregate debt discount	$ 1,900,000
Amortization of debt discount		159,000
Term Loan from Avenue Venture Opportunities Fund L.P [Member] \| Convertible Debt [Member]
Debt Instrument [Line Items]
Aggregate debt discount	$ 418,000
Amortization of debt discount		$ 35,000
Eight Point Zero Percentage July Two Thousand And Nineteen Notes [Member] \| Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate		8.00%
Current interest rate		8.00%
Interest expense incurred		$ 40,000

XML 50 R40.htm IDEA: XBRL DOCUMENT

Loans and Convertible Notes Payable - Summary of Loans and Convertible Notes Payable (Details) - USD ($)
$ in Thousands

Mar. 31, 2022

Dec. 31, 2021

Gross

$ 5,000

Discount

(325)

(361)

Net

4,675

4,639

Less Current Portion, Net

(2,520)

(621)

Total - Loans Payable, Non-Current, Gross

9,782

11,924

Total - Loans Payable, Non-Current, Discount

(1,149)

(1,552)

Total - Loans Payable, Non-Current, Net

8,633

10,372

Loan Avenue [Member]

Gross

^[1]

12,638

Discount

^[1]

(1,485)

(1,645)

Net

^[1]

11,153

10,993

Less Current Portion, Gross

^[1]

(2,856)

(714)

Less Current Portion, Discount

^[1]

336

Less Current Portion, Net

^[1]

(2,520)

(621)

Convertible Note Payable Rosalind [Member]

Gross

2,000

Net

2,000

Convertible Loan Payable Avenue [Member]

Gross

3,000

Discount

(325)

(361)

Net

$ 2,675

$ 2,639

[1]	The gross amount includes the 4.25% final payment of $637.5.

XML 51 R41.htm IDEA: XBRL DOCUMENT

Loans and Convertible Notes Payable - Summary of Loans and Convertible Notes Payable (Details) (Parenthetical)	3 Months Ended
	Mar. 31, 2022 USD ($)
Equity Method Investments And Cost Method Investments [Abstract]
Percentage of final payment included in gross amount	4.25%
Final payment	$ 638,000

XML 52 R42.htm IDEA: XBRL DOCUMENT

Loans and Convertible Notes Payable - Summary of Remaining Maturities of Company's Loan and Convertible Note Payables (Details) $ in Thousands	Mar. 31, 2022 USD ($)
Debt Instrument [Line Items]
Loans	$ 12,638
Convertible Notes	5,000
Total	17,638
Year ended December 31, 2022
Debt Instrument [Line Items]
Loans	714
Total	714
Year ended December 31, 2023
Debt Instrument [Line Items]
Loans	8,571
Total	8,571
Year ended December 31, 2024
Debt Instrument [Line Items]
Loans	3,353
Convertible Notes	5,000
Total	$ 8,353

XML 53 R43.htm IDEA: XBRL DOCUMENT

Loans and Convertible Notes Payable - Summary of Avenue Warrant Valued Using the Black-Scholes Option Pricing Method (Details)		3 Months Ended
	Aug. 06, 2021	Mar. 31, 2022
Contractual term (years)	5 years 25 days
Expected volatility	187.00%
Risk-free interest rate	0.77%
Expected dividends	0.00%	0.00%

XML 54 R44.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Preferred Stock Issuances - Additional Information (Details) - $ / shares	Mar. 31, 2022	Mar. 30, 2022	Dec. 31, 2021
Stockholders Equity Note [Line Items]
Preferred stock, shares authorized (in shares)	10,000,000		10,000,000
Preferred stock, par value (in dollars per share)	$ 0.01		$ 0.01
Common stock, par value (in dollars per share)	$ 0.01		$ 0.01
Common stock, shares authorized (in shares)	40,000,000		40,000,000
Preferred stock, shares outstanding (in shares)	11,357		11,357
Series A Preferred Stock [Member]
Stockholders Equity Note [Line Items]
Preferred stock, shares authorized (in shares)	4,200
Series B Preferred Stock [Member]
Stockholders Equity Note [Line Items]
Preferred stock, shares authorized (in shares)	2,360
Series C Preferred Stock [Member]
Stockholders Equity Note [Line Items]
Preferred stock, shares authorized (in shares)	590
Series D Preferred Stock [Member]
Stockholders Equity Note [Line Items]
Preferred stock, shares authorized (in shares)	10,000
Series E Preferred Stock [Member]
Stockholders Equity Note [Line Items]
Preferred stock, shares authorized (in shares)	40,000
Series E1 Preferred Stock [Member]
Stockholders Equity Note [Line Items]
Preferred stock, shares authorized (in shares)	12,960
Series E Convertible Preferred Stock [Member]
Stockholders Equity Note [Line Items]
Preferred stock, shares outstanding (in shares)		11,707
Series E-1 Convertible Preferred Stock [Member]
Stockholders Equity Note [Line Items]
Preferred stock, shares outstanding (in shares)		11,707

XML 55 R45.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Equity Incentive Plan - Additional Information (Details) - shares	Mar. 31, 2022	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of common shares reserved for issuance	2,475,000
Number of common shares remained available to be issued		737,957

XML 56 R46.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Summary of Employee Stock Purchase Plan (Details) - May 2022 Employee Stock Purchase Plan (ESPP) [Member]	1 Months Ended
	Aug. 31, 2021 shares
Stockholders Equity Note [Line Items]
Share-based compensation arrangement by share-based payment award number of shares authorized	260,295
Share-based compensation arrangement by share-based payment award purchase price of common stock, percent	85.00%

XML 57 R47.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - At-the-Market Offering - Additional Information (Details) - USD ($)		3 Months Ended
	Aug. 18, 2020	Mar. 31, 2022
Stockholders Equity Note [Line Items]
Number of Shares Sold		0
Cantor Fitzgerald & Co [Member]
Stockholders Equity Note [Line Items]
Percentage of commission on aggregate gross proceeds	3.00%
Roth Capital Partners L L C
Stockholders Equity Note [Line Items]
Percentage of fee on gross sale price per share	1.05%
Percentage of underwriting fee to be received on company offerings	35.00%
Common stock offering period	90 days
Maximum [Member] \| Cantor Fitzgerald & Co [Member]
Stockholders Equity Note [Line Items]
At-the-market offering, aggregate offering price	$ 10,000,000.0
Legal fees and disbursements	$ 50,000

XML 58 R48.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Stock Incentive Plans - Additional Information (Details) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2022 USD ($) $ / shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted average estimated fair value of the stock options granted \| $ / shares	$ 6.86
Unrecognized compensation expense related to non-vested share-based compensation awards \| $	$ 9.2
Cost expected to be recognized over weighted average period	3 years

XML 59 R49.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Schedule of Assumptions to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model (Details)		3 Months Ended
	Aug. 06, 2021	Mar. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	187.00%
Expected terms (years)	5 years 25 days
Risk-free interest rate	0.77%
Expected dividends	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility		174.81%
Expected terms (years)		5 years 5 months 15 days
Risk-free interest rate		1.75%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility		177.09%
Expected terms (years)		6 years 5 months 15 days
Risk-free interest rate		1.90%

XML 60 R50.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Summary of Stock Option Activity (Details) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022 USD ($) $ / shares shares
Stockholders' Equity Note [Abstract]
Number of Shares, Outstanding \| shares	1,732,460
Number of Shares, Granted \| shares	549,333
Number of Shares, Expired \| shares	(6,650)
Number of Shares, Cancelled/Forfeited \| shares	(37,040)
Number of Shares, Outstanding \| shares	2,238,103
Number of Shares, Exercisable \| shares	766,619
Weighted Average Exercise Price, Outstanding \| $ / shares	$ 11.69
Weighted Average Exercise Price, Granted \| $ / shares	7.10
Weighted Average Exercise Price, Expired \| $ / shares	10.88
Weighted Average Exercise Price, Cancelled/Forfeited \| $ / shares	10.42
Weighted Average Exercise Price, Outstanding \| $ / shares	10.60
Weighted Average Exercise Price, Exercisable \| $ / shares	$ 11.83
Weighted Average Remaining Contractual Term (Years), Outstanding	9 years 2 months 12 days
Weighted Average Remaining Contractual Term (Years), Exercisable	8 years 8 months 12 days
Aggregate Intrinsic Value, Outstanding \| $	$ 0
Aggregate Intrinsic Value, Exercisable \| $	$ 0

XML 61 R51.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Summary of Stock Option Shares Outstanding and Exercisable (Details) - shares	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding Number of Options	2,238,103	1,732,460
Weighted Average Remaining Contractual Term (Years), Exercisable	8 years 8 months 12 days
Number of Shares, Exercisable	766,619
$6.61 - $9.99 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding Number of Options	825,256
Weighted Average Remaining Contractual Term (Years), Exercisable	9 years 2 months 12 days
Number of Shares, Exercisable	110,389
$10.00 - $14.99 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding Number of Options	1,280,348
Weighted Average Remaining Contractual Term (Years), Exercisable	8 years 8 months 12 days
Number of Shares, Exercisable	592,317
$15.00 - $24.99 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding Number of Options	132,000
Weighted Average Remaining Contractual Term (Years), Exercisable	8 years 6 months
Number of Shares, Exercisable	63,414
$25 + [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding Number of Options	499
Weighted Average Remaining Contractual Term (Years), Exercisable	6 years 9 months 18 days
Number of Shares, Exercisable	499

XML 62 R52.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Summary of Recognized Share-based Compensation Cost (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation (Income) expense	$ 1,474	$ 2,148
Selling, General and Administrative [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation (Income) expense	919	1,466
Research and Development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation (Income) expense	503	630
Cost of Goods Sold [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation (Income) expense	$ 52	$ 52

XML 63 R53.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Summary of Warrant Activity (Details)	3 Months Ended
	Mar. 31, 2022 $ / shares shares
Warrants outstanding [Roll Forward]
Outstanding, beginning of period (in shares) \| shares	3,894,498
Warrants issued (in shares) \| shares	0
Warrants exercised (in shares) \| shares	0
Warrants expired (in shares) \| shares	0
Outstanding, end of period (in shares) \| shares	3,894,498
Exercisable, end of period (in shares) \| shares	3,894,498
Warrants, Exercise Price per Share [Roll Forward]
Outstanding, beginning of period (in dollars per share) \| $ / shares	$ 9.27
Warrants issued (in dollars per share) \| $ / shares	0
Warrants exercised (in dollars per share) \| $ / shares	0
Warrants expired (in dollars per share) \| $ / shares	0
Outstanding, ending of period (in dollars per share) \| $ / shares	9.27
Exercisable, (in dollars per share) \| $ / shares	$ 9.27
Weighted average remaining life	3 years
Weighted average remaining life, Exercisable	3 years

XML 64 R54.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Summary of Warrants Outstanding and Exercisable (Details) - shares	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Class Of Warrant Or Right [Line Items]
Warrants Outstanding, Number Outstanding	3,894,498	3,894,498
Weighted average remaining life	3 years
Warrants Exercisable, Number Exercisable	3,894,498
$0.01 [Member]
Class Of Warrant Or Right [Line Items]
Warrants Outstanding, Number Outstanding	283,755
Weighted average remaining life	3 years 8 months 12 days
Warrants Exercisable, Number Exercisable	283,755
$10.00 [Member]
Class Of Warrant Or Right [Line Items]
Warrants Outstanding, Number Outstanding	3,610,743
Weighted average remaining life	2 years 10 months 24 days
Warrants Exercisable, Number Exercisable	3,610,743

XML 65 R55.htm IDEA: XBRL DOCUMENT

Net Loss per Common Share - Anti-Dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	7,756,353	7,266,995
Stock Options [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	2,238,103	1,078,499
Common stock warrants - equity [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	3,894,498	3,994,107
Assumed conversion of Series E and Series E-1 Preferred Stock [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	1,135,721	2,048,101
Assumed conversion of convertible Notes [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	488,031	146,288

XML 66 R56.htm IDEA: XBRL DOCUMENT

Net Loss per Common Share - Additional Information (Details)	3 Months Ended
	Mar. 31, 2022 shares
Earnings Per Share [Abstract]
Pre-funded penny warrants outstanding	283,755

XML 67 R57.htm IDEA: XBRL DOCUMENT

Net Loss per Common Share - Summary of Reconciliation of Weighted Average Shares Outstanding Calculation (Details) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Earnings Per Share [Abstract]
Weighted average shares issued	7,906,728	6,125,922
Weighted average pre-funded warrants	283,755	371,000
Weighted average shares outstanding	8,190,483	6,496,922

XML 68 R58.htm IDEA: XBRL DOCUMENT

Commitments and contingencies - Additional Information (Details) € in Millions	Mar. 31, 2021	Apr. 01, 2020	Mar. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Apr. 01, 2021 USD ($)	Apr. 01, 2021 EUR (€)
Loss Contingencies [Line Items]
Percentage of enrolled patients	87.00%
Inventory			$ 2,011,000	$ 1,412,000
Medac [Member]
Loss Contingencies [Line Items]
Due from related parties					$ 1,200	€ 1
Agreement date		Dec. 10, 2018
Inventory			$ 200,000

- Definition

For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.10(3))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(C))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.3)
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

+ Details

XML 69 d290302d10q_htm.xml IDEA: XBRL DOCUMENT 0000872912 2021-12-31 0000872912 2022-03-31 0000872912 2022-01-01 2022-03-31 0000872912 2021-01-01 2021-03-31 0000872912 2020-12-31 0000872912 2021-03-30 2021-03-31 0000872912 2022-05-11 0000872912 2021-03-31 0000872912 2021-08-06 2021-08-06 0000872912 srt:MinimumMember 2022-01-01 2022-03-31 0000872912 srt:MaximumMember 2022-01-01 2022-03-31 0000872912 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-03-31 0000872912 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-03-31 0000872912 us-gaap:CostOfSalesMember 2022-01-01 2022-03-31 0000872912 dcth:RangeOfExercisePricesPointZeroOneRangeMember 2022-01-01 2022-03-31 0000872912 dcth:RangeOfExercisePricesTenPointZeroRangeMember 2022-01-01 2022-03-31 0000872912 us-gaap:ProductMember 2022-01-01 2022-03-31 0000872912 us-gaap:ProductAndServiceOtherMember 2022-01-01 2022-03-31 0000872912 country:US 2022-01-01 2022-03-31 0000872912 country:IE 2022-01-01 2022-03-31 0000872912 dcth:ExercisePriceRangeFromSixPointSixOneToNinePointNineNineMember 2022-01-01 2022-03-31 0000872912 dcth:ExercisePriceRangeFromTenPointZeroZeroToFourteenPointNineNineMember 2022-01-01 2022-03-31 0000872912 dcth:ExercisePriceRangeFromFifteenPointZeroZeroToTwentyFourPointNineNineMember 2022-01-01 2022-03-31 0000872912 dcth:ExercisePriceRangeAboveTwentyFiveMember 2022-01-01 2022-03-31 0000872912 dcth:TermLoanFromAvenueVentureOpportunitiesFundLpMember 2022-01-01 2022-03-31 0000872912 us-gaap:BuildingMember 2022-01-01 2022-03-31 0000872912 us-gaap:ComputerEquipmentMember 2022-01-01 2022-03-31 0000872912 us-gaap:EquipmentMember 2022-01-01 2022-03-31 0000872912 us-gaap:FurnitureAndFixturesMember 2022-01-01 2022-03-31 0000872912 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2022-01-01 2022-03-31 0000872912 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000872912 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000872912 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0000872912 dcth:TermLoanFromAvenueVentureOpportunitiesFundLpMember dcth:NonConvertibleDebtMember 2022-01-01 2022-03-31 0000872912 dcth:TermLoanFromAvenueVentureOpportunitiesFundLpMember us-gaap:ConvertibleDebtMember 2022-01-01 2022-03-31 0000872912 dcth:EightPointZeroPercentageJulyTwoThousandAndNineteenNotesMember us-gaap:ConvertibleNotesPayableMember 2022-01-01 2022-03-31 0000872912 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0000872912 dcth:CommonStockWarrantsEquityMember 2022-01-01 2022-03-31 0000872912 dcth:AssumedConversionOfConvertibleNotesMember 2022-01-01 2022-03-31 0000872912 dcth:AssumedConversionOfSeriesEAndSeriesEOnePreferredStockMember 2022-01-01 2022-03-31 0000872912 dcth:RangeOfExercisePricesPointZeroOneRangeMember 2022-03-31 0000872912 dcth:RangeOfExercisePricesTenPointZeroRangeMember 2022-03-31 0000872912 country:US 2022-03-31 0000872912 country:IE 2022-03-31 0000872912 dcth:ExercisePriceRangeFromSixPointSixOneToNinePointNineNineMember 2022-03-31 0000872912 dcth:ExercisePriceRangeFromTenPointZeroZeroToFourteenPointNineNineMember 2022-03-31 0000872912 dcth:ExercisePriceRangeFromFifteenPointZeroZeroToTwentyFourPointNineNineMember 2022-03-31 0000872912 dcth:ExercisePriceRangeAboveTwentyFiveMember 2022-03-31 0000872912 us-gaap:LandBuildingsAndImprovementsMember 2022-03-31 0000872912 us-gaap:ComputerEquipmentMember 2022-03-31 0000872912 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2022-03-31 0000872912 us-gaap:EquipmentMember 2022-03-31 0000872912 us-gaap:FurnitureAndFixturesMember 2022-03-31 0000872912 us-gaap:SeriesAPreferredStockMember 2022-03-31 0000872912 us-gaap:SeriesBPreferredStockMember 2022-03-31 0000872912 us-gaap:SeriesCPreferredStockMember 2022-03-31 0000872912 us-gaap:SeriesDPreferredStockMember 2022-03-31 0000872912 us-gaap:SeriesEPreferredStockMember 2022-03-31 0000872912 dcth:SeriesE1PreferredStockMember 2022-03-31 0000872912 dcth:LoanAvenueMember 2022-03-31 0000872912 dcth:ConvertibleNotePayableRosalindMember 2022-03-31 0000872912 dcth:ConvertibleLoanPayableAvenueMember 2022-03-31 0000872912 dcth:DecemberThirtyFirstTwoThousandTwentyTwoMember 2022-03-31 0000872912 dcth:DecemberThirtyFirstTwoThousandTwentyThreeMember 2022-03-31 0000872912 dcth:DecemberThirtyFirstTwoThousandTwentyFourMember 2022-03-31 0000872912 dcth:EightPointZeroPercentageJulyTwoThousandAndNineteenNotesMember us-gaap:ConvertibleNotesPayableMember 2022-03-31 0000872912 dcth:MedacMember 2022-03-31 0000872912 us-gaap:LandBuildingsAndImprovementsMember 2021-12-31 0000872912 us-gaap:ComputerEquipmentMember 2021-12-31 0000872912 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2021-12-31 0000872912 us-gaap:EquipmentMember 2021-12-31 0000872912 us-gaap:FurnitureAndFixturesMember 2021-12-31 0000872912 dcth:ConvertibleNotePayableRosalindMember 2021-12-31 0000872912 dcth:LoanAvenueMember 2021-12-31 0000872912 dcth:ConvertibleLoanPayableAvenueMember 2021-12-31 0000872912 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-03-31 0000872912 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0000872912 us-gaap:CostOfSalesMember 2021-01-01 2021-03-31 0000872912 us-gaap:ProductMember 2021-01-01 2021-03-31 0000872912 us-gaap:ProductAndServiceOtherMember 2021-01-01 2021-03-31 0000872912 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000872912 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000872912 us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0000872912 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000872912 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0000872912 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0000872912 dcth:CommonStockWarrantsEquityMember 2021-01-01 2021-03-31 0000872912 dcth:AssumedConversionOfConvertibleNotesMember 2021-01-01 2021-03-31 0000872912 dcth:AssumedConversionOfSeriesEAndSeriesEOnePreferredStockMember 2021-01-01 2021-03-31 0000872912 dcth:TermLoanFromAvenueVentureOpportunitiesFundLpMember 2021-08-06 2021-08-06 0000872912 dcth:SecuredConvertibleNotesPayableMember us-gaap:SeriesEPreferredStockMember 2021-08-06 2021-08-06 0000872912 dcth:TermLoanFromAvenueVentureOpportunitiesFundLpMember us-gaap:WarrantMember 2021-08-06 2021-08-06 0000872912 srt:MaximumMember dcth:TermLoanFromAvenueVentureOpportunitiesFundLpMember 2021-08-06 2021-08-06 0000872912 srt:MinimumMember dcth:TermLoanFromAvenueVentureOpportunitiesFundLpMember 2021-08-06 2021-08-06 0000872912 srt:MaximumMember dcth:TermLoanFromAvenueVentureOpportunitiesFundLpMember 2021-08-06 0000872912 dcth:SecuredConvertibleNotesPayableMember 2021-08-06 0000872912 dcth:TermLoanFromAvenueVentureOpportunitiesFundLpMember 2021-08-06 0000872912 dcth:SecuredConvertibleNotesPayableMember us-gaap:SeriesEPreferredStockMember 2021-08-06 0000872912 dcth:TermLoanFromAvenueVentureOpportunitiesFundLpMember us-gaap:WarrantMember 2021-08-06 0000872912 dcth:TermLoanFromAvenueVentureOpportunitiesFundLpMember us-gaap:ConvertibleDebtMember 2021-08-06 0000872912 dcth:TermLoanFromAvenueVentureOpportunitiesFundLpMember dcth:NonConvertibleDebtMember 2021-08-06 0000872912 us-gaap:SeriesEPreferredStockMember 2021-06-30 0000872912 dcth:CantorFitzgeraldAndCoMember 2020-08-18 2020-08-18 0000872912 srt:MaximumMember dcth:CantorFitzgeraldAndCoMember 2020-08-18 2020-08-18 0000872912 dcth:RothCapitalPartnersLLCMember 2020-08-18 2020-08-18 0000872912 srt:MaximumMember dcth:CantorFitzgeraldAndCoMember 2020-08-18 0000872912 dcth:RothCapitalPartnersLLCMember 2020-08-18 0000872912 dcth:MedacMember 2021-04-01 0000872912 dcth:MedacMember 2020-04-01 2020-04-01 0000872912 dcth:SeriesEConvertiblePreferredStockMember 2022-03-30 0000872912 dcth:SeriesE1ConvertiblePreferredStockMember 2022-03-30 0000872912 dcth:MayTwoThousandAndTwentyTwoEmployeeStockPurchasePlanMember 2021-08-31 0000872912 dcth:MayTwoThousandAndTwentyTwoEmployeeStockPurchasePlanMember 2021-08-01 2021-08-31 0000872912 us-gaap:CommonStockMember 2021-12-31 0000872912 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000872912 us-gaap:RetainedEarningsMember 2021-12-31 0000872912 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000872912 us-gaap:PreferredStockMember 2021-12-31 0000872912 us-gaap:CommonStockMember 2022-03-31 0000872912 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000872912 us-gaap:RetainedEarningsMember 2022-03-31 0000872912 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0000872912 us-gaap:PreferredStockMember 2022-03-31 0000872912 us-gaap:CommonStockMember 2020-12-31 0000872912 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000872912 us-gaap:RetainedEarningsMember 2020-12-31 0000872912 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000872912 us-gaap:PreferredStockMember 2020-12-31 0000872912 us-gaap:CommonStockMember 2021-03-31 0000872912 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000872912 us-gaap:RetainedEarningsMember 2021-03-31 0000872912 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0000872912 us-gaap:PreferredStockMember 2021-03-31 shares pure iso4217:USD utr:Year utr:Day iso4217:EUR utr:Month iso4217:USD shares 0000872912 --12-31 DE NY Q1 false 10-Q true 2022-03-31 2022 false 001-16133 DELCATH SYSTEMS, INC. 06-1245881 1633 Broadway Suite 22C New York 10019 212 489-2100 Common stock, $0.01 par value per share DCTH NASDAQ Yes Yes Non-accelerated Filer true false false 7906728

16340000

22802000

4151000

178000

44000

2011000

1412000

2704000

2743000

25384000

31152000

1406000

1348000

527000

624000

27317000

33124000

1243000

638000

4495000

4109000

170000

404000

416000

2520000

621000

8662000

5954000

122000

207000

8633000

10372000

4675000

4639000

22092000

21172000

0.01

10000000

11357

0.01

40000000

7906728

79000

434305000

432831000

-429179000

-420976000

20000

18000

5225000

11952000

27317000

33124000

207000

261000

171000

127000

33000

112000

345000

276000

4240000

3707000

3648000

3296000

7888000

7003000

-7543000

-6727000

-645000

-41000

-15000

21000

-8203000

-6747000

2000

94000

-8201000

-6653000

-1.00

-1.04

8190483

6496922

11357

7906728

79000

432831000

-420976000

18000

11952000

1474000

-8203000

2000

11357

7906728

79000

434305000

-429179000

20000

5225000

20631

5996101

60000

417449000

-395327000

-104000

22078000

2148000

2636

57000

-150

15000

237520 3000 2373000 2376000

-6747000

94000

20481

6251257

63000

422027000

-402074000

-10000

20006000

-8203000

-6747000

1474000 2148000

31000

39000

97000 155000

194000

40000

39000

-39000

-301000

134000

18000

599000

254000

953000

164000

-97000 -155000

-170000

-239000

-6375000

-4567000

89000

9000

-89000

-9000

2376000

2000

94000

-6462000

-2106000

26953000

28756000

20491000

26650000

16340000

26600000

4151000

50000

20491000

26650000

411000

3000

57000

<div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: "Times New Roman";"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risks and Uncertainties </div></div></div></div> <div style="font-family: "Times New Roman"; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although the Company is not aware of any direct impacts of the war between the Ukraine and the Russian Federation on its supply chain, the war could adversely impact the Company’s ability to obtain components and/or significantly increase the cost of obtaining such components for the Company’s products from its third-party suppliers in a timely manner or at all. In addition, at this time, the Company is not aware of any direct impacts, the increase in COVID cases and associated restrictions, which could adversely impact the Company’s ability to obtain components and/or significantly increase the cost of obtaining such components for the Company’s products from its third-party suppliers in a timely manner or at all. </div></div></div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: "Times New Roman";"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidity and Going Concern </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The accompanying interim condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred significant losses and has an accumulated deficit of $429.2 million as of March 31, 2022. These losses, among other factors, raise substantial doubt about the Company’s ability to continue as a going concern. </div> <div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company’s existence is dependent upon management’s ability to obtain additional funding sources or to enter into strategic alliances. Adequate additional financing may not be available to the Company on acceptable terms, or at all. If the Company is unable to raise additional capital and/or enter into strategic alliances when needed or on attractive terms, it would be forced to delay, reduce, or eliminate its research and development programs or any commercialization efforts. There can be no assurance that the Company’s efforts will result in the resolution of the Company’s liquidity needs. If the Company is not able to continue as a going concern, it is likely that holders of its common stock will lose all of their investment. The accompanying interim condensed consolidated financial statements do not include any adjustments that might result should the Company be unable to continue as a going concern. </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. Additional working capital will be required to continue operations. Operations of the Company are subject to certain risks and uncertainties, including, among others, uncertainty of product development and clinical trial results; uncertainty regarding regulatory approval; technological uncertainty; uncertainty regarding patents and proprietary rights; comprehensive government regulations; limited commercial manufacturing, marketing, or sales experience; and dependence on key personnel.</div>

-429200000

<div style="margin-top: 18pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: "Times New Roman";"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recently Adopted Accounting Pronouncements </div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="font-family: "Times New Roman"; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; text-indent: 0px;"><div style="display:inline;">In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06, “Accounting</div> for Convertible Instruments and Contracts in an Entity’s Own Equity.” ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> requires entities to provide expanded disclosures about the terms and features of convertible instruments and amends certain guidance in Accounting Standards Codification 260, Earnings per Share, relating to the computation of earnings per share for convertible instruments and contracts in an entity’s own equity. The guidance becomes effective for the Company on January 1, 2024, with early adoption permitted. The Company early adopted ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> on January 1, 2022 and the adoption did not have any immediate effect on the Company’s condensed consolidated financial statements. Going forward, the Company will no longer be required to assess convertible instruments for beneficial conversion features. </div></div> <div style="font-family: "Times New Roman"; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; text-indent: 0px;"><div style="display:inline;">In October 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-10</div> “Codification Improvements”, which improves consistency by amending the Codification to include all disclosure guidance in the appropriate disclosure sections and clarifies application of various provisions in the Codification by amending and adding new headings, cross referencing to other guidance, and refining or correcting terminology. The guidance was effective for the Company beginning in the first quarter of fiscal year 2022 with early adoption permitted. The Company adopted this guidance on January 1, 2022 and it did not have a material impact on its condensed consolidated financial statements. </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On May 3, 2021, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2021-04,</div> “Earnings Per Share” (Topic 260), “Debt—Modifications and Extinguishments” (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-50),</div> “Compensation—Stock Compensation” (Topic 718), and “Derivatives and Hedging—Contracts in Entity’s Own Equity” (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40):</div> “Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options.” This new standard provides clarification and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (such as warrants) that remain equity classified after modification or exchange. This standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Issuers should apply the new standard prospectively to modifications or exchanges occurring after the effective date of the new standard. Early adoption is permitted, including adoption in an interim period. If an issuer elects to early adopt the new standard in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The Company adopted this guidance on January 1, 2022 and it did not have a material impact on its condensed consolidated financial statements. </div></div>

16340000

22802000

4000000 4000000 101000 101000 50000 50000

20491000

26953000

841000

767000

881000

645000

289000

2011000

1412000

1630000 1630000

645000

890000

429000

223000

2704000

2743000

<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%; vertical-align: top;;text-align:left;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(5)</div></div></div></td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property, Plant, and Equipment </div></div></div></div></td></tr></table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"/> <div style="font-family: "Times New Roman"; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; text-indent: 0px;"><div style="display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property, plant, and equipment consist of the following (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><br/></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 56%;"/> <td style="width: 9%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 8%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 8%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31,<br/>2022</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/>2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated Useful Life</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;"> </div></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Buildings and land</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,222</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,222</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="text-align: right; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">30 years-<br/>Buildings</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Enterprise hardware and software</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,858</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,858</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">3 years</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Leaseholds</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,788</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,796</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">Lesser of<br/>lease<br/>term or<br/>estimated<br/>useful<br/>life</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Equipment</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,184</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,094</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">7 years</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Furniture</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">202</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">203</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="margin-bottom: 0px; margin-top: 0px; text-align: right; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">5 years</div></div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td> <td><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td> <td><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td> <td><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Property, plant and equipment, gross</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,254</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,173</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Accumulated depreciation</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,848</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,825</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td> <td><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td> <td><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td> <td><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Property, plant and equipment, net</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,406</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,348</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"> </div></td></tr> <tr> <td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 1pt; font-family: "Times New Roman"; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"><div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"><div style="font-size: 1pt; line-height: 1pt; margin-bottom: 0px; margin-top: 0px;"> </div></td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"><div style="font-size: 1pt; line-height: 1pt; margin-bottom: 0px; margin-top: 0px;"> </div></td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"><div style="font-size: 1pt; line-height: 1pt; margin-bottom: 0px; margin-top: 0px;"> </div></td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"><div style="font-size: 1pt; line-height: 1pt; margin-bottom: 0px; margin-top: 0px;"> </div></td></tr></table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="clear: both; max-height: 0pt; text-indent: 0px;"/> <div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div><div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="clear: both; max-height: 0pt; text-indent: 0px;"/> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Depreciation expense for the three months ended March 31, 2022 was approximately $31,000 as compared to approximately $39,000 for the same period in 2021. </div>

1222000

P30Y

1858000

P3Y

1788000

1796000

Lesser ofleaseterm orestimatedusefullife

1184000

1094000

P7Y

202000

203000

P5Y

6254000

6173000

4848000

4825000

1406000

1348000

31000

39000

<div style="font-family: "Times New Roman"; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses consist of the following (in thousands): </div></div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 76%;"/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31,<br/>2022</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/>2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Clinical expenses</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,578</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,517</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Compensation, excluding taxes</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">796</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">893</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Short term financing</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">315</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">551</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Professional fees</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,298</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">603</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Interest on convertible note</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">433</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">393</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Other</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">75</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">152</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Total accrued expenses</div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,495</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,109</td> <td style="white-space:nowrap;vertical-align:bottom"> </td></tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"/> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div>

1578000 1517000

796000

893000

315000 551000

1298000

603000

433000

393000

75000

152000

4495000

4109000

<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7)</div></div></td> <td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: "Times New Roman"; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Leases </div></div></td></tr></table> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> (“ROU”) assets and lease liabilities when it obtains the right to control an asset under a leasing arrangement with an initial term greater than twelve months. The Company leases its facilities under <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancellable</div> operating and financing leases. </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates the nature of each lease at the inception of an arrangement to determine whether it is an operating or financing lease and recognizes the ROU asset and lease liabilities based on the present value of future minimum lease payments over the expected lease term. The Company’s leases do not generally contain an implicit interest rate and therefore the Company uses the incremental borrowing rate it would expect to pay to borrow on a similar collateralized basis over a similar term in order to determine the present value of its lease payments. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"> </div> <div style="font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the Company’s operating leases as of and for the three months ended March 31, 2022 (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 80%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">U.S.</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ireland</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Lease cost:</div><br/></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Operating lease cost</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">101</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">109</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Other information:</div><br/></div> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Operating cash flows out from operating leases</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(101</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div><br/></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div><br/></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(109</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Weighted average remaining lease term</div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">0.9</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">4.4</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> </tr> <tr style="break-inside: avoid; font-family: "Times New Roman"; font-size: 10pt;"> <td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Weighted average discount rate - operating leases</div> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">8</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">% </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">8</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">% </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="font-family: "Times New Roman"; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Remaining maturities of the Company’s operating leases, excluding short-term leases, are as follows (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 80%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">U.S.</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ireland</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Year ended December 31, 2022</div><br/></div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">304</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div><br/></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">35</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">339</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Year ended December 31, 2023</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">67</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">46</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Year ended December 31, 2024</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">46</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">46</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Year ended December 31, 2025</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">46</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">46</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Year ended December 31, 2026</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Total</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">371</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">199</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">570 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Less present value discount</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(30</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(44</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal; white-space: nowrap;">Operating lease liabilities included in the<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>consolidated balance sheets at March 31, 2022</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div><br/></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">357</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">169 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">526</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/>

P12M

<div style="font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the Company’s operating leases as of and for the three months ended March 31, 2022 (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 80%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">U.S.</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ireland</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Lease cost:</div><br/></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Operating lease cost</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">101</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">109</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Other information:</div><br/></div> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Operating cash flows out from operating leases</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(101</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div><br/></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(8</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div><br/></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(109</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Weighted average remaining lease term</div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">0.9</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">4.4</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> </tr> <tr style="break-inside: avoid; font-family: "Times New Roman"; font-size: 10pt;"> <td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Weighted average discount rate - operating leases</div> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">8</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">% </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> </td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">8</td> <td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">% </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/>

101000

8000

109000

101000

8000

109000

P0Y10M24D P4Y4M24D

0.08

<div style="font-family: "Times New Roman"; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Remaining maturities of the Company’s operating leases, excluding short-term leases, are as follows (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 80%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">U.S.</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ireland</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Year ended December 31, 2022</div><br/></div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">304</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div><br/></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">35</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">339</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Year ended December 31, 2023</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">67</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">46</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Year ended December 31, 2024</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">46</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">46</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Year ended December 31, 2025</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">46</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">46</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Year ended December 31, 2026</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">26 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Total</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">371</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">199</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">570 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Less present value discount</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(14</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(30</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(44</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal; white-space: nowrap;">Operating lease liabilities included in the<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>consolidated balance sheets at March 31, 2022</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div><br/></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">357</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">169 </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">526</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/>

304000

35000

339000

67000

46000

113000

46000

26000

371000

199000

570000

14000

30000

44000

357000

169000

526000

<div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <div style="clear: both; max-height: 0pt; text-indent: 0px;"/> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%; vertical-align: top;;text-align:left;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(8)</div></div></div></td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loans and Convertible Notes Payable </div></div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 62%;"/> <td style="width: 1%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 1%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 1%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 1%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 1%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 1%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in thousands):</div></div></div></td> </tr> </table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"/> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 62%;"/> <td style="width: 1%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 1%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 1%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 1%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 1%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 1%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> </table> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31, 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Discount</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Discount</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Loan - Avenue <div style="font-size:85%; vertical-align:top;display:inline;;font-size:9.4px">[1] </div></div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,638</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,485</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,153</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,638</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,645</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,993</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Loan - Avenue <div style="font-size:85%; vertical-align:top;display:inline;;font-size:9.4px">[1] </div>- Less Current Portion</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,856</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">336</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,520</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(714</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">93</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(621</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Total - Loans Payable, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Current</div></div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,782</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,149</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,633</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 11,924</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,552</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,372</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Convertible Note Payable - Rosalind</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Convertible Portion of Loan Payable - Avenue</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(325</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,675</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(361</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,639</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Total - Convertible Notes Payable - <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Current</div></div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(325</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,675</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(361</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,639</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;"><div style="font-size:85%; vertical-align:top;display:inline;;font-size:9.4px">[1]</div> </td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: "Times New Roman"; text-align: left; line-height: normal;">The gross amount includes the 4.25% final payment of $638,000. </div> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Remaining maturities of the Company’s loan and convertible note payables are as follows (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 71%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Loans</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Convertible</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Notes</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Year ended December 31, 2022</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">714</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">714</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Year ended December 31, 2023</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,571</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,571</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Year ended December 31, 2024</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,353</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,353</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Total</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,638</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,638</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Term Loan from Avenue Venture Opportunities Fund, L.P. </div></div></div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;">On August 6, 2021, the Company entered into a Loan and Security Agreement (the “Avenue Loan Agreement”) with Avenue Venture Opportunities Fund, L.P. (the “Lender,” or “Avenue”) for a term loan in an aggregate principal amount of up to $20 <div style="letter-spacing: 0px; top: 0px;;display:inline;">million </div>(the “Avenue Loan”). The Avenue Loan bears interest at an annual rate equal to the greater of (a) the sum of 7.70% plus the prime rate as reported in The Wall Street Journal and (b) 10.95%. The interest rate at March 31, 2022 was 10.95%. The Avenue Loan is secured by all of the Company’s assets globally, including intellectual property. The Avenue Loan matures on August 1, 2024. </div> <div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;">The initial tranche of the Avenue Loan is $15.0 <div style="letter-spacing: 0px; top: 0px;;display:inline;">million, </div>including $4.0 <div style="letter-spacing: 0px; top: 0px;;display:inline;">million </div>which has been funded into a restricted account and will be released upon achievement of (a)(x) positive FOCUS trial efficacy per the trial’s predefined Statistical Analysis Plan (SAP) (specifically the Overall Response Rate exceeds the <div style="letter-spacing: 0px; top: 0px;;display:inline;">pre-specified</div> threshold for success defined in the SAP by a statistically significant amount); and (y) based on data contained within the FOCUS trial database and appropriate for use with the U.S. Food and Drug Administration, safety and tolerability among FOCUS trial participants is within the range of currently approved and commonly used cytotoxic chemotherapeutic agents; and (b) raising subsequent net equity proceeds of at least $20<div style="letter-spacing: 0px; top: 0px;;display:inline;"> million</div>. The Company may request an additional $5.0 <div style="letter-spacing: 0px; top: 0px;;display:inline;">million </div>of gross proceeds between October 1, 2022 and December 31, 2022, with funding, subject to the approval of Avenue’s Investment Committee. </div> <div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;">Up to $3<div style="letter-spacing: 0px; top: 0px;;display:inline;"> million</div> of the principal amount of the Avenue Loan outstanding may be converted, at the option of Avenue, into shares of the Company’s common stock at a conversion price of $11.98 per share. </div> <div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;">In connection with the Avenue Loan, the Company issued to Avenue a warrant (the “Avenue Warrant”) to purchase 127,755 shares of common stock at an exercise price per share equal to $0.01. The Avenue Warrant is exercisable until August 31, 2026. </div> <div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;">The Company will make monthly interest-only payments during the first fifteen months of the term of the Avenue Loan, which could be increased to up to twenty-four months upon the achievement of specified performance milestones. Following the interest-only period, the Company will make equal monthly payments of principal plus interest until the maturity date, when all remaining principal outstanding and accrued interest must be paid. If the Company prepays the Avenue Loan, it will be required to pay (a) a prepayment fee of 3% if the Avenue Loan is prepaid during the interest-only period; and (b) a prepayment fee of 1% if the Avenue Loan is prepaid after the interest-only period. The Company must make an incremental final payment equal to 4.25% of the aggregate funding. </div> <div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;">The Company paid an aggregate commitment fee of $150,000 at closing. Upon funding a second tranche of the Avenue Loan, the Lender will earn a 1.0% fee on the $5.0 million of incremental committed capital, for a total commitment fee of $0.2 million. </div> <div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;">The Avenue Loan Agreement requires the Company to make and maintain representations and warranties and other agreements that are customary in loan agreements of this type. The Avenue Loan Agreement also contains customary events of default, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-payment</div> of principal or interest, violations of covenants, bankruptcy and material judgments. </div> <div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;">The Company determined that the embedded conversion option associated with the Avenue Loan was not required to be bifurcated. The Company determined that the Avenue Warrant met the criteria to be equity-classified. The $0.6 million value of the final payment was treated as original issue discount. The $1.2 million relative fair value of the Avenue Warrant was credited to Additional Paid in Capital while it was debited as debt discount. Of the $563,000 of cash issuance costs, $519,000 was allocated to the Avenue Loan and was recorded as debit discount, while $44,000 was allocated to the Avenue Warrant and was debited to Additional Paid in Capital. Of the $2.3 million of aggregate debt discount, $1.9 million was allocated to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-convertible</div> portion of the Avenue Loan, while $418,000 was allocated to the convertible portion of the Avenue Loan. Aggregate debt discount amortization of $0.2 million was recorded during the three months ended March 31, 2022, including $159,000 related to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-convertible</div> portion of the Avenue Loan and $35,000 related to the convertible portion of the Avenue Loan. The Company also determined that the convertible portion of the Avenue Loan did not include a beneficial conversion feature, because the effective conversion price exceeded the commitment date market price of the Company’s common stock. Interest expense incurred was $0.4 million for the three months ended March 31, 2022. </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Avenue Warrant was valued at issuance at $1.3 million using the Black-Scholes option pricing method using the following assumptions:<br/></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 89%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">August 6,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Contractual term (years)</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.07</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Expected volatility</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">187.0</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Risk-free interest rate</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.77</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Expected dividends</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.00</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: "Times New Roman";"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Convertible Notes Payable </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company has $2.0 million of principal outstanding related to Senior Secured Promissory Notes (the “Rosalind Notes”) which bear interest at 8% per annum. Pursuant to their original terms, the Rosalind Notes were convertible into Series E Preferred Stock at a price of $1,500 per share and were to mature on July 16, 2021<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">.</div></div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>Interest expense was $40 for the three months ended March 31, 2022 and 2021, respectively. </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On August 6, 2021, the Company executed an agreement to amend the Rosalind Notes to (a) reduce the conversion price to $1,198 per share of the Company’s Series E Convertible Preferred Stock; and (b) extend the maturity date to October 30, 2024. </div> <div style="font-family: "Times New Roman"; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, in order to induce Avenue. to provide the Avenue Loan described above, the holders of the Rosalind Notes agreed to subordinate (a) all of the Company’s indebtedness and obligations to the holders; and (b) all of the holders’ security interest, to the Avenue Loan and Avenue’s security interest in the Company’s property. </div></div><br/></div>

<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31, 2022</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="10" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Discount</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Discount</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Loan - Avenue <div style="font-size:85%; vertical-align:top;display:inline;;font-size:9.4px">[1] </div></div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,638</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,485</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,153</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,638</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,645</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,993</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Loan - Avenue <div style="font-size:85%; vertical-align:top;display:inline;;font-size:9.4px">[1] </div>- Less Current Portion</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,856</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">336</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,520</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(714</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">93</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(621</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Total - Loans Payable, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Current</div></div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,782</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,149</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,633</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"> 11,924</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,552</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,372</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Convertible Note Payable - Rosalind</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Convertible Portion of Loan Payable - Avenue</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(325</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,675</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(361</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,639</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Total - Convertible Notes Payable - <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Current</div></div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(325</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,675</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(361</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,639</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;"> </div> <table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;"><div style="font-size:85%; vertical-align:top;display:inline;;font-size:9.4px">[1]</div> </td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: "Times New Roman"; text-align: left; line-height: normal;">The gross amount includes the 4.25% final payment of $638,000. </div> </td> </tr> </table>

12638000 -1485000 11153000 12638000 -1645000 10993000 -2856000 336000

2520000

-714000 93000

621000

9782000 -1149000

8633000

11924000 -1552000

10372000

2000000 2000000 2000000 2000000 3000000 -325000 2675000 3000000 -361000 2639000 5000000 -325000 4675000 5000000 -361000 4639000 0.0425 638000

<div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Remaining maturities of the Company’s loan and convertible note payables are as follows (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 71%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Loans</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Convertible</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Notes</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Year ended December 31, 2022</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">714</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">714</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Year ended December 31, 2023</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,571</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,571</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Year ended December 31, 2024</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,353</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,353</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Total</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">12,638</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,638</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/>

714000

8571000

3353000

5000000

8353000

12638000

5000000

17638000

20000000

The Avenue Loan bears interest at an annual rate equal to the greater of (a) the sum of 7.70% plus the prime rate as reported in The Wall Street Journal and (b) 10.95%. The interest rate at March 31, 2022 was 10.95%. The Avenue Loan is secured by all of the Company’s assets globally, including intellectual property.

0.0770

0.1095

2024-08-01

15000000.0 4000000.0

20000000

5000000.0 127755

0.01

2026-08-31

monthly

P15M P24M 0.03 0.01 0.0425

150000

0.010 5000000.0 200000 600000

1200000

563000

519000

44000

2300000

1900000

418000

200000

159000

35000

400000

<div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Avenue Warrant was valued at issuance at $1.3 million using the Black-Scholes option pricing method using the following assumptions:<br/></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 89%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">August 6,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Contractual term (years)</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.07</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Expected volatility</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">187.0</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Risk-free interest rate</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.77</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Expected dividends</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.00</td> <td style="white-space:nowrap;vertical-align:bottom">% </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/>

1300000

P5Y25D

1.870

0.0077

0.0000

2000000.0

0.08

1500

40000

1198

2024-10-30

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: "Times New Roman"; font-size: 10pt; border: 0px; width: 100%; text-indent: 0px;"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(9)</div></div></td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: "Times New Roman"; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Stockholders’ Equity </div></div> </td> </tr> </table> <div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Authorized Shares </div></div></div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company is authorized to issue 40,000,000 shares of common stock, $0.01 par value, and</div> 10,000,000 shares of preferred stock, $0.01 par value. To date, the Company has designated the following preferred stock: Series A (4,200 shares), Series B (2,360 shares), Series C (590 shares), Series D (10,000 shares), Series E (40,000 shares) and Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">E-1</div> (12,960 shares). </div> <div style="font-family: "Times New Roman"; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Preferred Stock </div></div></div></div></div> <div style="font-family: "Times New Roman"; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March 30, 2022, there were an aggregate of 11,707 shares of Series E and Series E-1 Convertible Preferred Stock outstanding. </div></div></div> <div style="font-family: "Times New Roman"; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Omnibus Equity Incentive Plan </div></div></div></div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;">On September 30, 2020, the Company’s 2020 Omnibus Equity Incentive Plan (the “2020 Plan”) was adopted by the Company’s Board of Directors. On November 23, 2020, the Company’s stockholders approved the 2020 Plan. The 2020 Plan will continue in effect until the tenth anniversary of the date of its adoption by the Board or until earlier terminated by the Board. The 2020 Plan is administered by the Board of Directors or a committee designated by the Board of Directors. The 2020 Plan provides for the grant of incentive stock options, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-qualified</div> stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards, as well as other stock-based awards or cash awards that are deemed to be consistent with the purposes of the plan to Company employees, directors and consultants. As of March 31, 2022, there are 2,475,000 shares of common stock reserved under the 2020 Plan, of which 737,957 remained available to be issued. </div> <div style="font-family: "Times New Roman"; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Employee Stock Purchase Plan </div></div></div></div></div> <div style="font-family: "Times New Roman"; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2021, the Company’s Board of Directors, with shareholder approval in May 2022, adopted the Employee Stock Purchase Plan (ESPP). The Company ESPP’s plan provides for a maximum of 260,295 shares of common stock to <div style="display:inline;">be purchased by </div>participating employees. Employees who elect to participate in the Company’s ESPP will be able to purchase common stock at the lower of 85% of the fair market value of common stock on the first or last day of the applicable six-month offering period. </div></div></div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Equity Offerings and Placements </div></div></div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">At-the-Market</div></div> Offering </div></div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;">On August 18, 2020, the Company entered into a sales agreement with Cantor Fitzgerald & Co. (“Cantor Fitzgerald”), pursuant to which the Company may offer and sell, from time to time, through Cantor Fitzgerald, as sales agent or principal, shares of the Company’s common stock, (the “Placement Shares”), having an aggregate offering price of up to $10.0 million (the “ATM Offering”). The Company has no obligation to sell any Placement Shares under the sales agreement. Subject to the terms and conditions of the sales agreement, Cantor Fitzgerald is required to use commercially reasonable efforts, consistent with its normal trading and sales practices, applicable state and federal law, rules and regulations and the rules of the Nasdaq Stock Market, to sell Placement Shares from time to time based upon the Company’s instructions, including any price, time or size limits specified by the Company. The Company will pay Cantor Fitzgerald a commission of 3.0% of the aggregate gross proceeds from each sale of Placement Shares, reimburse Cantor Fitzgerald’s legal fees and disbursements up to $50,000 and provide Cantor Fitzgerald with customary indemnification and contribution rights. The sales agreement may be terminated by Cantor Fitzgerald or the Company upon notice to the other party as provided in the sales agreement, or by Cantor Fitzgerald at any time in certain circumstances, including the occurrence of a material and adverse change in the Company’s business or financial condition that makes it impractical or inadvisable to market the Placement Shares or to enforce contracts for the sale of the Placement Shares. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt; text-indent: 0px;"> </div> <div style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In connection with the ATM Offering, in consideration for a fee equal to 1.05% of the gross sales price per share sold in the ATM Offering, ROTH Capital Advisors, LLC (“Roth”) waived, solely with respect to the ATM Offering, (i) Roth’s right, pursuant to certain engagement letters dated August 14, 2019 and January 13, 2020 between Roth and the Company, to act as placement agent or underwriter with respect to offerings of the Company’s securities and to receive a minimum of 35% of the fees paid to the agents or underwriters for such offerings and (ii) the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> provision included in a certain underwriting agreement dated May 1, 2020 between Roth and the Company requiring the prior written consent of Roth for any offer or sale of the Company’s common stock by the Company during the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">90-day</div> period following the date of such underwriting agreement. </div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">There were no shares sold during the three months ended March 31, 2022. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: "Times New Roman";"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Options </div></div></div></div> <div style="font-family: "Times New Roman"; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company values stock options using the Black-Scholes option pricing model and used the following assumptions during the reporting periods: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 61%;"/> <td style="width: 12%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 18%; vertical-align: bottom;"/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="5" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended March 31,</div></div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> 2022</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.375pt;"> <div style="line-height: normal;"> </div> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; text-align: center; border-bottom: 0.75pt solid black;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><br/></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 61%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Expected terms (years)</div><br/></div> </td> <td style="vertical-align: bottom; width: 12%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space: nowrap; vertical-align: bottom; text-indent: 0px;;text-align:right;">5.46 <div style="letter-spacing: 0px; top: 0px;;display:inline;">-<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div>6.46</td> <td style="white-space: nowrap; vertical-align: bottom; padding: 0px;"> <div style="line-height: normal;"> </div> </td> <td style="vertical-align: bottom; width: 18%; text-indent: 0px; text-align: center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">N/A</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><br/></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; width: 61%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div><br/></div> </td> <td style="vertical-align: bottom; width: 12%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space: nowrap; vertical-align: bottom; text-indent: 0px;;text-align:right;">174.81% <div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div> 177.09</td> <td style="white-space:nowrap;vertical-align:bottom"> <div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div><br/></div> </td> <td style="vertical-align: bottom; width: 18%; text-indent: 0px; text-align: center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">N/A</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><br/></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top; width: 61%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Risk-free interest rate</div> </td> <td style="vertical-align: bottom; width: 12%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space: nowrap; vertical-align: bottom; text-indent: 0px;;text-align:right;">1.75% <div style="letter-spacing: 0px; top: 0px;;display:inline;">-</div> 1.90</td> <td style="white-space:nowrap;vertical-align:bottom"> <div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div><br/></div> </td> <td style="vertical-align: bottom; width: 18%; text-indent: 0px; text-align: center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">N/A</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><br/></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top; width: 61%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Expected dividends</div> </td> <td style="vertical-align: bottom; width: 12%;"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.00 </td> <td style="white-space:nowrap;vertical-align:bottom"> <div style="line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">%</div><br/></div> </td> <td style="vertical-align: bottom; width: 18%; text-align: center;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">N/A</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><br/></td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The weighted average estimated fair value of the stock options granted during the three months ended March 31, 2022 was approximately $6.86 per share. </div> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">The following is a summary of stock option activity for the three months ended March 31, 2022:</div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 40%;"/> <td style="width: 11%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 10%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 11%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 11%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of Option</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted Average</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Price Per Share</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted Average</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remaining Contractual</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Term</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in years)</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate Intrinsic</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Outstanding at January 1, 2022</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,732,460</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11.69</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Granted</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">549,333</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.10</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Expired</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6,650</td> <td style="white-space:nowrap;vertical-align:bottom">)</td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10.88</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Cancelled/Forfeited</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(37,040</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10.42</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Outstanding at March 31, 2022</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,238,103</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10.60</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.2</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Exercisable at March 31, 2022</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">766,619</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11.83</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.7</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr> <td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 1pt; font-family: "Times New Roman"; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> </table> <div style="font-family: "Times New Roman"; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes information for stock option shares outstanding and exercisable at March 31, 2022: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 42%;"/> <td style="width: 13%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 13%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 13%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options Exercisable</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: "Times New Roman"; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: "Times New Roman"; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Range of Exercise Prices</div></div></div></div> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Outstanding Number</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">of Options</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted Average</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remaining Option Term (in</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">years)</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of Options</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">$6.61 - $9.99</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">825,256</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.2</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">110,389</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">$10.00 - $14.99</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,280,348</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.7</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">592,317</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">$15.00 - $24.99</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">132,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.5</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">63,414</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">$25 +</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">499</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.8</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">499</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,238,103</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.7</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">766,619</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-family: "Times New Roman"; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following is a summary of share-based compensation expense in the statement of operations for the three months ended March 31, 2022 (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 78%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended March 31,</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Selling, general and administrative</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">919</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,466</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Research and development</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">503</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">630</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Cost of goods sold</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">52</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">52</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Total</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,474</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,148</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">At March 31, 2022, there was $9.2 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million of aggregate unrecognized compensation expense related employee and board stock option grants. The cost is expected to be recognized over a weighted average period of 3 years. </div></div></div> <div style="margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%; font-size: 10pt; font-family: "Times New Roman";"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Warrants </div></div></div></div> <div style="font-family: "Times New Roman"; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following is a summary of warrant activity for the three months ended March 31, 2022: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 57%;"/> <td style="width: 9%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 9%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 9%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Warrants</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted Average<br/>Exercise Price</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted Average<br/>Remaining Life<br/>(in years)</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Outstanding at January 1, 2022</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,894,498</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.27</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Warrants issued</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Warrants exercised</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Warrants expired</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Outstanding at March 31, 2022</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,894,498</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.27</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.0</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Exercisable at March 31, 2022</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,894,498</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.27</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.0</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information related to stock warrants at March 31, 2022 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 43%;"/> <td style="width: 12%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 12%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 12%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Warrants Exercisable</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: "Times New Roman"; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: "Times New Roman"; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Range of Exercise Prices</div></div></div></div> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Outstanding Number<br/>of Warrants</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted Average<br/>Remaining Warrant Term<br/>(in years)</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of Warrants</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">$0.01</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">283,755</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.7</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">283,755</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">$10.00</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,610,743</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.9</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,610,743</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,894,498</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.0</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,894,498</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr> <td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> </table>

40000000

0.01

10000000

0.01

4200

2360

590

10000

40000

12960

11707

2475000

737957

260295

0.85

10000000.0 0.030 50000 0.0105 0.35 P90D

P5Y5M15D

P6Y5M15D

1.7481

1.7709

0.0175

0.0190

0.0000

6.86

<div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">The following is a summary of stock option activity for the three months ended March 31, 2022:</div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 40%;"/> <td style="width: 11%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 10%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 11%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 11%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of Option</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted Average</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Price Per Share</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted Average</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remaining Contractual</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Term</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in years)</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate Intrinsic</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Outstanding at January 1, 2022</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,732,460</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11.69</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Granted</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">549,333</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7.10</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Expired</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6,650</td> <td style="white-space:nowrap;vertical-align:bottom">)</td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10.88</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Cancelled/Forfeited</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(37,040</td> <td style="white-space:nowrap;vertical-align:bottom">) </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10.42</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Outstanding at March 31, 2022</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,238,103</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10.60</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.2</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Exercisable at March 31, 2022</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">766,619</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11.83</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.7</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr> <td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 1pt; font-family: "Times New Roman"; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> </table>

1732460

11.69

549333

7.10

6650

10.88

37040

10.42

2238103

10.60

P9Y2M12D

766619

11.83

P8Y8M12D

<div style="font-family: "Times New Roman"; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes information for stock option shares outstanding and exercisable at March 31, 2022: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 42%;"/> <td style="width: 13%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 13%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 13%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options Exercisable</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: "Times New Roman"; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: "Times New Roman"; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Range of Exercise Prices</div></div></div></div> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Outstanding Number</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">of Options</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted Average</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remaining Option Term (in</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">years)</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of Options</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">$6.61 - $9.99</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">825,256</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.2</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">110,389</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">$10.00 - $14.99</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,280,348</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.7</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">592,317</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">$15.00 - $24.99</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">132,000</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.5</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">63,414</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: "Times New Roman"; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">$25 +</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">499</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.8</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">499</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,238,103</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.7</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">766,619</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table>

825256

P9Y2M12D

110389

1280348

P8Y8M12D

592317

132000

P8Y6M

63414

499

P6Y9M18D

499

2238103

P8Y8M12D

766619

<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-family: "Times New Roman"; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following is a summary of share-based compensation expense in the statement of operations for the three months ended March 31, 2022 (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 78%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended March 31,</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Selling, general and administrative</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">919</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,466</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Research and development</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">503</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">630</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Cost of goods sold</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">52</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">52</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Total</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,474</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,148</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table>

919000 1466000 503000 630000 52000 52000 1474000 2148000

9200000

P3Y

<div style="font-family: "Times New Roman"; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following is a summary of warrant activity for the three months ended March 31, 2022: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 57%;"/> <td style="width: 9%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 9%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 9%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Warrants</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted Average<br/>Exercise Price</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted Average<br/>Remaining Life<br/>(in years)</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Outstanding at January 1, 2022</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,894,498</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.27</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Warrants issued</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Warrants exercised</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Warrants expired</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">— </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Outstanding at March 31, 2022</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,894,498</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.27</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.0</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Exercisable at March 31, 2022</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,894,498</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom">$</td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.27</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.0</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table>

3894498

9.27 0 0 0 0 0 0

3894498

9.27 P3Y 3894498 9.27 P3Y <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information related to stock warrants at March 31, 2022 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="font-size: 0px;"> <td style="width: 43%;"/> <td style="width: 12%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 12%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 12%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Warrants Exercisable</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: "Times New Roman"; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: "Times New Roman"; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Range of Exercise Prices</div></div></div></div> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Outstanding Number<br/>of Warrants</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted Average<br/>Remaining Warrant Term<br/>(in years)</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of Warrants</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">$0.01</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">283,755</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.7</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">283,755</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">$10.00</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,610,743</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.9</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,610,743</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,894,498</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.0</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,894,498</td> <td style="white-space:nowrap;vertical-align:bottom"> </td> </tr> <tr> <td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.5pt double black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 1.25pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> </tr> </table>

283755

P3Y8M12D 283755

3610743

P2Y10M24D 3610743

3894498

P3Y 3894498

<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"> <tr style="page-break-inside:avoid"> <td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(10)</div></div></td> <td style="vertical-align:top;text-align:left;"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: "Times New Roman"; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Net Loss per Common Share</div></div> </td> </tr> </table> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Basic net loss per share is determined by dividing net loss by the weighted average shares of common stock outstanding during the period, without consideration of potentially dilutive securities, except for those shares that are issuable for little or no cash consideration. Diluted net loss per share is determined by dividing net loss by diluted weighted average shares outstanding. Diluted weighted average shares reflects the dilutive effect, if any, of potentially dilutive common shares, such as stock options and warrants calculated using the treasury stock method. In periods with reported net operating losses, all common stock options and warrants are generally deemed anti-dilutive such that basic net loss per share and diluted net loss per share are equal. </div> <div style="font-family: "Times New Roman"; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following potentially dilutive securities were excluded from the computation of earnings per share as of March 31, 2022 and 2021 because their effects would be anti-dilutive: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="color: white; line-height: 0pt; visibility: hidden;"> <td style="width: 76%;"> </td> <td style="width: 2%; vertical-align: bottom;"> </td> <td> </td> <td style="white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td> </td> <td style="width: 2%; vertical-align: bottom;"> </td> <td> </td> <td style="white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td> </td> </tr> <tr style="font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31,</div></div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Stock options</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;">2,238,103</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;">1,078,499</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Common stock warrants - equity</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;">3,894,498</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;">3,994,107</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Assumed conversion of Series E and Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">E-1</div> Preferred Stock</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;">1,135,721</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;">2,048,101</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Assumed conversion of convertible notes</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;">488,031</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;">146,288</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Total</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;">7,756,353</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;">7,266,995</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">At March 31, 2022, the Company had 283,755 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants outstanding. The following table provides a reconciliation of the weighted average shares outstanding calculation for the three months ended March 31, 2022 and 2021: </div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="color: white; line-height: 0pt; visibility: hidden;"> <td style="width: 76%;"> </td> <td style="width: 2%; vertical-align: bottom;"> </td> <td> </td> <td style="white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td> </td> <td style="width: 2%; vertical-align: bottom;"> </td> <td> </td> <td style="white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td> </td> </tr> <tr style="font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended March 31,</div></div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Weighted average shares issued</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;">7,906,728</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;">6,125,922</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Weighted average <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;">283,755</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;">371,000</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Weighted average shares outstanding</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;">8,190,483</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;">6,496,922</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table>

<div style="font-family: "Times New Roman"; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following potentially dilutive securities were excluded from the computation of earnings per share as of March 31, 2022 and 2021 because their effects would be anti-dilutive: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="color: white; line-height: 0pt; visibility: hidden;"> <td style="width: 76%;"> </td> <td style="width: 2%; vertical-align: bottom;"> </td> <td> </td> <td style="white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td> </td> <td style="width: 2%; vertical-align: bottom;"> </td> <td> </td> <td style="white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td> </td> </tr> <tr style="font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March 31,</div></div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Stock options</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;">2,238,103</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;">1,078,499</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Common stock warrants - equity</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;">3,894,498</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;">3,994,107</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Assumed conversion of Series E and Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">E-1</div> Preferred Stock</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;">1,135,721</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;">2,048,101</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Assumed conversion of convertible notes</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;">488,031</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;">146,288</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Total</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;">7,756,353</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;">7,266,995</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table>

2238103

1078499

3894498

3994107

1135721

2048101

488031

146288

7756353

7266995

283755

The following table provides a reconciliation of the weighted average shares outstanding calculation for the three months ended March 31, 2022 and 2021: <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"> <tr style="color: white; line-height: 0pt; visibility: hidden;"> <td style="width: 76%;"> </td> <td style="width: 2%; vertical-align: bottom;"> </td> <td> </td> <td style="white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td> </td> <td style="width: 2%; vertical-align: bottom;"> </td> <td> </td> <td style="white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td> </td> </tr> <tr style="font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three months ended March 31,</div></div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Weighted average shares issued</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;">7,906,728</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;">6,125,922</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Weighted average <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;">283,755</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;">371,000</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="page-break-inside:avoid ; font-family:Def.-Times; font-size:10pt;background-color:#cceeff"> <td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: "Times New Roman"; line-height: normal;">Weighted average shares outstanding</div> </td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;">8,190,483</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align:bottom"> </td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;">6,496,922</div></td> <td style="white-space:nowrap;vertical-align:bottom"><div style="font-family: "Times New Roman"; letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size:1px"> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align:bottom"> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table>

7906728

6125922

283755 371000

8190483

6496922

<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-family: "Times New Roman", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(11)</div></div></div></div></td> <td style="vertical-align: top;;text-align:left;"> <div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: "Times New Roman", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div></div></div> </td> </tr> </table> <div style="font-family: "Times New Roman", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: "Times New Roman", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: "Times New Roman", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: "Times New Roman", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: "Times New Roman", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: "Times New Roman", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: "Times New Roman", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: "Times New Roman", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: "Times New Roman", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: "Times New Roman", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: "Times New Roman", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="clear: both; max-height: 0px;"/> <div style="font-family: "Times New Roman", Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As discussed in Note 14 Income Taxes of the Company’s Annual Report, the Company has a valuation allowance against the full amount of its net deferred tax assets. The Company currently provides a valuation allowance against deferred tax assets when it is more likely than not that some portion or all of its deferred tax assets will not be realized. The Company has not recognized any unrecognized tax benefits in its balance sheet. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: "Times New Roman"; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is subject to income tax in the U.S., as well as various state and international jurisdictions. The federal and state tax authorities can generally reduce a net operating loss (but not create taxable income) for a period outside the statute of limitations in order to determine the correct amount of net operating loss which may be allowed as a deduction against income for a period within the statute of limitations. Additional information regarding the statutes of limitations can be found in Note 14 Income Taxes of the Company’s Annual Report. </div></div></div>

1000000

1200

2018-12-10 0.87

200000

The gross amount includes the 4.25% final payment of $637.5.

EXCEL 70 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
-8?20$3;8T.P6BP^0"X99K>]9!:GDG:1?WZ$4-Z/6'O1EHA=;(B7J M:$3Q\**W]];=W5A[)Q[JROC98!W"YFPT\L5:U=+_93?*0,[*NEH&V'6W([]Q M2I9^K52HJU$R'D]'M=1F\.[MOJR%&^$=&U01M#60&!.^:'7OG_/CKMAIKV]T MI5OI$CA* M\;>LI"F40) ) 9GT"/DU09 I 9GV KF,.' J@LP(R*Q'R$XD5DA6!."9A3YHA)OSX1\5=\_'^K=[*"X[V0IA37R@<$^9J ?,T+ M.3<[. :?>41T!L"Z TOT,*IC=2E^/BPB=6MC==56$,#?;YU#C?08ZJ%'G-C MPMDN/)Z(!;1WX:3!C(]Y$T_$E*1'F$7ROBC<5CT'$W-1ZI@PN^-"R9]H*$=, MF"5Q8:5IZQDT;;O8SX'KBTOH5'GH%#QB3,H2$V9-+(,M[M:V*I7S?S1U+738 M*#E,F.UP">5>6._%)KZGMJZM$G73KM37*BYB1$Z, M25DH9;80W?'HO$*4A5)F"]&8&9[$IBR4,5N(QLPQ)F6AC-E"-.848U(6RKBG MR$C,4XQ)62ACMM#!3O%0@.I7RG6F?S)RA:6'N3/ ?-J88TS*0AFSA8Y@[AM[ MC$E9*.MC) 3J#$/HS W_PYB4A3)F"QV+9DP&N6-,RD(9LX6.83ZI$V-2%LJ8 M+436S>XJ)66AG-E"-"9V>DY9*&>V$(V)G9Y3%LJ9+41C8J?GE(7R?BSTA(F= MGE,6RIDM='QR!AK/SJIA3J[T][68TPZ/,"9EH9S90A0F/'F,25DH?^%5G@*O M\H@AQJ0LE#<6&NT_ABK52AM57L(E/*07LBH63L2_=G$WR^/:S&I;5>>0=F6@ M.UGNOZW:?Q?V[CM02P,$% @ "7NK5!,G[+KO 0 I2( !H !X;"]? M)_ !,]BW $:&BH46\ M@!4F%Y'$ECT(>'NB4(1E49P&S:JLL>7MO_IDC7WWE/=MV77'<;OKQ]G'87\< ME\VVE/Y?2N-JFP_M>-7U^7BZLNZ&0UM.RV&3^G;UVFYRTOE\D8:?,YK[NY\S M9\^???Z?B=UZO5OEAV[U=LC'\LO@]-X-K^,VY]+,GMMAD\NR21_[R^DQG0]R M=9KBOJK01Z*^JM!'HKZJT$ M>BOJK01Z*^JM!'HKZJT$>BOJK01Z&^IM!'H;ZFT$>AOJ;01ZVV2SA$!O0[V- M0&]#O8U ;T.]C4!O0[V-0&]#O8U ;T.]C4!O1[V=0&]'O9U ;T>]G4!O1[V= M0&^?;'83Z.VHMQ/H[:BW$^CMJ+<3Z.VHMQ/H[:BW$^@=J'<0Z!VH=Q#H':AW M$.@=J'<0Z!VH=Q#H'9./E01Z!^H=!'H'ZAT$>@?J'7^I]U@^]WF\]'RO\?E_ M274YW9LOCS\OOT^BA(LSS@G^2KG_ E!+ P04 " )>ZM48B/G&-@! !( M(@ $P %M#;VYT96YT7U1Y<&5S72YX;6S-VEU/@S 4!N"_LG!K1M>O^1'G MC7JK7O@'*IP-,J!-V\WY[RU,331*7&;B>P.!MN<]M,ESQ>7CBZ,PV;5-%Q99 M%:.[8"P4%;4FY-91ET:6UK_8LX4:[,B)F:S.2ML%ZF+T]C7R*XN;VAI M-DV[7-8%E;;8 MM&E)'IPG4X:**+9-OB]Z,IXNI!.S-/A<>]'TJ^> MNE2(?*S'/_$C,94^^ONH/^V2RE]FI^U]MGX]G$=@P^WX/?Y\QA_U#^Q#@/0A M0?I0('UHD#[F('V<@O1Q!M+'.4@??(;2"(JH'(54CF(J1T&5HZC*45CE**YR M%%@YBJP"15:!(JM D56@R"I09!4HL@H4606*K )%5H$BJT215:+(*E%DE2BR M2A19)8JL$D56B2*K1)%5HLBJ4&15*+(J%%D5BJP*15:%(JM"D56AR*I09%4H MLFH4636*K!I%5HTBJT:15:/(JE%DU2BRZO^4]ZM46DT^+.\ K M @ $0 @ &O 9&]C4')O<',O8V]R92YX;6Q02P$"% ,4 M " )>ZM4F5R<(Q & "<)P $P @ '- 0 >&PO=&AE M;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( E[JU20G9G:3P4 /H5 8 M " @0X( !X;"]W;W)KZM4\Z[NN+D% "T%P & @(&3#0 >&PO=V]R M:W-H965T&UL4$L! A0#% @ "7NK5 O3")#8 @ S0D M !@ ("!@A, 'AL+W=OZM4Q-CC#"T% M !B%0 & @(%"&P >&PO=V]R:W-H965T&UL4$L! A0#% @ "7NK5"*5^U(H!@ F!@ !@ ("! MI2 'AL+W=O 8 " @0,G !X;"]W;W)KZM4KO1(F^@" #-!@ & M @($A,P >&PO=V]R:W-H965T&UL4$L! A0#% @ M"7NK5%=6I/1: @ 4 !@ ("!/S8 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ "7NK5+&1 ML3)G"0 \Q< !D ("!2D8 'AL+W=OZM4)T[(/0L+ !D' &0 M @('H3P >&PO=V]R:W-H965T&UL4$L! A0#% @ "7NK5)!L7$BB P 30@ !D M ("!HU\ 'AL+W=OZM45#]M4W@$ "&"@ &0 @(%\8P >&PO M=V]R:W-H965T0@ M *P6 9 " @2MH !X;"]W;W)K&UL4$L! A0#% @ "7NK5,S6A[^L @ _04 !D ("! MVW 'AL+W=OZM4 M6.:_>F@" %!0 &0 @(&^
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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 72 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 73 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 133 268 1 true 55 0 false 8 false false R1.htm 1001 - Document - Cover Page Sheet http://www.delcath.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.delcath.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.delcath.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss Condensed Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 1005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) Sheet http://www.delcath.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit Condensed Consolidated Statements of Stockholders' Equity (Deficit) Statements 5 false false R6.htm 1006 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 1007 - Disclosure - General Sheet http://www.delcath.com/role/General General Notes 7 false false R8.htm 1008 - Disclosure - Cash, Cash Equivalents and Restricted Cash Sheet http://www.delcath.com/role/CashCashEquivalentsAndRestrictedCash Cash, Cash Equivalents and Restricted Cash Notes 8 false false R9.htm 1009 - Disclosure - Inventories Sheet http://www.delcath.com/role/Inventories Inventories Notes 9 false false R10.htm 1010 - Disclosure - Prepaid Expenses and Other Current Assets Sheet http://www.delcath.com/role/PrepaidExpensesAndOtherCurrentAssets Prepaid Expenses and Other Current Assets Notes 10 false false R11.htm 1011 - Disclosure - Property, Plant, and Equipment Sheet http://www.delcath.com/role/PropertyPlantAndEquipment Property, Plant, and Equipment Notes 11 false false R12.htm 1012 - Disclosure - Accrued Expenses Sheet http://www.delcath.com/role/AccruedExpenses Accrued Expenses Notes 12 false false R13.htm 1013 - Disclosure - Leases Sheet http://www.delcath.com/role/Leases Leases Notes 13 false false R14.htm 1014 - Disclosure - Loans and Convertible Notes Payable Notes http://www.delcath.com/role/LoansAndConvertibleNotesPayable Loans and Convertible Notes Payable Notes 14 false false R15.htm 1015 - Disclosure - Stockholders' Equity Sheet http://www.delcath.com/role/StockholdersEquity Stockholders' Equity Notes 15 false false R16.htm 1016 - Disclosure - Net Loss per Common Share Sheet http://www.delcath.com/role/NetLossPerCommonShare Net Loss per Common Share Notes 16 false false R17.htm 1017 - Disclosure - Income Taxes Sheet http://www.delcath.com/role/IncomeTaxes Income Taxes Notes 17 false false R18.htm 1018 - Disclosure - Commitments and Contingencies Sheet http://www.delcath.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 18 false false R19.htm 1019 - Disclosure - General (Policies) Sheet http://www.delcath.com/role/GeneralPolicies General (Policies) Policies 19 false false R20.htm 1020 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Tables) Sheet http://www.delcath.com/role/CashCashEquivalentsAndRestrictedCashTables Cash, Cash Equivalents and Restricted Cash (Tables) Tables http://www.delcath.com/role/CashCashEquivalentsAndRestrictedCash 20 false false R21.htm 1021 - Disclosure - Inventories (Tables) Sheet http://www.delcath.com/role/InventoriesTables Inventories (Tables) Tables http://www.delcath.com/role/Inventories 21 false false R22.htm 1022 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) Sheet http://www.delcath.com/role/PrepaidExpensesAndOtherCurrentAssetsTables Prepaid Expenses and Other Current Assets (Tables) Tables http://www.delcath.com/role/PrepaidExpensesAndOtherCurrentAssets 22 false false R23.htm 1023 - Disclosure - Property, Plant, and Equipment (Tables) Sheet http://www.delcath.com/role/PropertyPlantAndEquipmentTables Property, Plant, and Equipment (Tables) Tables http://www.delcath.com/role/PropertyPlantAndEquipment 23 false false R24.htm 1024 - Disclosure - Accrued Expenses (Tables) Sheet http://www.delcath.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://www.delcath.com/role/AccruedExpenses 24 false false R25.htm 1025 - Disclosure - Leases (Tables) Sheet http://www.delcath.com/role/LeasesTables Leases (Tables) Tables http://www.delcath.com/role/Leases 25 false false R26.htm 1026 - Disclosure - Loans and Convertible Notes Payable (Tables) Notes http://www.delcath.com/role/LoansAndConvertibleNotesPayableTables Loans and Convertible Notes Payable (Tables) Tables http://www.delcath.com/role/LoansAndConvertibleNotesPayable 26 false false R27.htm 1027 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.delcath.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.delcath.com/role/StockholdersEquity 27 false false R28.htm 1028 - Disclosure - Net Loss per Common Share (Tables) Sheet http://www.delcath.com/role/NetLossPerCommonShareTables Net Loss per Common Share (Tables) Tables http://www.delcath.com/role/NetLossPerCommonShare 28 false false R29.htm 1029 - Disclosure - General - Additional Information (Details) Sheet http://www.delcath.com/role/GeneralAdditionalInformationDetails General - Additional Information (Details) Details 29 false false R30.htm 1030 - Disclosure - Cash, Cash Equivalents and Restricted Cash - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details) Sheet http://www.delcath.com/role/CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashDetails Cash, Cash Equivalents and Restricted Cash - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details) Details 30 false false R31.htm 1031 - Disclosure - Inventories - Schedule of Inventories (Details) Sheet http://www.delcath.com/role/InventoriesScheduleOfInventoriesDetails Inventories - Schedule of Inventories (Details) Details 31 false false R32.htm 1032 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) Sheet http://www.delcath.com/role/PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) Details 32 false false R33.htm 1033 - Disclosure - Property, Plant, and Equipment - Components of Property, Plant, and Equipment (Details) Sheet http://www.delcath.com/role/PropertyPlantAndEquipmentComponentsOfPropertyPlantAndEquipmentDetails Property, Plant, and Equipment - Components of Property, Plant, and Equipment (Details) Details 33 false false R34.htm 1034 - Disclosure - Property, Plant, and Equipment - Additional Information (Details) Sheet http://www.delcath.com/role/PropertyPlantAndEquipmentAdditionalInformationDetails Property, Plant, and Equipment - Additional Information (Details) Details 34 false false R35.htm 1035 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details) Sheet http://www.delcath.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails Accrued Expenses - Schedule of Accrued Expenses (Details) Details 35 false false R36.htm 1036 - Disclosure - Leases - Additional Information (Details) Sheet http://www.delcath.com/role/LeasesAdditionalInformationDetails Leases - Additional Information (Details) Details 36 false false R37.htm 1037 - Disclosure - Leases - Summary of Operating and Financing Leases (Details) Sheet http://www.delcath.com/role/LeasesSummaryOfOperatingAndFinancingLeasesDetails Leases - Summary of Operating and Financing Leases (Details) Details 37 false false R38.htm 1038 - Disclosure - Leases - Schedule of Remaining Maturity of Operating Leases Excluding Short-Term Leases (Details) Sheet http://www.delcath.com/role/LeasesScheduleOfRemainingMaturityOfOperatingLeasesExcludingShortTermLeasesDetails Leases - Schedule of Remaining Maturity of Operating Leases Excluding Short-Term Leases (Details) Details 38 false false R39.htm 1039 - Disclosure - Loans and Convertible Notes Payable - Additional Information (Details) Notes http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails Loans and Convertible Notes Payable - Additional Information (Details) Details 39 false false R40.htm 1040 - Disclosure - Loans and Convertible Notes Payable - Summary of Loans and Convertible Notes Payable (Details) Notes http://www.delcath.com/role/LoansAndConvertibleNotesPayableSummaryOfLoansAndConvertibleNotesPayableDetails Loans and Convertible Notes Payable - Summary of Loans and Convertible Notes Payable (Details) Details 40 false false R41.htm 1041 - Disclosure - Loans and Convertible Notes Payable - Summary of Loans and Convertible Notes Payable (Details) (Parenthetical) Notes http://www.delcath.com/role/LoansAndConvertibleNotesPayableSummaryOfLoansAndConvertibleNotesPayableDetailsParenthetical Loans and Convertible Notes Payable - Summary of Loans and Convertible Notes Payable (Details) (Parenthetical) Details 41 false false R42.htm 1042 - Disclosure - Loans and Convertible Notes Payable - Summary of Remaining Maturities of Company's Loan and Convertible Note Payables (Details) Notes http://www.delcath.com/role/LoansAndConvertibleNotesPayableSummaryOfRemainingMaturitiesOfCompanysLoanAndConvertibleNotePayablesDetails Loans and Convertible Notes Payable - Summary of Remaining Maturities of Company's Loan and Convertible Note Payables (Details) Details 42 false false R43.htm 1043 - Disclosure - Loans and Convertible Notes Payable - Summary of Avenue Warrant Valued Using the Black-Scholes Option Pricing Method (Details) Notes http://www.delcath.com/role/LoansAndConvertibleNotesPayableSummaryOfAvenueWarrantValuedUsingTheBlackScholesOptionPricingMethodDetails Loans and Convertible Notes Payable - Summary of Avenue Warrant Valued Using the Black-Scholes Option Pricing Method (Details) Details 43 false false R44.htm 1044 - Disclosure - Stockholders' Equity - Preferred Stock Issuances - Additional Information (Details) Sheet http://www.delcath.com/role/StockholdersEquityPreferredStockIssuancesAdditionalInformationDetails Stockholders' Equity - Preferred Stock Issuances - Additional Information (Details) Details 44 false false R45.htm 1045 - Disclosure - Stockholders' Equity - Equity Incentive Plan - Additional Information (Details) Sheet http://www.delcath.com/role/StockholdersEquityEquityIncentivePlanAdditionalInformationDetails Stockholders' Equity - Equity Incentive Plan - Additional Information (Details) Details 45 false false R46.htm 1046 - Disclosure - Stockholders' Equity - Summary of Employee Stock Purchase Plan (Details) Sheet http://www.delcath.com/role/StockholdersEquitySummaryOfEmployeeStockPurchasePlanDetails Stockholders' Equity - Summary of Employee Stock Purchase Plan (Details) Details 46 false false R47.htm 1047 - Disclosure - Stockholders' Equity - At-the-Market Offering - Additional Information (Details) Sheet http://www.delcath.com/role/StockholdersEquityAtTheMarketOfferingAdditionalInformationDetails Stockholders' Equity - At-the-Market Offering - Additional Information (Details) Details 47 false false R48.htm 1048 - Disclosure - Stockholders' Equity - Stock Incentive Plans - Additional Information (Details) Sheet http://www.delcath.com/role/StockholdersEquityStockIncentivePlansAdditionalInformationDetails Stockholders' Equity - Stock Incentive Plans - Additional Information (Details) Details 48 false false R49.htm 1049 - Disclosure - Stockholders' Equity - Schedule of Assumptions to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model (Details) Sheet http://www.delcath.com/role/StockholdersEquityScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails Stockholders' Equity - Schedule of Assumptions to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model (Details) Details 49 false false R50.htm 1050 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Details) Sheet http://www.delcath.com/role/StockholdersEquitySummaryOfStockOptionActivityDetails Stockholders' Equity - Summary of Stock Option Activity (Details) Details 50 false false R51.htm 1051 - Disclosure - Stockholders' Equity - Summary of Stock Option Shares Outstanding and Exercisable (Details) Sheet http://www.delcath.com/role/StockholdersEquitySummaryOfStockOptionSharesOutstandingAndExercisableDetails Stockholders' Equity - Summary of Stock Option Shares Outstanding and Exercisable (Details) Details 51 false false R52.htm 1052 - Disclosure - Stockholders' Equity - Summary of Recognized Share-based Compensation Cost (Details) Sheet http://www.delcath.com/role/StockholdersEquitySummaryOfRecognizedShareBasedCompensationCostDetails Stockholders' Equity - Summary of Recognized Share-based Compensation Cost (Details) Details 52 false false R53.htm 1053 - Disclosure - Stockholders' Equity - Summary of Warrant Activity (Details) Sheet http://www.delcath.com/role/StockholdersEquitySummaryOfWarrantActivityDetails Stockholders' Equity - Summary of Warrant Activity (Details) Details 53 false false R54.htm 1054 - Disclosure - Stockholders' Equity - Summary of Warrants Outstanding and Exercisable (Details) Sheet http://www.delcath.com/role/StockholdersEquitySummaryOfWarrantsOutstandingAndExercisableDetails Stockholders' Equity - Summary of Warrants Outstanding and Exercisable (Details) Details 54 false false R55.htm 1055 - Disclosure - Net Loss per Common Share - Anti-Dilutive Securities Excluded from Computation of Earnings Per Share (Details) Sheet http://www.delcath.com/role/NetLossPerCommonShareAntiDilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails Net Loss per Common Share - Anti-Dilutive Securities Excluded from Computation of Earnings Per Share (Details) Details 55 false false R56.htm 1056 - Disclosure - Net Loss per Common Share - Additional Information (Details) Sheet http://www.delcath.com/role/NetLossPerCommonShareAdditionalInformationDetails Net Loss per Common Share - Additional Information (Details) Details 56 false false R57.htm 1057 - Disclosure - Net Loss per Common Share - Summary of Reconciliation of Weighted Average Shares Outstanding Calculation (Details) Sheet http://www.delcath.com/role/NetLossPerCommonShareSummaryOfReconciliationOfWeightedAverageSharesOutstandingCalculationDetails Net Loss per Common Share - Summary of Reconciliation of Weighted Average Shares Outstanding Calculation (Details) Details 57 false false R58.htm 1058 - Disclosure - Commitments and contingencies - Additional Information (Details) Sheet http://www.delcath.com/role/CommitmentsAndContingenciesAdditionalInformationDetails Commitments and contingencies - Additional Information (Details) Details 58 false false All Reports Book All Reports d290302d10q.htm d290302dex311.htm d290302dex312.htm d290302dex321.htm d290302dex322.htm dcth-20220331.xsd dcth-20220331_cal.xml dcth-20220331_def.xml dcth-20220331_lab.xml dcth-20220331_pre.xml http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 76 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d290302d10q.htm": { "axisCustom": 1, "axisStandard": 14, "contextCount": 133, "dts": { "calculationLink": { "local": [ "dcth-20220331_cal.xml" ] }, "definitionLink": { "local": [ "dcth-20220331_def.xml" ] }, "inline": { "local": [ "d290302d10q.htm" ] }, "labelLink": { "local": [ "dcth-20220331_lab.xml" ] }, "presentationLink": { "local": [ "dcth-20220331_pre.xml" ] }, "schema": { "local": [ "dcth-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 434, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 6, "total": 6 }, "keyCustom": 62, "keyStandard": 206, "memberCustom": 26, "memberStandard": 29, "nsprefix": "dcth", "nsuri": "http://www.delcath.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "1001 - Document - Cover Page", "role": "http://www.delcath.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "dcth:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1010 - Disclosure - Prepaid Expenses and Other Current Assets", "role": "http://www.delcath.com/role/PrepaidExpensesAndOtherCurrentAssets", "shortName": "Prepaid Expenses and Other Current Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "dcth:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1011 - Disclosure - Property, Plant, and Equipment", "role": "http://www.delcath.com/role/PropertyPlantAndEquipment", "shortName": "Property, Plant, and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1012 - Disclosure - Accrued Expenses", "role": "http://www.delcath.com/role/AccruedExpenses", "shortName": "Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "dcth:LesseeOperatingAndFinanceLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1013 - Disclosure - Leases", "role": "http://www.delcath.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "dcth:LesseeOperatingAndFinanceLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1014 - Disclosure - Loans and Convertible Notes Payable", "role": "http://www.delcath.com/role/LoansAndConvertibleNotesPayable", "shortName": "Loans and Convertible Notes Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1015 - Disclosure - Stockholders' Equity", "role": "http://www.delcath.com/role/StockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1016 - Disclosure - Net Loss per Common Share", "role": "http://www.delcath.com/role/NetLossPerCommonShare", "shortName": "Net Loss per Common Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1017 - Disclosure - Income Taxes", "role": "http://www.delcath.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1018 - Disclosure - Commitments and Contingencies", "role": "http://www.delcath.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "dcth:RiskAndUncertaintiesPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1019 - Disclosure - General (Policies)", "role": "http://www.delcath.com/role/GeneralPolicies", "shortName": "General (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "dcth:RiskAndUncertaintiesPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "PAsOn03_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "PAsOn03_31_2022", "decimals": "-3", "lang": null, "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1020 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Tables)", "role": "http://www.delcath.com/role/CashCashEquivalentsAndRestrictedCashTables", "shortName": "Cash, Cash Equivalents and Restricted Cash (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1021 - Disclosure - Inventories (Tables)", "role": "http://www.delcath.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "dcth:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1022 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)", "role": "http://www.delcath.com/role/PrepaidExpensesAndOtherCurrentAssetsTables", "shortName": "Prepaid Expenses and Other Current Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "dcth:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1023 - Disclosure - Property, Plant, and Equipment (Tables)", "role": "http://www.delcath.com/role/PropertyPlantAndEquipmentTables", "shortName": "Property, Plant, and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1024 - Disclosure - Accrued Expenses (Tables)", "role": "http://www.delcath.com/role/AccruedExpensesTables", "shortName": "Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "dcth:ScheduleOfOperatingAndFinancingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1025 - Disclosure - Leases (Tables)", "role": "http://www.delcath.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "dcth:ScheduleOfOperatingAndFinancingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1026 - Disclosure - Loans and Convertible Notes Payable (Tables)", "role": "http://www.delcath.com/role/LoansAndConvertibleNotesPayableTables", "shortName": "Loans and Convertible Notes Payable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P08_06_2021To08_06_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1027 - Disclosure - Stockholders' Equity (Tables)", "role": "http://www.delcath.com/role/StockholdersEquityTables", "shortName": "Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "lang": "en-US", "name": "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1028 - Disclosure - Net Loss per Common Share (Tables)", "role": "http://www.delcath.com/role/NetLossPerCommonShareTables", "shortName": "Net Loss per Common Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "PAsOn03_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1029 - Disclosure - General - Additional Information (Details)", "role": "http://www.delcath.com/role/GeneralAdditionalInformationDetails", "shortName": "General - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "div", "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "PAsOn03_31_2022", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockSharesIssued", "div", "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "PAsOn03_31_2022", "decimals": "INF", "lang": null, "name": "us-gaap:PreferredStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "PAsOn03_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1030 - Disclosure - Cash, Cash Equivalents and Restricted Cash - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details)", "role": "http://www.delcath.com/role/CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashDetails", "shortName": "Cash, Cash Equivalents and Restricted Cash - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "PAsOn03_31_2022", "decimals": "-3", "lang": null, "name": "dcth:LoanAgreementRestrictedCash", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "PAsOn03_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1031 - Disclosure - Inventories - Schedule of Inventories (Details)", "role": "http://www.delcath.com/role/InventoriesScheduleOfInventoriesDetails", "shortName": "Inventories - Schedule of Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "PAsOn03_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "dcth:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "PAsOn03_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "dcth:PrepaidClinicalTrialExpensesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1032 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)", "role": "http://www.delcath.com/role/PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails", "shortName": "Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "dcth:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "PAsOn03_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "dcth:PrepaidClinicalTrialExpensesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "PAsOn03_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1033 - Disclosure - Property, Plant, and Equipment - Components of Property, Plant, and Equipment (Details)", "role": "http://www.delcath.com/role/PropertyPlantAndEquipmentComponentsOfPropertyPlantAndEquipmentDetails", "shortName": "Property, Plant, and Equipment - Components of Property, Plant, and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "PAsOn03_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1034 - Disclosure - Property, Plant, and Equipment - Additional Information (Details)", "role": "http://www.delcath.com/role/PropertyPlantAndEquipmentAdditionalInformationDetails", "shortName": "Property, Plant, and Equipment - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "PAsOn03_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "dcth:AccruedClinicalExpensesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1035 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)", "role": "http://www.delcath.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails", "shortName": "Accrued Expenses - Schedule of Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "PAsOn03_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "dcth:AccruedClinicalExpensesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "div", "dcth:LesseeOperatingAndFinanceLeasesTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "PAsOn03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1036 - Disclosure - Leases - Additional Information (Details)", "role": "http://www.delcath.com/role/LeasesAdditionalInformationDetails", "shortName": "Leases - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "dcth:LesseeOperatingAndFinanceLeasesTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "PAsOn03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "dcth:ScheduleOfOperatingAndFinancingLeasesTableTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1037 - Disclosure - Leases - Summary of Operating and Financing Leases (Details)", "role": "http://www.delcath.com/role/LeasesSummaryOfOperatingAndFinancingLeasesDetails", "shortName": "Leases - Summary of Operating and Financing Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "dcth:ScheduleOfOperatingAndFinancingLeasesTableTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "PAsOn03_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1038 - Disclosure - Leases - Schedule of Remaining Maturity of Operating Leases Excluding Short-Term Leases (Details)", "role": "http://www.delcath.com/role/LeasesScheduleOfRemainingMaturityOfOperatingLeasesExcludingShortTermLeasesDetails", "shortName": "Leases - Schedule of Remaining Maturity of Operating Leases Excluding Short-Term Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "PAsOn03_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": "-5", "first": true, "lang": null, "name": "dcth:AvenueWarrantValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1039 - Disclosure - Loans and Convertible Notes Payable - Additional Information (Details)", "role": "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails", "shortName": "Loans and Convertible Notes Payable - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": "-5", "first": true, "lang": null, "name": "dcth:AvenueWarrantValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CostOfRevenue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss", "role": "http://www.delcath.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CostOfRevenue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LongTermDebtTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "PAsOn03_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "dcth:NotesAndLoansPayableGross", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1040 - Disclosure - Loans and Convertible Notes Payable - Summary of Loans and Convertible Notes Payable (Details)", "role": "http://www.delcath.com/role/LoansAndConvertibleNotesPayableSummaryOfLoansAndConvertibleNotesPayableDetails", "shortName": "Loans and Convertible Notes Payable - Summary of Loans and Convertible Notes Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LongTermDebtTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "PAsOn03_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "dcth:NotesAndLoansPayableGross", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:LongTermDebtTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": "4", "first": true, "lang": null, "name": "dcth:PercentageOfFinalPaymentIncludedInGrossAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1041 - Disclosure - Loans and Convertible Notes Payable - Summary of Loans and Convertible Notes Payable (Details) (Parenthetical)", "role": "http://www.delcath.com/role/LoansAndConvertibleNotesPayableSummaryOfLoansAndConvertibleNotesPayableDetailsParenthetical", "shortName": "Loans and Convertible Notes Payable - Summary of Loans and Convertible Notes Payable (Details) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:LongTermDebtTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": "4", "first": true, "lang": null, "name": "dcth:PercentageOfFinalPaymentIncludedInGrossAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "PAsOn03_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LoansPayable", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1042 - Disclosure - Loans and Convertible Notes Payable - Summary of Remaining Maturities of Company's Loan and Convertible Note Payables (Details)", "role": "http://www.delcath.com/role/LoansAndConvertibleNotesPayableSummaryOfRemainingMaturitiesOfCompanysLoanAndConvertibleNotePayablesDetails", "shortName": "Loans and Convertible Notes Payable - Summary of Remaining Maturities of Company's Loan and Convertible Note Payables (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "PAsOn03_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LoansPayable", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P08_06_2021To08_06_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1043 - Disclosure - Loans and Convertible Notes Payable - Summary of Avenue Warrant Valued Using the Black-Scholes Option Pricing Method (Details)", "role": "http://www.delcath.com/role/LoansAndConvertibleNotesPayableSummaryOfAvenueWarrantValuedUsingTheBlackScholesOptionPricingMethodDetails", "shortName": "Loans and Convertible Notes Payable - Summary of Avenue Warrant Valued Using the Black-Scholes Option Pricing Method (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R44": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "PAsOn03_31_2022", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1044 - Disclosure - Stockholders' Equity - Preferred Stock Issuances - Additional Information (Details)", "role": "http://www.delcath.com/role/StockholdersEquityPreferredStockIssuancesAdditionalInformationDetails", "shortName": "Stockholders' Equity - Preferred Stock Issuances - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "PAsOn03_31_2022_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis", "decimals": "INF", "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "PAsOn03_31_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1045 - Disclosure - Stockholders' Equity - Equity Incentive Plan - Additional Information (Details)", "role": "http://www.delcath.com/role/StockholdersEquityEquityIncentivePlanAdditionalInformationDetails", "shortName": "Stockholders' Equity - Equity Incentive Plan - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "PAsOn03_31_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "div", "div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "PAsOn08_31_2021_MayTwoThousandAndTwentyTwoEmployeeStockPurchasePlanMemberDCTHPlanAxis", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1046 - Disclosure - Stockholders' Equity - Summary of Employee Stock Purchase Plan (Details)", "role": "http://www.delcath.com/role/StockholdersEquitySummaryOfEmployeeStockPurchasePlanDetails", "shortName": "Stockholders' Equity - Summary of Employee Stock Purchase Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "PAsOn08_31_2021_MayTwoThousandAndTwentyTwoEmployeeStockPurchasePlanMemberDCTHPlanAxis", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1047 - Disclosure - Stockholders' Equity - At-the-Market Offering - Additional Information (Details)", "role": "http://www.delcath.com/role/StockholdersEquityAtTheMarketOfferingAdditionalInformationDetails", "shortName": "Stockholders' Equity - At-the-Market Offering - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1048 - Disclosure - Stockholders' Equity - Stock Incentive Plans - Additional Information (Details)", "role": "http://www.delcath.com/role/StockholdersEquityStockIncentivePlansAdditionalInformationDetails", "shortName": "Stockholders' Equity - Stock Incentive Plans - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P08_06_2021To08_06_2021", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unitRef": "Unit_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1049 - Disclosure - Stockholders' Equity - Schedule of Assumptions to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model (Details)", "role": "http://www.delcath.com/role/StockholdersEquityScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails", "shortName": "Stockholders' Equity - Schedule of Assumptions to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022_MinimumMembersrtRangeAxis", "decimals": "4", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "PAsOn12_31_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit)", "role": "http://www.delcath.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "PAsOn12_31_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "PAsOn12_31_2021", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1050 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Details)", "role": "http://www.delcath.com/role/StockholdersEquitySummaryOfStockOptionActivityDetails", "shortName": "Stockholders' Equity - Summary of Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "PAsOn03_31_2022", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1051 - Disclosure - Stockholders' Equity - Summary of Stock Option Shares Outstanding and Exercisable (Details)", "role": "http://www.delcath.com/role/StockholdersEquitySummaryOfStockOptionSharesOutstandingAndExercisableDetails", "shortName": "Stockholders' Equity - Summary of Stock Option Shares Outstanding and Exercisable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "PAsOn03_31_2022_ExercisePriceRangeFromSixPointSixOneToNinePointNineNineMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "dcth:ShareBasedCompensationIncomeExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1052 - Disclosure - Stockholders' Equity - Summary of Recognized Share-based Compensation Cost (Details)", "role": "http://www.delcath.com/role/StockholdersEquitySummaryOfRecognizedShareBasedCompensationCostDetails", "shortName": "Stockholders' Equity - Summary of Recognized Share-based Compensation Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "dcth:ShareBasedCompensationIncomeExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "PAsOn12_31_2021", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1053 - Disclosure - Stockholders' Equity - Summary of Warrant Activity (Details)", "role": "http://www.delcath.com/role/StockholdersEquitySummaryOfWarrantActivityDetails", "shortName": "Stockholders' Equity - Summary of Warrant Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": "INF", "lang": null, "name": "dcth:ClassOfWarrantOrRightIssued", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "PAsOn03_31_2022", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1054 - Disclosure - Stockholders' Equity - Summary of Warrants Outstanding and Exercisable (Details)", "role": "http://www.delcath.com/role/StockholdersEquitySummaryOfWarrantsOutstandingAndExercisableDetails", "shortName": "Stockholders' Equity - Summary of Warrants Outstanding and Exercisable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "dcth:ScheduleOfInformationRelatedToStockWarrantsOutstandingAndExercisableTableTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "PAsOn03_31_2022_RangeOfExercisePricesPointZeroOneRangeMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "decimals": "INF", "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1055 - Disclosure - Net Loss per Common Share - Anti-Dilutive Securities Excluded from Computation of Earnings Per Share (Details)", "role": "http://www.delcath.com/role/NetLossPerCommonShareAntiDilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "shortName": "Net Loss per Common Share - Anti-Dilutive Securities Excluded from Computation of Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": "INF", "first": true, "lang": null, "name": "dcth:NumberOfSharesPreFundedPennyWarrantsOutstanding", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1056 - Disclosure - Net Loss per Common Share - Additional Information (Details)", "role": "http://www.delcath.com/role/NetLossPerCommonShareAdditionalInformationDetails", "shortName": "Net Loss per Common Share - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": "INF", "first": true, "lang": null, "name": "dcth:NumberOfSharesPreFundedPennyWarrantsOutstanding", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesIssuedBasic", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1057 - Disclosure - Net Loss per Common Share - Summary of Reconciliation of Weighted Average Shares Outstanding Calculation (Details)", "role": "http://www.delcath.com/role/NetLossPerCommonShareSummaryOfReconciliationOfWeightedAverageSharesOutstandingCalculationDetails", "shortName": "Net Loss per Common Share - Summary of Reconciliation of Weighted Average Shares Outstanding Calculation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesIssuedBasic", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "div", "us-gaap:CommitmentsDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P03_30_2021To03_31_2021", "decimals": "2", "first": true, "lang": null, "name": "dcth:PercentageOfEnrolledPatients", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1058 - Disclosure - Commitments and contingencies - Additional Information (Details)", "role": "http://www.delcath.com/role/CommitmentsAndContingenciesAdditionalInformationDetails", "shortName": "Commitments and contingencies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:CommitmentsDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P03_30_2021To03_31_2021", "decimals": "2", "first": true, "lang": null, "name": "dcth:PercentageOfEnrolledPatients", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": "-3", "lang": null, "name": "dcth:StockOptionCompensationIncomeExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1007 - Disclosure - General", "role": "http://www.delcath.com/role/General", "shortName": "General", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1008 - Disclosure - Cash, Cash Equivalents and Restricted Cash", "role": "http://www.delcath.com/role/CashCashEquivalentsAndRestrictedCash", "shortName": "Cash, Cash Equivalents and Restricted Cash", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1009 - Disclosure - Inventories", "role": "http://www.delcath.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "body", "html" ], "baseRef": "d290302d10q.htm", "contextRef": "P01_01_2022To03_31_2022", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 55, "tag": { "country_IE": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IRELAND", "terseLabel": "Ireland [Member]" } } }, "localname": "IE", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.delcath.com/role/LeasesScheduleOfRemainingMaturityOfOperatingLeasesExcludingShortTermLeasesDetails", "http://www.delcath.com/role/LeasesSummaryOfOperatingAndFinancingLeasesDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "U.S. [Member]" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.delcath.com/role/LeasesScheduleOfRemainingMaturityOfOperatingLeasesExcludingShortTermLeasesDetails", "http://www.delcath.com/role/LeasesSummaryOfOperatingAndFinancingLeasesDetails" ], "xbrltype": "domainItemType" }, "dcth_AccruedClinicalExpensesCurrent": { "auth_ref": [], "calculation": { "http://www.delcath.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Clinical Expenses Current", "label": "Accrued Clinical Expenses Current", "terseLabel": "Clinical expenses" } } }, "localname": "AccruedClinicalExpensesCurrent", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "dcth_AgreementDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement date.", "label": "Agreement Date", "terseLabel": "Agreement date" } } }, "localname": "AgreementDate", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "dcth_AmortizationOfRightOfUseAssets": { "auth_ref": [], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortization of right of use assets.", "label": "Amortization Of Right Of Use Assets", "terseLabel": "Non-cash lease expense" } } }, "localname": "AmortizationOfRightOfUseAssets", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "dcth_AssumedConversionOfConvertibleNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assumed conversion of convertible notes.", "label": "Assumed Conversion Of Convertible Notes [Member]", "terseLabel": "Assumed conversion of convertible Notes [Member]" } } }, "localname": "AssumedConversionOfConvertibleNotesMember", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/NetLossPerCommonShareAntiDilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "dcth_AssumedConversionOfSeriesEAndSeriesEOnePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assumed conversion of Series E and Series E-1 Preferred Stock.", "label": "Assumed Conversion Of Series E And Series E One Preferred Stock [Member]", "terseLabel": "Assumed conversion of Series E and Series E-1 Preferred Stock [Member]" } } }, "localname": "AssumedConversionOfSeriesEAndSeriesEOnePreferredStockMember", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/NetLossPerCommonShareAntiDilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "dcth_AtTheMarketOfferingAggregateOfferingPrice": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "At-The-Market Offering, Aggregate Offering Price.", "label": "At The Market Offering Aggregate Offering Price", "terseLabel": "At-the-market offering, aggregate offering price" } } }, "localname": "AtTheMarketOfferingAggregateOfferingPrice", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/StockholdersEquityAtTheMarketOfferingAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dcth_AvenueWarrantValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Avenue warrant value.", "label": "Avenue Warrant Value", "terseLabel": "Avenue warrant value" } } }, "localname": "AvenueWarrantValue", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dcth_BasisOfCondensedConsolidatedFinancialStatementPresentationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Basis of condensed consolidated financial statement presentation.", "label": "Basis Of Condensed Consolidated Financial Statement Presentation [Abstract]" } } }, "localname": "BasisOfCondensedConsolidatedFinancialStatementPresentationAbstract", "nsuri": "http://www.delcath.com/20220331", "xbrltype": "stringItemType" }, "dcth_CantorFitzgeraldAndCoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cantor fitzgerald and co [Member].", "label": "Cantor Fitzgerald And Co [Member]", "terseLabel": "Cantor Fitzgerald & Co [Member]" } } }, "localname": "CantorFitzgeraldAndCoMember", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/StockholdersEquityAtTheMarketOfferingAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dcth_ClassOfWarrantOrRightExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant or right exercisable.", "label": "Class Of Warrant Or Right Exercisable", "periodEndLabel": "Exercisable, end of period (in shares)", "terseLabel": "Warrants Exercisable, Number Exercisable" } } }, "localname": "ClassOfWarrantOrRightExercisable", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfWarrantActivityDetails", "http://www.delcath.com/role/StockholdersEquitySummaryOfWarrantsOutstandingAndExercisableDetails" ], "xbrltype": "sharesItemType" }, "dcth_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant or right exercisable weighted average exercise price.", "label": "Class Of Warrant Or Right Exercisable Weighted Average Exercise Price", "periodEndLabel": "Exercisable, (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "dcth_ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant or right exercisable weighted average remaining contractual term.", "label": "Class Of Warrant Or Right Exercisable Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining life, Exercisable" } } }, "localname": "ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualTerm", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfWarrantActivityDetails" ], "xbrltype": "durationItemType" }, "dcth_ClassOfWarrantOrRightExercisesInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of each class of warrants or rights exercised during the period.", "label": "Class Of Warrant Or Right Exercises In Period", "negatedLabel": "Warrants exercised (in shares)" } } }, "localname": "ClassOfWarrantOrRightExercisesInPeriod", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "dcth_ClassOfWarrantOrRightExpiredInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of each class of warrants or rights that expired during the period.", "label": "Class Of Warrant Or Right Expired In Period", "negatedLabel": "Warrants expired (in shares)" } } }, "localname": "ClassOfWarrantOrRightExpiredInPeriod", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "dcth_ClassOfWarrantOrRightIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of each class of warrants or rights issued during the period.", "label": "Class Of Warrant Or Right Issued", "terseLabel": "Warrants issued (in shares)" } } }, "localname": "ClassOfWarrantOrRightIssued", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "dcth_ClassOfWarrantOrRightWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price for warrants or rights outstanding.", "label": "Class Of Warrant Or Right Weighted Average Exercise Price", "periodEndLabel": "Outstanding, ending of period (in dollars per share)", "periodStartLabel": "Outstanding, beginning of period (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightWeightedAverageExercisePrice", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "dcth_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price for warrants or rights to acquire and convert their warrants into shares that were exercised during the period.", "label": "Class Of Warrant Or Right Weighted Average Exercise Price Exercises In Period", "terseLabel": "Warrants exercised (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "dcth_ClassOfWarrantOrRightWeightedAverageExercisePriceExpirationsInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price per share for warrants or rights for securities that expired in period.", "label": "Class Of Warrant Or Right Weighted Average Exercise Price Expirations In Period", "terseLabel": "Warrants expired (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceExpirationsInPeriod", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "dcth_ClassOfWarrantOrRightWeightedAverageExercisePriceIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price for the number of warrants or rights issued for the unvested, forfeitable warrants or rights in period.", "label": "Class Of Warrant Or Right Weighted Average Exercise Price Issued", "terseLabel": "Warrants issued (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceIssued", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "dcth_ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Class Of Warrant Or Right Weighted Average Exercise Price Roll Forward", "terseLabel": "Warrants, Exercise Price per Share [Roll Forward]" } } }, "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceRollForward", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfWarrantActivityDetails" ], "xbrltype": "stringItemType" }, "dcth_ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for each class of warrants or rights outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Class Of Warrant Or Right Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining life" } } }, "localname": "ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfWarrantActivityDetails", "http://www.delcath.com/role/StockholdersEquitySummaryOfWarrantsOutstandingAndExercisableDetails" ], "xbrltype": "durationItemType" }, "dcth_CommonStockOfferingPeriodOfRestrictionCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock offering period of restriction common stock.", "label": "Common Stock Offering Period Of Restriction Common Stock", "terseLabel": "Common stock offering period" } } }, "localname": "CommonStockOfferingPeriodOfRestrictionCommonStock", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/StockholdersEquityAtTheMarketOfferingAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "dcth_CommonStockWarrantsEquityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock warrants equity member.", "label": "Common Stock Warrants Equity [Member]", "terseLabel": "Common stock warrants - equity [Member]" } } }, "localname": "CommonStockWarrantsEquityMember", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/NetLossPerCommonShareAntiDilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "dcth_ConvertibleLoanPayableAvenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Loan Payable Avenue [Member]" } } }, "localname": "ConvertibleLoanPayableAvenueMember", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableSummaryOfLoansAndConvertibleNotesPayableDetails" ], "xbrltype": "domainItemType" }, "dcth_ConvertibleNotePayableRosalindMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note Payable Rosalind [Member]" } } }, "localname": "ConvertibleNotePayableRosalindMember", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableSummaryOfLoansAndConvertibleNotesPayableDetails" ], "xbrltype": "domainItemType" }, "dcth_ConvertibleNotesPayableOriginalIssueDiscount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Convertible notes payable original issue discount.", "label": "Convertible Notes Payable Original Issue Discount", "terseLabel": "Original issue discount" } } }, "localname": "ConvertibleNotesPayableOriginalIssueDiscount", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dcth_DebtInstrumentCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument, commitment fee, percentage.", "label": "Debt Instrument Commitment Fee Percentage", "terseLabel": "Debt instrument, commitment fee, percentage" } } }, "localname": "DebtInstrumentCommitmentFeePercentage", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "dcth_DebtInstrumentCommitmentFeesUponFundingOfSecondTrancheOfLoan": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt instrument, commitment fees upon funding of second tranche of loan.", "label": "Debt Instrument Commitment Fees Upon Funding Of Second Tranche Of Loan", "terseLabel": "Debt instrument, commitment fee upon funding of second tranche of loan" } } }, "localname": "DebtInstrumentCommitmentFeesUponFundingOfSecondTrancheOfLoan", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dcth_DebtInstrumentIncrementalFinalPaymentPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument, incremental final payment, percentage.", "label": "Debt Instrument Incremental Final Payment Percentage", "terseLabel": "Debt instrument, incremental final payment" } } }, "localname": "DebtInstrumentIncrementalFinalPaymentPercentage", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "dcth_DebtInstrumentPeriodicPaymentInterestTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument periodic payment interest term.", "label": "Debt Instrument Periodic Payment Interest Term", "verboseLabel": "Periodic interest payments, term" } } }, "localname": "DebtInstrumentPeriodicPaymentInterestTerm", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "dcth_DebtInstrumentPrepaymentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument prepayment fee percentage.", "label": "Debt Instrument Prepayment Fee Percentage", "terseLabel": "Prepayment fee, percentage" } } }, "localname": "DebtInstrumentPrepaymentFeePercentage", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "dcth_DecemberThirtyFirstTwoThousandTwentyFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "December thirty first two thousand twenty four.", "label": "December Thirty First Two Thousand Twenty Four [Member]", "terseLabel": "Year ended December 31, 2024" } } }, "localname": "DecemberThirtyFirstTwoThousandTwentyFourMember", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableSummaryOfRemainingMaturitiesOfCompanysLoanAndConvertibleNotePayablesDetails" ], "xbrltype": "domainItemType" }, "dcth_DecemberThirtyFirstTwoThousandTwentyThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "December thirty first two thousand twenty three.", "label": "December Thirty First Two Thousand Twenty Three [Member]", "terseLabel": "Year ended December 31, 2023" } } }, "localname": "DecemberThirtyFirstTwoThousandTwentyThreeMember", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableSummaryOfRemainingMaturitiesOfCompanysLoanAndConvertibleNotePayablesDetails" ], "xbrltype": "domainItemType" }, "dcth_DecemberThirtyFirstTwoThousandTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "December thirty first two thousand twenty two.", "label": "December Thirty First Two Thousand Twenty Two [Member]", "terseLabel": "Year ended December 31, 2022" } } }, "localname": "DecemberThirtyFirstTwoThousandTwentyTwoMember", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableSummaryOfRemainingMaturitiesOfCompanysLoanAndConvertibleNotePayablesDetails" ], "xbrltype": "domainItemType" }, "dcth_DiscountOnNotesAndLoansPayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Discount on notes and loans payable.", "label": "Discount On Notes And Loans Payable", "terseLabel": "Discount" } } }, "localname": "DiscountOnNotesAndLoansPayable", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableSummaryOfLoansAndConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "dcth_DiscountOnNotesAndLoansPayableCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Discount on notes and loans payable current.", "label": "Discount On Notes And Loans Payable Current", "terseLabel": "Less Current Portion, Discount" } } }, "localname": "DiscountOnNotesAndLoansPayableCurrent", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableSummaryOfLoansAndConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "dcth_DiscountOnNotesAndLoansPayableNonurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Discount on notes and loans payable nonurrent.", "label": "Discount On Notes And Loans Payable Nonurrent", "terseLabel": "Total - Loans Payable, Non-Current, Discount" } } }, "localname": "DiscountOnNotesAndLoansPayableNonurrent", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableSummaryOfLoansAndConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "dcth_EightPointZeroPercentageJulyTwoThousandAndNineteenNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Eight point zero percentage july two thousand and nineteen notes.", "label": "Eight Point Zero Percentage July Two Thousand And Nineteen Notes [Member]" } } }, "localname": "EightPointZeroPercentageJulyTwoThousandAndNineteenNotesMember", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dcth_EquityMethodInvestmentsAndCostMethodInvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Method Investments And Cost Method Investments [Abstract]", "label": "Equity Method Investments And Cost Method Investments [Abstract]" } } }, "localname": "EquityMethodInvestmentsAndCostMethodInvestmentsAbstract", "nsuri": "http://www.delcath.com/20220331", "xbrltype": "stringItemType" }, "dcth_ExercisePriceRangeAboveTwentyFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price range above twenty five.", "label": "Exercise Price Range Above Twenty Five [Member]", "terseLabel": "$25 + [Member]" } } }, "localname": "ExercisePriceRangeAboveTwentyFiveMember", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfStockOptionSharesOutstandingAndExercisableDetails" ], "xbrltype": "domainItemType" }, "dcth_ExercisePriceRangeFromFifteenPointZeroZeroToTwentyFourPointNineNineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price range from fifteen point zero zero to twenty four point nine nine.", "label": "Exercise Price Range From Fifteen Point Zero Zero To Twenty Four Point Nine Nine [Member]", "terseLabel": "$15.00 - $24.99 [Member]" } } }, "localname": "ExercisePriceRangeFromFifteenPointZeroZeroToTwentyFourPointNineNineMember", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfStockOptionSharesOutstandingAndExercisableDetails" ], "xbrltype": "domainItemType" }, "dcth_ExercisePriceRangeFromSixPointSixOneToNinePointNineNineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price range from six point six one to nine point nine nine.", "label": "Exercise Price Range From Six Point Six One To Nine Point Nine Nine [Member]", "terseLabel": "$6.61 - $9.99 [Member]" } } }, "localname": "ExercisePriceRangeFromSixPointSixOneToNinePointNineNineMember", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfStockOptionSharesOutstandingAndExercisableDetails" ], "xbrltype": "domainItemType" }, "dcth_ExercisePriceRangeFromTenPointZeroZeroToFourteenPointNineNineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price range from ten point zero zero to fourteen point nine nine.", "label": "Exercise Price Range From Ten Point Zero Zero To Fourteen Point Nine Nine [Member]", "terseLabel": "$10.00 - $14.99 [Member]" } } }, "localname": "ExercisePriceRangeFromTenPointZeroZeroToFourteenPointNineNineMember", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfStockOptionSharesOutstandingAndExercisableDetails" ], "xbrltype": "domainItemType" }, "dcth_FinalPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Final payment.", "label": "Final Payment", "terseLabel": "Final payment" } } }, "localname": "FinalPayment", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableSummaryOfLoansAndConvertibleNotesPayableDetailsParenthetical" ], "xbrltype": "monetaryItemType" }, "dcth_IncreaseDecreaseInOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in operating lease liabilities.", "label": "Increase Decrease In Operating Lease Liabilities", "terseLabel": "Decrease in lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "dcth_InitialTrancheOfLoan": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Initial tranche of loan.", "label": "Initial Tranche Of Loan", "terseLabel": "Initial tranche of loan" } } }, "localname": "InitialTrancheOfLoan", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dcth_LegalFeesAndDisbursements": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of expense provided in the period for legal fees and disbursements.", "label": "Legal Fees And Disbursements", "terseLabel": "Legal fees and disbursements" } } }, "localname": "LegalFeesAndDisbursements", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/StockholdersEquityAtTheMarketOfferingAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dcth_LesseeOperatingAndFinanceLeasesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee operating and finance leases.", "label": "Lessee Operating And Finance Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingAndFinanceLeasesTextBlock", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "dcth_LettersOfCreditRestrictedCash": { "auth_ref": [], "calculation": { "http://www.delcath.com/role/CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Letters of credit restricted cash.", "label": "Letters Of Credit Restricted Cash", "terseLabel": "Letters of credit" } } }, "localname": "LettersOfCreditRestrictedCash", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "dcth_LiquidityAndGoingConcernPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Liquidity and going concern.", "label": "Liquidity And Going Concern Policy [Text Block]", "terseLabel": "Liquidity and Going Concern" } } }, "localname": "LiquidityAndGoingConcernPolicyTextBlock", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/GeneralPolicies" ], "xbrltype": "textBlockItemType" }, "dcth_LoanAgreementRestrictedCash": { "auth_ref": [], "calculation": { "http://www.delcath.com/role/CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashDetails": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Loan agreement restricted cash.", "label": "Loan Agreement Restricted Cash", "terseLabel": "Restricted balance for loan agreement" } } }, "localname": "LoanAgreementRestrictedCash", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "dcth_LoanAvenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan Avenue [Member]" } } }, "localname": "LoanAvenueMember", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableSummaryOfLoansAndConvertibleNotesPayableDetails" ], "xbrltype": "domainItemType" }, "dcth_MayTwoThousandAndTwentyTwoEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "May two thousand and twenty two employee stock purchase plan [Member].", "label": "May Two Thousand And Twenty Two Employee Stock Purchase Plan [Member]", "terseLabel": "May 2022 Employee Stock Purchase Plan (ESPP) [Member]" } } }, "localname": "MayTwoThousandAndTwentyTwoEmployeeStockPurchasePlanMember", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfEmployeeStockPurchasePlanDetails" ], "xbrltype": "domainItemType" }, "dcth_MedacMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medac.", "label": "Medac [Member]" } } }, "localname": "MedacMember", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dcth_NonConvertibleDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non convertible debt.", "label": "Non Convertible Debt [Member]" } } }, "localname": "NonConvertibleDebtMember", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dcth_NotesAndLoansPayableGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Notes and loans payable gross.", "label": "Notes And Loans Payable Gross", "terseLabel": "Gross" } } }, "localname": "NotesAndLoansPayableGross", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableSummaryOfLoansAndConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "dcth_NotesAndLoansPayableGrossCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Notes and loans payable gross current.", "label": "Notes And Loans Payable Gross Current", "terseLabel": "Less Current Portion, Gross" } } }, "localname": "NotesAndLoansPayableGrossCurrent", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableSummaryOfLoansAndConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "dcth_NotesAndLoansPayableGrossNonCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Notes and loans payable gross non current.", "label": "Notes And Loans Payable Gross Non Current", "terseLabel": "Total - Loans Payable, Non-Current, Gross" } } }, "localname": "NotesAndLoansPayableGrossNonCurrent", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableSummaryOfLoansAndConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "dcth_NotesAndLoansPayableNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Notes and loans payable net.", "label": "Notes And Loans Payable Net", "terseLabel": "Net" } } }, "localname": "NotesAndLoansPayableNet", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableSummaryOfLoansAndConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "dcth_NumberOfCommonSharesRemainedAvailableToBeIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of common shares remained available to be issued.", "label": "Number Of Common Shares Remained Available To Be Issued", "terseLabel": "Number of common shares remained available to be issued" } } }, "localname": "NumberOfCommonSharesRemainedAvailableToBeIssued", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/StockholdersEquityEquityIncentivePlanAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "dcth_NumberOfSharesPreFundedPennyWarrantsOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares pre-funded penny warrants outstanding.", "label": "Number Of Shares Pre Funded Penny Warrants Outstanding", "terseLabel": "Pre-funded penny warrants outstanding" } } }, "localname": "NumberOfSharesPreFundedPennyWarrantsOutstanding", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/NetLossPerCommonShareAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "dcth_OperatingLeaseAndFinancingLeaseWeightedAverageRemainingLeaseTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease and financing lease weighted average remaining lease term.", "label": "Operating Lease And Financing Lease Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term" } } }, "localname": "OperatingLeaseAndFinancingLeaseWeightedAverageRemainingLeaseTerm", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/LeasesSummaryOfOperatingAndFinancingLeasesDetails" ], "xbrltype": "durationItemType" }, "dcth_OtherLeaseInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other lease information.", "label": "Other Lease Information [Abstract]", "terseLabel": "Other information" } } }, "localname": "OtherLeaseInformationAbstract", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/LeasesSummaryOfOperatingAndFinancingLeasesDetails" ], "xbrltype": "stringItemType" }, "dcth_PercentageOfCommissionOnAggregateGrossProceeds": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage Of Commission On Aggregate Gross Proceeds.", "label": "Percentage Of Commission On Aggregate Gross Proceeds", "terseLabel": "Percentage of commission on aggregate gross proceeds" } } }, "localname": "PercentageOfCommissionOnAggregateGrossProceeds", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/StockholdersEquityAtTheMarketOfferingAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "dcth_PercentageOfEnrolledPatients": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage Of enrolled patients.", "label": "Percentage Of Enrolled Patients", "terseLabel": "Percentage of enrolled patients" } } }, "localname": "PercentageOfEnrolledPatients", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "dcth_PercentageOfFinalPaymentIncludedInGrossAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of final payment included in gross amount.", "label": "Percentage Of Final Payment Included In Gross Amount", "terseLabel": "Percentage of final payment included in gross amount" } } }, "localname": "PercentageOfFinalPaymentIncludedInGrossAmount", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableSummaryOfLoansAndConvertibleNotesPayableDetailsParenthetical" ], "xbrltype": "percentItemType" }, "dcth_PercentageOfUnderwritingFeeToBeReceivedByRelatedParty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage Of Underwriting Fee To Be Received on company offerings.", "label": "Percentage Of Underwriting Fee To Be Received By Related Party", "terseLabel": "Percentage of underwriting fee to be received on company offerings" } } }, "localname": "PercentageOfUnderwritingFeeToBeReceivedByRelatedParty", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/StockholdersEquityAtTheMarketOfferingAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "dcth_PercentageOnSaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage On Sale Of Stock Consideration Received On Transaction.", "label": "Percentage On Sale Of Stock Consideration Received On Transaction", "terseLabel": "Percentage of fee on gross sale price per share" } } }, "localname": "PercentageOnSaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/StockholdersEquityAtTheMarketOfferingAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "dcth_PlanAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan [Axis].", "label": "Plan [Axis]" } } }, "localname": "PlanAxis", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfEmployeeStockPurchasePlanDetails" ], "xbrltype": "stringItemType" }, "dcth_PlanDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan [Domain].", "label": "Plan [Domain]" } } }, "localname": "PlanDomain", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfEmployeeStockPurchasePlanDetails" ], "xbrltype": "domainItemType" }, "dcth_PrepaidClinicalTrialExpensesCurrent": { "auth_ref": [], "calculation": { "http://www.delcath.com/role/PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid clinical trial expenses current.", "label": "Prepaid Clinical Trial Expenses Current", "terseLabel": "Clinical trial expenses" } } }, "localname": "PrepaidClinicalTrialExpensesCurrent", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "dcth_PrepaidExpensesAndOtherCurrentAssetsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepaid expenses and other current assets.", "label": "Prepaid Expenses And Other Current Assets [Text Block]", "terseLabel": "Prepaid Expenses And Other Current Assets" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsTextBlock", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/PrepaidExpensesAndOtherCurrentAssets" ], "xbrltype": "textBlockItemType" }, "dcth_RangeOfExercisePricesPointZeroOneRangeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Range of exercise prices Point zero one range.", "label": "Range Of Exercise Prices Point Zero One Range [Member]", "terseLabel": "$0.01 [Member]" } } }, "localname": "RangeOfExercisePricesPointZeroOneRangeMember", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfWarrantsOutstandingAndExercisableDetails" ], "xbrltype": "domainItemType" }, "dcth_RangeOfExercisePricesTenPointZeroRangeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Range of exercise prices Ten point zero range.", "label": "Range Of Exercise Prices Ten Point Zero Range [Member]", "terseLabel": "$10.00 [Member]" } } }, "localname": "RangeOfExercisePricesTenPointZeroRangeMember", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfWarrantsOutstandingAndExercisableDetails" ], "xbrltype": "domainItemType" }, "dcth_RiskAndUncertaintiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Risk and uncertainties.", "label": "Risk And Uncertainties Policy [Text Block]", "terseLabel": "Risk and Uncertainties" } } }, "localname": "RiskAndUncertaintiesPolicyTextBlock", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/GeneralPolicies" ], "xbrltype": "textBlockItemType" }, "dcth_RothCapitalPartnersLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Roth Capital Partners, LLC.", "label": "Roth Capital Partners L L C [Member]", "terseLabel": "Roth Capital Partners L L C" } } }, "localname": "RothCapitalPartnersLLCMember", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/StockholdersEquityAtTheMarketOfferingAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dcth_ScheduleOfInformationRelatedToStockWarrantsOutstandingAndExercisableTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Information Related to Stock Warrants Outstanding and Exercisable.", "label": "Schedule Of Information Related To Stock Warrants Outstanding And Exercisable Table [Text Block]", "terseLabel": "Schedule of Information Related to Stock Warrants Outstanding and Exercisable" } } }, "localname": "ScheduleOfInformationRelatedToStockWarrantsOutstandingAndExercisableTableTextBlock", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "dcth_ScheduleOfOperatingAndFinancingLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of operating and financing leases.", "label": "Schedule Of Operating And Financing Leases Table [Text Block]", "terseLabel": "Summary of Operating and Financing Leases" } } }, "localname": "ScheduleOfOperatingAndFinancingLeasesTableTextBlock", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "dcth_SecondTrancheOfLoan": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Second tranche of loan.", "label": "Second Tranche Of Loan", "terseLabel": "Second tranche of loan" } } }, "localname": "SecondTrancheOfLoan", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dcth_SecuredConvertibleNotesPayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Secured convertible notes payable.", "label": "Secured Convertible Notes Payable [Member]" } } }, "localname": "SecuredConvertibleNotesPayableMember", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dcth_SecurityForCreditCardsRestrictedCash": { "auth_ref": [], "calculation": { "http://www.delcath.com/role/CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashDetails": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Security for credit cards restricted cash.", "label": "Security For Credit Cards Restricted Cash", "terseLabel": "Security for credit cards" } } }, "localname": "SecurityForCreditCardsRestrictedCash", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashDetails" ], "xbrltype": "monetaryItemType" }, "dcth_SeriesE1ConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series E-1 convertible preferred stock.", "label": "Series E1 Convertible Preferred Stock [Member]", "terseLabel": "Series E-1 Convertible Preferred Stock [Member]" } } }, "localname": "SeriesE1ConvertiblePreferredStockMember", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/StockholdersEquityPreferredStockIssuancesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dcth_SeriesE1PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series e1 preferred stock member", "label": "Series E1 Preferred Stock [Member]", "terseLabel": "Series E1 Preferred Stock [Member]" } } }, "localname": "SeriesE1PreferredStockMember", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/StockholdersEquityPreferredStockIssuancesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dcth_SeriesEConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series E convertible preferred stock.", "label": "Series E Convertible Preferred Stock [Member]", "terseLabel": "Series E Convertible Preferred Stock [Member]" } } }, "localname": "SeriesEConvertiblePreferredStockMember", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/StockholdersEquityPreferredStockIssuancesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dcth_ShareBasedCompensationIncomeExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share-based compensation (Income) expense.", "label": "Share Based Compensation Income Expense", "terseLabel": "Share-based compensation (Income) expense" } } }, "localname": "ShareBasedCompensationIncomeExpense", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfRecognizedShareBasedCompensationCostDetails" ], "xbrltype": "monetaryItemType" }, "dcth_SharesSettledForServices": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Shares settled for services.", "label": "Shares settled for services", "terseLabel": "Issuance of restricted stock for accrued fees due to a former board member" } } }, "localname": "SharesSettledForServices", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "dcth_ShortTermFnancing": { "auth_ref": [], "calculation": { "http://www.delcath.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Short-term financing.", "label": "Short Term Fnancing", "terseLabel": "Short-term financing" } } }, "localname": "ShortTermFnancing", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "dcth_StockIssuedDuringPeriodValueExerciseOfWarrantsForCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value exercise of warrants for common stock", "label": "Stock Issued During Period Value Exercise Of Warrants For Common Stock", "terseLabel": "Exercise of warrants into common stock" } } }, "localname": "StockIssuedDuringPeriodValueExerciseOfWarrantsForCommonStock", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "dcth_StockIssuedDuringPeriodValueExerciseOfWarrantsForCommonStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period value exercise of warrants for common stock shares", "label": "Stock Issued During Period Value Exercise Of Warrants For Common Stock Shares", "terseLabel": "Exercise of warrants into common stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodValueExerciseOfWarrantsForCommonStockShares", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "dcth_StockOptionCompensationIncomeExpense": { "auth_ref": [], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Stock option compensation (income) expense.", "label": "Stock Option Compensation Income Expense", "terseLabel": "Stock option compensation expense" } } }, "localname": "StockOptionCompensationIncomeExpense", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "dcth_StockholdersEquityNoteLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stockholders equity note.", "label": "Stockholders Equity Note [Line Items]", "terseLabel": "Stockholders Equity Note [Line Items]" } } }, "localname": "StockholdersEquityNoteLineItems", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/StockholdersEquityAtTheMarketOfferingAdditionalInformationDetails", "http://www.delcath.com/role/StockholdersEquityPreferredStockIssuancesAdditionalInformationDetails", "http://www.delcath.com/role/StockholdersEquitySummaryOfEmployeeStockPurchasePlanDetails" ], "xbrltype": "stringItemType" }, "dcth_StockholdersEquityNoteTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stockholders equity note.", "label": "Stockholders Equity Note [Table]", "terseLabel": "Stockholders Equity Note [Table]" } } }, "localname": "StockholdersEquityNoteTable", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/StockholdersEquityAtTheMarketOfferingAdditionalInformationDetails", "http://www.delcath.com/role/StockholdersEquityPreferredStockIssuancesAdditionalInformationDetails", "http://www.delcath.com/role/StockholdersEquitySummaryOfEmployeeStockPurchasePlanDetails" ], "xbrltype": "stringItemType" }, "dcth_TermLoanFromAvenueVentureOpportunitiesFundLpMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Term Loan From Avenue Venture Opportunities Fund LP [Member]", "terseLabel": "Term Loan from Avenue Venture Opportunities Fund L.P [Member]" } } }, "localname": "TermLoanFromAvenueVentureOpportunitiesFundLpMember", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dcth_TrancheLoanFundedIntoRestrictedAccount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Tranche loan funded into restricted account.", "label": "Tranche Loan Funded Into Restricted Account", "terseLabel": "Loan amount funded into restricted account" } } }, "localname": "TrancheLoanFundedIntoRestrictedAccount", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dcth_WarrantsIssuedTopurchaseOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants issued to purchase of common stock.", "label": "Warrants Issued ToPurchase Of Common Stock", "terseLabel": "Warrants issued to purchase of common stock" } } }, "localname": "WarrantsIssuedTopurchaseOfCommonStock", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "dcth_WarrantsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Warrants Outstanding Roll Forward", "terseLabel": "Warrants outstanding [Roll Forward]" } } }, "localname": "WarrantsOutstandingRollForward", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfWarrantActivityDetails" ], "xbrltype": "stringItemType" }, "dcth_WeightedAverageNumberOfSharesPreFundedWarrants1": { "auth_ref": [], "calculation": { "http://www.delcath.com/role/NetLossPerCommonShareSummaryOfReconciliationOfWeightedAverageSharesOutstandingCalculationDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Weighted average number of shares pre funded warrants 1.", "label": "Weighted Average Number Of Shares Pre Funded Warrants1", "terseLabel": "Weighted average pre-funded warrants" } } }, "localname": "WeightedAverageNumberOfSharesPreFundedWarrants1", "nsuri": "http://www.delcath.com/20220331", "presentation": [ "http://www.delcath.com/role/NetLossPerCommonShareSummaryOfReconciliationOfWeightedAverageSharesOutstandingCalculationDetails" ], "xbrltype": "sharesItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r430" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_MaximumMember": { "auth_ref": [ "r198", "r231", "r257", "r258", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r395", "r398", "r421", "r422" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails", "http://www.delcath.com/role/StockholdersEquityAtTheMarketOfferingAdditionalInformationDetails", "http://www.delcath.com/role/StockholdersEquityScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r198", "r231", "r257", "r258", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r395", "r398", "r421", "r422" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails", "http://www.delcath.com/role/StockholdersEquityScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r147", "r252", "r253", "r354", "r394", "r396" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r147", "r252", "r253", "r354", "r394", "r396" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r198", "r231", "r255", "r257", "r258", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r395", "r398", "r421", "r422" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.delcath.com/role/CommitmentsAndContingenciesAdditionalInformationDetails", "http://www.delcath.com/role/LeasesAdditionalInformationDetails", "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails", "http://www.delcath.com/role/StockholdersEquityAtTheMarketOfferingAdditionalInformationDetails", "http://www.delcath.com/role/StockholdersEquityEquityIncentivePlanAdditionalInformationDetails", "http://www.delcath.com/role/StockholdersEquityScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails", "http://www.delcath.com/role/StockholdersEquityStockIncentivePlansAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r198", "r231", "r255", "r257", "r258", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r395", "r398", "r421", "r422" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.delcath.com/role/CommitmentsAndContingenciesAdditionalInformationDetails", "http://www.delcath.com/role/LeasesAdditionalInformationDetails", "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails", "http://www.delcath.com/role/StockholdersEquityAtTheMarketOfferingAdditionalInformationDetails", "http://www.delcath.com/role/StockholdersEquityEquityIncentivePlanAdditionalInformationDetails", "http://www.delcath.com/role/StockholdersEquityScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails", "http://www.delcath.com/role/StockholdersEquityStockIncentivePlansAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r148", "r149", "r252", "r254", "r397", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.delcath.com/role/LeasesScheduleOfRemainingMaturityOfOperatingLeasesExcludingShortTermLeasesDetails", "http://www.delcath.com/role/LeasesSummaryOfOperatingAndFinancingLeasesDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r148", "r149", "r252", "r254", "r397", "r408", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.delcath.com/role/LeasesScheduleOfRemainingMaturityOfOperatingLeasesExcludingShortTermLeasesDetails", "http://www.delcath.com/role/LeasesSummaryOfOperatingAndFinancingLeasesDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r151", "r339" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.delcath.com/role/CommitmentsAndContingenciesAdditionalInformationDetails", "http://www.delcath.com/role/StockholdersEquityStockIncentivePlansAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.delcath.com/role/CommitmentsAndContingenciesAdditionalInformationDetails", "http://www.delcath.com/role/StockholdersEquityStockIncentivePlansAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/AccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r40", "r343" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r4", "r23", "r152", "r153" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.delcath.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails", "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r10", "r11", "r44" ], "calculation": { "http://www.delcath.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r38", "r163" ], "calculation": { "http://www.delcath.com/role/PropertyPlantAndEquipmentComponentsOfPropertyPlantAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/PropertyPlantAndEquipmentComponentsOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r26", "r61", "r62", "r63", "r386", "r403", "r404" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets": { "order": 24.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "verboseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r60", "r63", "r70", "r71", "r72", "r102", "r103", "r104", "r304", "r399", "r400", "r431" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r24", "r285", "r343" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets": { "order": 22.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r102", "r103", "r104", "r282", "r283", "r284", "r309" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition", "terseLabel": "Compensation expense for issuance of stock options" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r194", "r243", "r248" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Fair value of warrants reclassified from liability to equity" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r78", "r88", "r218", "r322" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "verboseLabel": "Amortization of debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r88", "r218", "r226", "r227", "r324" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of debt discount" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/NetLossPerCommonShareAntiDilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/NetLossPerCommonShareAntiDilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/NetLossPerCommonShareAntiDilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/NetLossPerCommonShareAntiDilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r97", "r136", "r139", "r145", "r155", "r180", "r181", "r182", "r184", "r185", "r186", "r187", "r188", "r189", "r191", "r192", "r301", "r305", "r313", "r341", "r343", "r368", "r383" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r7", "r9", "r57", "r97", "r155", "r180", "r181", "r182", "r184", "r185", "r186", "r187", "r188", "r189", "r191", "r192", "r301", "r305", "r313", "r341", "r343" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r261", "r281" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquityAtTheMarketOfferingAdditionalInformationDetails", "http://www.delcath.com/role/StockholdersEquityStockIncentivePlansAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/GeneralPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingMember": { "auth_ref": [ "r162" ], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building [Member]", "terseLabel": "Buildings [Member]" } } }, "localname": "BuildingMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/PropertyPlantAndEquipmentComponentsOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Cash": { "auth_ref": [ "r36", "r343", "r405", "r406" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r36", "r90" ], "calculation": { "http://www.delcath.com/role/CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0 }, "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashDetails", "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.", "label": "Cash and Cash Equivalents Disclosure [Text Block]", "terseLabel": "Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "CashAndCashEquivalentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CashCashEquivalentsAndRestrictedCash" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r84", "r90", "r92" ], "calculation": { "http://www.delcath.com/role/CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "End of period", "periodStartLabel": "Beginning of period", "terseLabel": "Total", "totalLabel": "Total cash, cash equivalents and restricted cash shown in the statements of cash flows" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CashCashEquivalentsAndRestrictedCashScheduleOfCashCashEquivalentsAndRestrictedCashDetails", "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations [Abstract]", "verboseLabel": "Total Cash:" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r84", "r314" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in total cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r94", "r97", "r117", "r118", "r119", "r121", "r123", "r130", "r131", "r132", "r155", "r180", "r185", "r186", "r187", "r191", "r192", "r229", "r230", "r233", "r237", "r313", "r429" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.delcath.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit", "http://www.delcath.com/role/LeasesAdditionalInformationDetails", "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails", "http://www.delcath.com/role/StockholdersEquityPreferredStockIssuancesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r249", "r259" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]", "terseLabel": "Class of Warrant or Right" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit", "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]", "terseLabel": "Class of Warrant or Right" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit", "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Warrant exercise price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Warrant or Right [Line Items]", "terseLabel": "Class Of Warrant Or Right [Line Items]" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfWarrantsOutstandingAndExercisableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "periodEndLabel": "Outstanding, end of period (in shares)", "periodStartLabel": "Outstanding, beginning of period (in shares)", "terseLabel": "Warrants Outstanding, Number Outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfWarrantActivityDetails", "http://www.delcath.com/role/StockholdersEquitySummaryOfWarrantsOutstandingAndExercisableDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r249", "r259" ], "lang": { "en-us": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class of Warrant or Right [Table]", "terseLabel": "Class Of Warrant Or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfWarrantsOutstandingAndExercisableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r49", "r169", "r373", "r390" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 13)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsDisclosureTextBlock": { "auth_ref": [ "r168" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.", "label": "Commitments Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Number of common shares reserved for issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquityEquityIncentivePlanAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r102", "r103", "r309" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.delcath.com/role/StockholdersEquityPreferredStockIssuancesAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.delcath.com/role/StockholdersEquityPreferredStockIssuancesAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r22", "r243" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r22", "r343" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets": { "order": 21.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $.01 par value; 40,000,000 shares authorized; 7,906,728 shares issued and outstanding at March 31, 2022 and December 31, 2021" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r66", "r68", "r69", "r74", "r375", "r393" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total other comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Enterprise Hardware and Software [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/PropertyPlantAndEquipmentComponentsOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r193", "r195", "r196", "r198", "r208", "r209", "r210", "r214", "r215", "r216", "r217", "r218", "r224", "r225", "r226", "r227" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleLongTermNotesPayable": { "auth_ref": [ "r48" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets": { "order": 17.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible Notes Payable, Noncurrent", "terseLabel": "Convertible notes payable, non-current" } } }, "localname": "ConvertibleLongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableMember": { "auth_ref": [ "r17", "r369", "r382", "r407" ], "lang": { "en-us": { "role": { "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable [Member]" } } }, "localname": "ConvertibleNotesPayableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r76", "r97", "r155", "r180", "r181", "r182", "r185", "r186", "r187", "r188", "r189", "r191", "r192", "r313" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 9.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "negatedLabel": "Cost of goods sold" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of Goods Sold [Member]" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfRecognizedShareBasedCompensationCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r93", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r212", "r219", "r220", "r222", "r228" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Loans and Convertible Notes Payable" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r17", "r18", "r19", "r96", "r100", "r195", "r196", "r197", "r198", "r199", "r200", "r202", "r208", "r209", "r210", "r211", "r213", "r214", "r215", "r216", "r217", "r218", "r224", "r225", "r226", "r227", "r325", "r369", "r370", "r382" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails", "http://www.delcath.com/role/LoansAndConvertibleNotesPayableSummaryOfLoansAndConvertibleNotesPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Debt instrument, interest rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r197", "r223" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Debt instrument, conversion price" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r195", "r224", "r225", "r323", "r325", "r326" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt instrument, principal face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": { "auth_ref": [ "r48", "r378" ], "lang": { "en-us": { "role": { "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual).", "label": "Debt Instrument, Frequency of Periodic Payment", "terseLabel": "Frequency of periodic payment" } } }, "localname": "DebtInstrumentFrequencyOfPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r46", "r196" ], "lang": { "en-us": { "role": { "definitionGuidance": "Debt instrument, interest rate", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "presentationGuidance": "Current interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateTerms": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.", "label": "Debt Instrument, Interest Rate Terms", "terseLabel": "Debt instrument, interest rate term" } } }, "localname": "DebtInstrumentInterestRateTerms", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails", "http://www.delcath.com/role/LoansAndConvertibleNotesPayableSummaryOfRemainingMaturitiesOfCompanysLoanAndConvertibleNotePayablesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r47", "r198", "r311" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt Instrument, Maturity Date", "terseLabel": "Debt instrument maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r48", "r96", "r100", "r195", "r196", "r197", "r198", "r199", "r200", "r202", "r208", "r209", "r210", "r211", "r213", "r214", "r215", "r216", "r217", "r218", "r224", "r225", "r226", "r227", "r325" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails", "http://www.delcath.com/role/LoansAndConvertibleNotesPayableSummaryOfLoansAndConvertibleNotesPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "Information about timing of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period [Axis]" } } }, "localname": "DebtInstrumentRedemptionPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableSummaryOfRemainingMaturitiesOfCompanysLoanAndConvertibleNotePayablesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "Period as defined under terms of the debt agreement for debt redemption features.", "label": "Debt Instrument, Redemption, Period [Domain]" } } }, "localname": "DebtInstrumentRedemptionPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableSummaryOfRemainingMaturitiesOfCompanysLoanAndConvertibleNotePayablesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r48", "r96", "r100", "r195", "r196", "r197", "r198", "r199", "r200", "r202", "r208", "r209", "r210", "r211", "r213", "r214", "r215", "r216", "r217", "r218", "r221", "r224", "r225", "r226", "r227", "r244", "r245", "r246", "r247", "r322", "r323", "r325", "r326", "r380" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Debt Instrument [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r208", "r322", "r326" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "terseLabel": "Aggregate debt discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountCurrent": { "auth_ref": [ "r322", "r326" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.", "label": "Debt Instrument, Unamortized Discount, Current", "terseLabel": "Debit discount" } } }, "localname": "DebtInstrumentUnamortizedDiscountCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts": { "auth_ref": [ "r78" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the charge against earnings during the period for commitment fees and debt issuance expenses.", "label": "Debt Related Commitment Fees and Debt Issuance Costs", "verboseLabel": "Debt instrument, commitment fee" } } }, "localname": "DebtRelatedCommitmentFeesAndDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "auth_ref": [ "r39" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "terseLabel": "Prepaid Expenses and Other Current Assets" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets": { "order": 13.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred Revenue, Current", "terseLabel": "Deferred revenue, current" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r88", "r161" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.delcath.com/role/PropertyPlantAndEquipmentAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeNet": { "auth_ref": [ "r312" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives.", "label": "Derivative, Fair Value, Net", "terseLabel": "Fair value of the Avenue Warrant" } } }, "localname": "DerivativeFairValueOfDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueFromRelatedParties": { "auth_ref": [ "r99", "r183", "r185", "r186", "r190", "r191", "r192", "r338", "r372", "r391" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.", "label": "Due from Related Parties", "terseLabel": "Due from related parties" } } }, "localname": "DueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r122" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Basic and diluted loss per common share" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted [Abstract]", "terseLabel": "Common share data:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r124", "r126", "r127", "r128" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss per Common Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/NetLossPerCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r314" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "verboseLabel": "Foreign currency effects on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.delcath.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Compensation, excluding taxes" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfRecognizedShareBasedCompensationCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r280" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation expense related to non-vested share-based compensation awards" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquityStockIncentivePlansAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Cost expected to be recognized over weighted average period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquityStockIncentivePlansAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock Options [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/NetLossPerCommonShareAntiDilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Equipment [Member]" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/PropertyPlantAndEquipmentComponentsOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r70", "r71", "r72", "r102", "r103", "r104", "r106", "r111", "r113", "r129", "r156", "r243", "r248", "r282", "r283", "r284", "r292", "r293", "r309", "r315", "r316", "r317", "r318", "r319", "r320", "r399", "r400", "r401", "r431" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit", "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails", "http://www.delcath.com/role/StockholdersEquityPreferredStockIssuancesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/PropertyPlantAndEquipmentComponentsOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r75", "r97", "r136", "r138", "r141", "r144", "r146", "r155", "r180", "r181", "r182", "r185", "r186", "r187", "r188", "r189", "r191", "r192", "r313" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 7.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r165", "r167" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfRecognizedShareBasedCompensationCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r167" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfRecognizedShareBasedCompensationCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r98", "r289", "r290", "r291", "r294", "r295", "r296", "r297", "r298" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r87" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Increase in accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r87" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Increase in accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r87", "r352" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Decrease in deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r87" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Increase in inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r87" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Decrease in prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpenseBorrowings": { "auth_ref": [ "r376" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate amount of interest expense on all borrowings.", "label": "Interest Expense, Borrowings", "terseLabel": "Interest expense incurred" } } }, "localname": "InterestExpenseBorrowings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 11.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest Income (Expense), Nonoperating, Net", "terseLabel": "Interest expense, net" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r83", "r85", "r91" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest expense" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r11", "r12", "r44" ], "calculation": { "http://www.delcath.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest Payable, Current", "terseLabel": "Interest on convertible note" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r157" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r53" ], "calculation": { "http://www.delcath.com/role/InventoriesScheduleOfInventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/InventoriesScheduleOfInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r56", "r343" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.delcath.com/role/InventoriesScheduleOfInventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories", "totalLabel": "Total inventories", "verboseLabel": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CommitmentsAndContingenciesAdditionalInformationDetails", "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets", "http://www.delcath.com/role/InventoriesScheduleOfInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r55" ], "calculation": { "http://www.delcath.com/role/InventoriesScheduleOfInventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/InventoriesScheduleOfInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r54" ], "calculation": { "http://www.delcath.com/role/InventoriesScheduleOfInventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work-in-process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/InventoriesScheduleOfInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandBuildingsAndImprovementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Real estate held and additions or improvements to real estate held and structures used in the conduct of business.", "label": "Land, Buildings and Improvements [Member]", "terseLabel": "Buildings and Land [Member]" } } }, "localname": "LandBuildingsAndImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/PropertyPlantAndEquipmentComponentsOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseContractualTermAxis": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "Information by contractual term of lease arrangement.", "label": "Lease Contractual Term [Axis]", "terseLabel": "Lease Contractual Term" } } }, "localname": "LeaseContractualTermAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseContractualTermDomain": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "Contractual term of lease arrangement.", "label": "Lease Contractual Term [Domain]", "terseLabel": "Lease Contractual Term" } } }, "localname": "LeaseContractualTermDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Lease Cost" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LeasesSummaryOfOperatingAndFinancingLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": { "auth_ref": [ "r162" ], "lang": { "en-us": { "role": { "documentation": "Assets held by a lessee under a capital lease and any addition or improvement to assets held under a lease arrangement (including addition or improvement to assets held by lessee under an operating lease arrangement).", "label": "Leaseholds and Leasehold Improvements [Member]", "terseLabel": "Leaseholds [Member]" } } }, "localname": "LeaseholdsAndLeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/PropertyPlantAndEquipmentComponentsOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee Lease Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LeasesScheduleOfRemainingMaturityOfOperatingLeasesExcludingShortTermLeasesDetails", "http://www.delcath.com/role/LeasesSummaryOfOperatingAndFinancingLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee Lease Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LeasesScheduleOfRemainingMaturityOfOperatingLeasesExcludingShortTermLeasesDetails", "http://www.delcath.com/role/LeasesSummaryOfOperatingAndFinancingLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Remaining Maturity of Operating Leases Excluding Short-Term Leases" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r335" ], "calculation": { "http://www.delcath.com/role/LeasesScheduleOfRemainingMaturityOfOperatingLeasesExcludingShortTermLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LeasesScheduleOfRemainingMaturityOfOperatingLeasesExcludingShortTermLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r335" ], "calculation": { "http://www.delcath.com/role/LeasesScheduleOfRemainingMaturityOfOperatingLeasesExcludingShortTermLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "Year ended December 31, 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LeasesScheduleOfRemainingMaturityOfOperatingLeasesExcludingShortTermLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r335" ], "calculation": { "http://www.delcath.com/role/LeasesScheduleOfRemainingMaturityOfOperatingLeasesExcludingShortTermLeasesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "Year ended December 31, 2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LeasesScheduleOfRemainingMaturityOfOperatingLeasesExcludingShortTermLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r335" ], "calculation": { "http://www.delcath.com/role/LeasesScheduleOfRemainingMaturityOfOperatingLeasesExcludingShortTermLeasesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "Year ended December 31, 2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LeasesScheduleOfRemainingMaturityOfOperatingLeasesExcludingShortTermLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r335" ], "calculation": { "http://www.delcath.com/role/LeasesScheduleOfRemainingMaturityOfOperatingLeasesExcludingShortTermLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "Year ended December 31, 2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LeasesScheduleOfRemainingMaturityOfOperatingLeasesExcludingShortTermLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r335" ], "calculation": { "http://www.delcath.com/role/LeasesScheduleOfRemainingMaturityOfOperatingLeasesExcludingShortTermLeasesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "Year ended December 31, 2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LeasesScheduleOfRemainingMaturityOfOperatingLeasesExcludingShortTermLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r335" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less present value discount" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LeasesScheduleOfRemainingMaturityOfOperatingLeasesExcludingShortTermLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lease term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r43", "r97", "r140", "r155", "r180", "r181", "r182", "r185", "r186", "r187", "r188", "r189", "r191", "r192", "r302", "r305", "r306", "r313", "r341", "r342" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r29", "r97", "r155", "r313", "r343", "r371", "r388" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r45", "r97", "r155", "r180", "r181", "r182", "r185", "r186", "r187", "r188", "r189", "r191", "r192", "r302", "r305", "r306", "r313", "r341", "r342", "r343" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationStatusAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by status of pending, threatened, or settled litigation.", "label": "Litigation Status [Axis]", "terseLabel": "Litigation Status" } } }, "localname": "LitigationStatusAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationStatusDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Status of pending, threatened, or settled litigation.", "label": "Litigation Status [Domain]", "terseLabel": "Litigation Status" } } }, "localname": "LitigationStatusDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LoansPayable": { "auth_ref": [ "r19", "r370", "r381" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).", "label": "Loans Payable", "terseLabel": "Loans" } } }, "localname": "LoansPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableSummaryOfRemainingMaturitiesOfCompanysLoanAndConvertibleNotePayablesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansPayableCurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets": { "order": 15.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.", "label": "Loans Payable, Current", "negatedLabel": "Less Current Portion, Net", "terseLabel": "Loan payable, current" } } }, "localname": "LoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets", "http://www.delcath.com/role/LoansAndConvertibleNotesPayableSummaryOfLoansAndConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-term Debt [Text Block]", "terseLabel": "Summary of Loans and Convertible Notes Payable" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermLoansPayable": { "auth_ref": [ "r48" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets": { "order": 18.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Loans Payable, Noncurrent", "terseLabel": "Loan payable, non-current", "verboseLabel": "Total - Loans Payable, Non-Current, Net" } } }, "localname": "LongTermLoansPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets", "http://www.delcath.com/role/LoansAndConvertibleNotesPayableSummaryOfLoansAndConvertibleNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r48", "r179" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r84" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r84" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r84", "r86", "r89" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r64", "r67", "r72", "r73", "r89", "r97", "r105", "r107", "r108", "r109", "r110", "r112", "r113", "r120", "r136", "r138", "r141", "r144", "r146", "r155", "r180", "r181", "r182", "r185", "r186", "r187", "r188", "r189", "r191", "r192", "r310", "r313", "r374", "r392" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.delcath.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.delcath.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.delcath.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "verboseLabel": "Recently Adopted and Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/GeneralPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Supplemental Disclosure of Non-Cash Investing and Financing Activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NotesAndLoansPayable": { "auth_ref": [ "r19", "r370", "r384" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of all notes and loans payable (with maturities initially due after one year or beyond the operating cycle if longer).", "label": "Notes and Loans Payable", "terseLabel": "Total" } } }, "localname": "NotesAndLoansPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableSummaryOfRemainingMaturitiesOfCompanysLoanAndConvertibleNotePayablesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r19", "r370", "r384" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes Payable", "terseLabel": "Convertible Notes" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableSummaryOfRemainingMaturitiesOfCompanysLoanAndConvertibleNotePayablesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r136", "r138", "r141", "r144", "r146" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r332", "r336" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LeasesSummaryOfOperatingAndFinancingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r328" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating lease liabilities included in the condensed consolidated balance sheets at March 31, 2022" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LeasesScheduleOfRemainingMaturityOfOperatingLeasesExcludingShortTermLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r328" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets": { "order": 14.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Lease liabilities, current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r328" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets": { "order": 16.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Lease liabilities, non-current" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r329", "r333" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "negatedTerseLabel": "Operating cash flows out from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LeasesSummaryOfOperatingAndFinancingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r327" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r334", "r336" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LeasesSummaryOfOperatingAndFinancingLeasesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r101", "r114", "r133", "r307" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "terseLabel": "General" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/General" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r10", "r11", "r12", "r44" ], "calculation": { "http://www.delcath.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r59" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r65", "r68", "r299", "r300", "r303" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Total comprehensive income" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r79" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 10.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPrepaidExpenseCurrent": { "auth_ref": [ "r5", "r8", "r159" ], "calculation": { "http://www.delcath.com/role/PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Other Prepaid Expense, Current", "terseLabel": "Other" } } }, "localname": "OtherPrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaidInKindInterest": { "auth_ref": [ "r88" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Paid-in-Kind Interest", "terseLabel": "Interest expense accrued related to convertible notes" } } }, "localname": "PaidInKindInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r82" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Payments of Financing Costs", "verboseLabel": "Cash issuance costs" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r80" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of property, plant and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r261", "r281" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LeasesAdditionalInformationDetails", "http://www.delcath.com/role/StockholdersEquityEquityIncentivePlanAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LeasesAdditionalInformationDetails", "http://www.delcath.com/role/StockholdersEquityEquityIncentivePlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r21", "r229" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.delcath.com/role/StockholdersEquityPreferredStockIssuancesAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.delcath.com/role/StockholdersEquityPreferredStockIssuancesAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r21", "r229" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.delcath.com/role/StockholdersEquityPreferredStockIssuancesAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r21", "r343" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets": { "order": 20.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "definitionGuidance": "Preferred stock, $.01 par value; 10,000,000 shares authorized; 11,357 shares issued and outstanding at March 31, 2022 and December 31, 2021", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r7", "r34", "r35" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.delcath.com/role/PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Total prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets", "http://www.delcath.com/role/PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current [Abstract]" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r6", "r8", "r158", "r159" ], "calculation": { "http://www.delcath.com/role/PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Insurance", "terseLabel": "Insurance premiums" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r81" ], "crdr": "debit", "lang": { "en-us": { "role": { "definitionGuidance": "Gross proceeds from ATM Offering", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from Issuance or Sale of Equity" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r81" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from Warrant Exercises", "verboseLabel": "Net proceeds from the exercise of warrants" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductAndServiceOtherMember": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.", "label": "Product and Service, Other [Member]", "terseLabel": "Other Revenue [Member]" } } }, "localname": "ProductAndServiceOtherMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "domainItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r253" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product Revenue [Member]" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r38", "r164" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/PropertyPlantAndEquipmentComponentsOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r166", "r409", "r410", "r411" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property, Plant, and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/PropertyPlantAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).", "label": "Property, Plant and Equipment, Estimated Useful Lives", "terseLabel": "Property, plant and equipment, estimated useful life" } } }, "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/PropertyPlantAndEquipmentComponentsOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r37", "r162" ], "calculation": { "http://www.delcath.com/role/PropertyPlantAndEquipmentComponentsOfPropertyPlantAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property, plant and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/PropertyPlantAndEquipmentComponentsOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property Plant And Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/PropertyPlantAndEquipmentComponentsOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r15", "r16", "r164", "r343", "r377", "r389" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.delcath.com/role/PropertyPlantAndEquipmentComponentsOfPropertyPlantAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant and equipment, net", "totalLabel": "Property, plant, and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets", "http://www.delcath.com/role/PropertyPlantAndEquipmentComponentsOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r15", "r164" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Components of property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/PropertyPlantAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r15", "r162" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/PropertyPlantAndEquipmentComponentsOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "verboseLabel": "Property, plant and equipment, estimated useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/PropertyPlantAndEquipmentComponentsOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r256", "r337", "r338" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CommitmentsAndContingenciesAdditionalInformationDetails", "http://www.delcath.com/role/StockholdersEquityAtTheMarketOfferingAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r256", "r337", "r340", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CommitmentsAndContingenciesAdditionalInformationDetails", "http://www.delcath.com/role/StockholdersEquityAtTheMarketOfferingAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r288", "r353", "r423" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfRecognizedShareBasedCompensationCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r92", "r367", "r385" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted Cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r14", "r90", "r92" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents, Current", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r25", "r248", "r285", "r343", "r387", "r402", "r404" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets": { "order": 23.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "verboseLabel": "Retained Earnings Accumulated Deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets", "http://www.delcath.com/role/GeneralAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r102", "r103", "r104", "r106", "r111", "r113", "r156", "r282", "r283", "r284", "r292", "r293", "r309", "r399", "r401" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r134", "r135", "r137", "r142", "r143", "r147", "r148", "r150", "r251", "r252", "r354" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 8.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.delcath.com/role/StockholdersEquityPreferredStockIssuancesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Number of Shares Sold" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquityAtTheMarketOfferingAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/AccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/NetLossPerCommonShareAntiDilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Anti-dilutive securities excluded from the computation of earnings per share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/NetLossPerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r260", "r279", "r287" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfRecognizedShareBasedCompensationCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r260", "r279", "r287" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of Recognized Share-based Compensation Cost" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r13", "r31", "r32", "r33" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r178" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "terseLabel": "Summary of Remaining Maturities of Company's Loan and Convertible Note Payables" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r38", "r164" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Schedule Of Property Plant And Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/PropertyPlantAndEquipmentComponentsOfPropertyPlantAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "auth_ref": [ "r14", "r92", "r367", "r385" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.", "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of Cash, Cash Equivalents, and Restricted Cash" } } }, "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CashCashEquivalentsAndRestrictedCashTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r261", "r281" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquityEquityIncentivePlanAdditionalInformationDetails", "http://www.delcath.com/role/StockholdersEquityScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails", "http://www.delcath.com/role/StockholdersEquityStockIncentivePlansAdditionalInformationDetails", "http://www.delcath.com/role/StockholdersEquitySummaryOfStockOptionSharesOutstandingAndExercisableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "verboseLabel": "Summary of Avenue Warrant Valued Using the Black-Scholes Option Pricing Method" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableTables", "http://www.delcath.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in stock options.", "label": "Schedule of Stock Options Roll Forward [Table Text Block]", "terseLabel": "Summary of Stock Option Activity" } } }, "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r249", "r259" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "terseLabel": "Summary of Warrant Activity" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "terseLabel": "Summary of reconciliation of weighted average shares outstanding calculation" } } }, "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/NetLossPerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r77" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 6.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, General and Administrative [Member]" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfRecognizedShareBasedCompensationCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquityPreferredStockIssuancesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series B Preferred Stock [Member]", "terseLabel": "Series B Preferred Stock [Member]" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquityPreferredStockIssuancesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesCPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series C preferred stock or outstanding series C preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series C Preferred Stock [Member]", "terseLabel": "Series C Preferred Stock [Member]" } } }, "localname": "SeriesCPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquityPreferredStockIssuancesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesDPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series D preferred stock or outstanding series D preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series D Preferred Stock [Member]", "terseLabel": "Series D Preferred Stock [Member]" } } }, "localname": "SeriesDPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquityPreferredStockIssuancesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesEPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series E preferred stock or outstanding series E preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series E Preferred Stock [Member]", "terseLabel": "Series E Preferred Stock [Member]" } } }, "localname": "SeriesEPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails", "http://www.delcath.com/role/StockholdersEquityPreferredStockIssuancesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividends" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableSummaryOfAvenueWarrantValuedUsingTheBlackScholesOptionPricingMethodDetails", "http://www.delcath.com/role/StockholdersEquityScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r275" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableSummaryOfAvenueWarrantValuedUsingTheBlackScholesOptionPricingMethodDetails", "http://www.delcath.com/role/StockholdersEquityScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableSummaryOfAvenueWarrantValuedUsingTheBlackScholesOptionPricingMethodDetails", "http://www.delcath.com/role/StockholdersEquityScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquityEquityIncentivePlanAdditionalInformationDetails", "http://www.delcath.com/role/StockholdersEquityScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails", "http://www.delcath.com/role/StockholdersEquityStockIncentivePlansAdditionalInformationDetails", "http://www.delcath.com/role/StockholdersEquitySummaryOfStockOptionSharesOutstandingAndExercisableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Share-based compensation arrangement by share-based payment award number of shares authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfEmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Number of Shares, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfStockOptionActivityDetails", "http://www.delcath.com/role/StockholdersEquitySummaryOfStockOptionSharesOutstandingAndExercisableDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "negatedLabel": "Number of Shares, Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Number of Shares, Cancelled/Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Number of Shares, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average estimated fair value of the stock options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquityStockIncentivePlansAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r281" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r265", "r281" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of Shares, Outstanding", "periodStartLabel": "Number of Shares, Outstanding", "terseLabel": "Outstanding Number of Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfStockOptionActivityDetails", "http://www.delcath.com/role/StockholdersEquitySummaryOfStockOptionSharesOutstandingAndExercisableDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price, Outstanding", "periodStartLabel": "Weighted Average Exercise Price, Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]", "terseLabel": "Summary of Stock Option Shares Outstanding and Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r259", "r263" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquityAtTheMarketOfferingAdditionalInformationDetails", "http://www.delcath.com/role/StockholdersEquityStockIncentivePlansAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Cancelled/Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]", "terseLabel": "Exercise Price Range" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfStockOptionSharesOutstandingAndExercisableDetails", "http://www.delcath.com/role/StockholdersEquitySummaryOfWarrantsOutstandingAndExercisableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Exercise Price Range [Domain]", "terseLabel": "Exercise Price Range" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfStockOptionSharesOutstandingAndExercisableDetails", "http://www.delcath.com/role/StockholdersEquitySummaryOfWarrantsOutstandingAndExercisableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r274", "r286" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected terms (years)", "verboseLabel": "Contractual term (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableSummaryOfAvenueWarrantValuedUsingTheBlackScholesOptionPricingMethodDetails", "http://www.delcath.com/role/StockholdersEquityScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r281" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term (Years), Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfStockOptionActivityDetails", "http://www.delcath.com/role/StockholdersEquitySummaryOfStockOptionSharesOutstandingAndExercisableDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term (Years), Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent", "verboseLabel": "Share-based compensation arrangement by share-based payment award purchase price of common stock, percent" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryOfEmployeeStockPurchasePlanDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short-term Debt, Type [Domain]" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r20", "r21", "r22", "r94", "r97", "r117", "r118", "r119", "r121", "r123", "r130", "r131", "r132", "r155", "r180", "r185", "r186", "r187", "r191", "r192", "r229", "r230", "r233", "r237", "r243", "r313", "r429" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.delcath.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit", "http://www.delcath.com/role/LeasesAdditionalInformationDetails", "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails", "http://www.delcath.com/role/StockholdersEquityPreferredStockIssuancesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r52", "r70", "r71", "r72", "r102", "r103", "r104", "r106", "r111", "r113", "r129", "r156", "r243", "r248", "r282", "r283", "r284", "r292", "r293", "r309", "r315", "r316", "r317", "r318", "r319", "r320", "r399", "r400", "r401", "r431" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit", "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails", "http://www.delcath.com/role/StockholdersEquityPreferredStockIssuancesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.delcath.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.delcath.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit", "http://www.delcath.com/role/LeasesAdditionalInformationDetails", "http://www.delcath.com/role/LoansAndConvertibleNotesPayableSummaryOfAvenueWarrantValuedUsingTheBlackScholesOptionPricingMethodDetails", "http://www.delcath.com/role/LoansAndConvertibleNotesPayableSummaryOfLoansAndConvertibleNotesPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r102", "r103", "r104", "r129", "r354" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.delcath.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.delcath.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit", "http://www.delcath.com/role/LeasesAdditionalInformationDetails", "http://www.delcath.com/role/LoansAndConvertibleNotesPayableSummaryOfAvenueWarrantValuedUsingTheBlackScholesOptionPricingMethodDetails", "http://www.delcath.com/role/LoansAndConvertibleNotesPayableSummaryOfLoansAndConvertibleNotesPayableDetails", "http://www.delcath.com/role/LoansAndConvertibleNotesPayableSummaryOfRemainingMaturitiesOfCompanysLoanAndConvertibleNotePayablesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r51", "r213", "r243", "r244", "r248" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Conversion of Preferred stock into common stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Shares settled for services (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period, Value, Issued for Services", "terseLabel": "Shares settled for services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r22", "r27", "r28", "r97", "r154", "r155", "r313", "r343" ], "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets": { "order": 19.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets", "http://www.delcath.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r95", "r230", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r248", "r250" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r321", "r344" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "verboseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquityStockIncentivePlansAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r321", "r344" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "verboseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquityStockIncentivePlansAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.delcath.com/role/StockholdersEquityPreferredStockIssuancesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental Disclosure of Cash Flow Information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TradingActivityByTypeAxis": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "Information by type of trading activity.", "label": "Trading Activity [Axis]", "terseLabel": "Trading Activity" } } }, "localname": "TradingActivityByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquityStockIncentivePlansAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TradingActivityByTypeDomain": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "Gains and losses on trading activities (including both derivative and nonderivative instruments) recognized in the statement of financial performance, separately by major types of items (such as fixed income/interest rates, foreign exchange, equity, commodity, and credit).", "label": "Trading Activity, by Type [Domain]", "terseLabel": "Trading Activity, by Type" } } }, "localname": "TradingActivityByTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquityStockIncentivePlansAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransactionDomain": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "Agreement between buyer and seller for the exchange of financial instruments.", "label": "Transaction [Domain]", "terseLabel": "Transaction" } } }, "localname": "TransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquityPreferredStockIssuancesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransactionTypeAxis": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.", "label": "Transaction Type [Axis]", "terseLabel": "Transaction Type" } } }, "localname": "TransactionTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/StockholdersEquityPreferredStockIssuancesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingMaturityDate": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.", "label": "Warrants and Rights Outstanding, Maturity Date", "terseLabel": "Warrants, maturity date" } } }, "localname": "WarrantsAndRightsOutstandingMaturityDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/LoansAndConvertibleNotesPayableAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "calculation": { "http://www.delcath.com/role/NetLossPerCommonShareSummaryOfReconciliationOfWeightedAverageSharesOutstandingCalculationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Weighted average number of basic and diluted shares outstanding", "totalLabel": "Weighted average shares outstanding" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.delcath.com/role/NetLossPerCommonShareSummaryOfReconciliationOfWeightedAverageSharesOutstandingCalculationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": { "auth_ref": [ "r115", "r116" ], "calculation": { "http://www.delcath.com/role/NetLossPerCommonShareSummaryOfReconciliationOfWeightedAverageSharesOutstandingCalculationDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).", "label": "Weighted Average Number of Shares Issued, Basic", "terseLabel": "Weighted average shares issued" } } }, "localname": "WeightedAverageNumberOfSharesIssuedBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.delcath.com/role/NetLossPerCommonShareSummaryOfReconciliationOfWeightedAverageSharesOutstandingCalculationDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r101": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r114": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2646-109256" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r128": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r133": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r157": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123364984&loc=d3e1205-110223" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r166": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r168": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r228": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r298": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r307": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "4F", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624186-113959" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10(3))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.7,8)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16)(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.3)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r424": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r425": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r426": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r427": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r428": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r429": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" } }, "version": "2.1" } ZIP 77 0001193125-22-147433-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-147433-xbrl.zip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end